



11) Publication number:

0 372 445 B1

### (2) EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification: 09.03.94 (51) Int. Cl.5: **C07D** 233/64, C07D 233/70,

(21) Application number: **89122302.6** 

(22) Date of filing: **03.12.89** 

C07D 233/84, C07D 233/70, C07D 233/84, C07D 233/88, C07D 491/044, C07D 491/056, C07D 405/14, C07D 409/14, A61K 31/415, //(C07D405/14, 307:00,307:00,233:00), (C07D409/14,333:00,333:00, 233:00)

- [54] Imidazoles for the treatment of atherosclerosis.
- Priority: 05.12.88 US 279981 10.10.89 US 416606
- Date of publication of application:13.06.90 Bulletin 90/24
- 45 Publication of the grant of the patent: 09.03.94 Bulletin 94/10
- Designated Contracting States:

AT BE CH DE ES FR GB GR IT LI LU NL SE

(56) References cited:

EP-A- 0 043 788 EP-A- 0 130 526 EP-A- 0 236 628 DE-A- 3 504 677 DE-A- 3 504 680 US-A- 4 137 234 US-A- 4 198 421

73 Proprietor: THE DU PONT MERCK PHARMA-CEUTICAL COMPANY Barley Mill Plaza, Building 25 Wilmington, Delaware 19880-0025(US)

Inventor: Billheimer, Jeffrey Thomas 1618 E. Lafayette Drive West Chester Pennsylvania 19382(US)

Inventor: Gillies, Peter John 55 Quail Hollow Drive

Hockessin Delaware 19707(US)
Inventor: Wexler, Ruth Richmond

2205 Patwynn Road

Wilmington Delaware 19810(US)

Inventor: Higley, C. Anne

17 Ballad Drive

Newark Delaware 19702(US)

Inventor: Maduskuie, Thomas Peter Jr.

613 Foulkstone Road

Wilmington Delaware 19810(US)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Representative: von Kreisler, Alek,
Dipl.-Chem. et al
Patentanwälte
von Kreisler-Selting-Werner
Postfach 10 22 41
D-50462 Köln (DE)

#### Description

5

30

#### Field of the Invention

This invention relates to imidazoles as inhibitors of acyl-CoA: cholesterol acyltransferase (ACAT), processes for their preparation, and their use as antihypercholesterolemic agents.

US-A-4 137 234 describes in Examples 21, 22 and 53 certain N-methyl-N'-[(3-(2-imidazolylthio)propyl]-urea compounds which are disclaimed herein.

#### 10 Background of the Invention

Hypercholesterolemia is an established risk factor in the development of atherosclerosis. Therapeutic agents which control the level of serum cholesterol have proven to be effective in the treatment of coronary artery disease. While agents exist that can modulate circulating levels of cholesterol carrying lipoproteins, these agents have little or no effect on the intestinal absorption of cholesterol. Dietary cholesterol can increase the level of serum cholesterol to levels which place an individual at increased risk for the development or exacerbation of atherosclerosis. Since much of the free or unesterified cholesterol that is absorbed by intestinal mucosal cells must first be esterified by ACAT prior to its incorporation and secretion into the bloodstream in large lipoprotein particles called chylomicrons, inhibition of ACAT can reduce the absorption of dietary cholesterol. In addition, the accumulation and storage of cholesteryl esters in the arterial wall is associated with increased activity of ACAT. Inhibition of the enzyme is expected to inhibit the formation or progression of atherosclerotic lesions in mammals.

There are a limited number of patents in the literature disclosing compounds which are useful as ACAT inhibitors in particular and antiatherosclerotic agents in general. For example, U.S. Patent No. 4,623,662, issued to De Vries on November 18, 1986, discloses ureas and thioureas as ACAT inhibitors useful for reducing the cholesterol ester content of an arterial wall, inhibiting atherosclerotic lesion development, and/or treatment of mammalian hyperlipidemia. U.S. Patent No. 4,722,927, issued to Holmes on February 2, 1988, discloses disubstituted pyrimidineamides of oleic and linoleic acids as ACAT inhibitors useful for inhibiting intestinal absorption of cholesterol.

U.S. Patent No, 4,460,598, issued to Lautenschläger et al. on July 17, 1984, discloses compounds of the formula:

R

R

$$R^2$$

N

 $R^3$ 
 $R^3$ 
 $R^4$ 
 $R^5$ 

wherein

50

 $R^1,\,R^2,\,R^3,\,R^4\,,\,R^5$  and  $R^6$ 

independently are H, F, Cl, Br, I, alkyl, alkoxy, or  $CF_3$ , with the proviso that one or several of  $R^1$  and  $R^2$ ,  $R^3$  and  $R^4$ , or  $R^5$  and  $R^6$  taken together represent methylenedioxy;

 $R^7$ 

is H, alkali metal ion, alkyl of 1 to 6 carbon atoms, or benzyl; and is 0 to 10.

n\_\_\_\_\_ is 0 to 10

The synthesis and the use of these compounds in the treatment of thromboembolic, inflammatory and/or atherosclerotic diseases is disclosed.

U.S. Patent No. 4,654,358, issued to Lautenschläger et al. on March 31, 1987, discloses compounds of the formula:

15

20

5

10

wherein

k is 0, 1, or 2,

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> independently are H, F, Cl, CH<sub>3</sub>, CH<sub>3</sub>O, or CF<sub>3</sub>;

 $R^4$  is H, Na, K,  $CH_3$ ,  $CH_3CH_2$ ,  $(CH_3)_2CH$ ,  $CH_3(CH_2)_2$ , or butyl;

A is  $C(CH_3)_2$ ,  $CH(CH_2)_mCH_3$ ,  $(CH_2)_n$ , or  $(CH_2)_{n-2}(CH(CH_3);$ 

m is 0 to 8; and

n is 2 to 10.

The synthesis and the use of these compounds in the treatment of inflammatory diseases, diseases of lipid metabolism, and/or hyperlipidemic diseases is disclosed.

German Laid Open Application No. DE 3504679, Lautenschläger et al., published August 14, 1986, discloses compounds of the formula:

30

35

$$R^{1}$$
 $N$ 
 $O-(CH_{2})_{m}C(CH_{2})_{n}CONR^{6}R^{7}$ 
 $R_{3}$ 

wherein

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup>

independently are H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 1 to 6 carbon atoms, or

45

40

50 R<sup>4</sup> and R<sup>5</sup>

R<sup>6</sup> and R<sup>7</sup>

independently are H,  $C_6\,H_5$ , or alkyl of 1 to 9 carbon atoms; independently are H, OH, saturated or unsaturated alkyl, cycloalkyl, or hydroxyalkyl of 1 to 10 carbon atoms,

$$(CH_{2})_{p} \xrightarrow{R^{10}} HC - CH_{2} \xrightarrow{R^{10}} HC - R^{14}$$

$$R^{11}, \qquad R^{12}, \qquad R^{12}$$

$$R^{13}$$

R8, R9, R10, R11, R12 and R13

independently are H, F, Cl, Br,  $NO_2$ ,  $CH_3CONH$ , OH, alkyl of 1 to 3 carbon atoms,  $CF_3$ , and alkoxy of 1 to 3 carbon atoms, with the proviso that  $R^8$  and  $R^9$ ,  $R^{10}$  and  $R^{11}$ , or  $R^{12}$  and  $R^{13}$  taken together represent

methylenedioxy;

R<sup>14</sup> is alkyl of 1 to 2 carbon atoms;

m and n taken together represent a whole number from 0 to 9;

p is 0 to 2; s is 0 to 2; and t is 0 or 2.

The synthesis and the use of these compounds in the treatment of thromboembolic, inflammatory, atherosclerotic, and lipid metabolism diseases in general is disclosed.

German Laid Open Application No. DE 3504680, Lautenschläger et al., published August 4, 1986, discloses compounds of the formula:

 $R^{1}$  N  $O-(CH_{2})_{m}C(CH_{2})_{n}XR^{6}$   $R_{5}$ 

35 wherein

15

20

25

30

45

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> independently are H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 1 to 6 carbon atoms, or

 $(CH_2)_p \xrightarrow{R^6}$ 

R<sup>1</sup> and R<sup>2</sup> can be taken together with the carbon atoms in the 4 and 5 position of the imidazole ring to represent a carbocyclic five- or six-membered aromatic or partially hydrogenated ring which may be substituted by R<sup>8</sup> or R<sup>9</sup>;

 $R^4$  and  $R^5$  independently are H,  $C_6H_5$ , or alkyl of 1 to 9 carbon atoms; is alkyl, cycloalkyl, or hydroxyalkyl of 1 to 20 carbon atoms, H, alk

is alkyl, cycloalkyl, or hydroxyalkyl of 1 to 20 carbon atoms, H, alkali metal if X is -COO-, 1-phenethyl, or

 $C_{\bullet}H_{2\bullet\cdot 1} \longrightarrow \mathbb{R}^{10}$ 

$\mathbb{R}^7$	is H, OH if X is -CONR <sup>7</sup> -, or alkyl of 1 to 4 carbon atoms;
R <sup>8</sup> , R <sup>9</sup> , R <sup>10</sup> and R <sup>11</sup>	are independently H, Cl, F, Br, NO2, CH3CONH, OH, alkyl of 1 to 3 carbon
	atoms, CF <sub>3</sub> , or alkoxy of 1 to 3 carbons, or R <sup>8</sup> and R <sup>9</sup> or R <sup>10</sup> and R <sup>11</sup> taken
	together represent methylenedioxy;
Χ	is a bond, O, $OC(=0)O$ , $C(=0)O$ , $CONR^7$ , $OC(=0)$ , or $OC(=0)NR^7$ ;
m and n	taken together represent a whole number from 0 to 9;
р	is 0 to 2;
S	is 0 to 2; and

The synthesis and the use of these compounds in the treatment of thromboembolic, inflammatory, atherosclerotic, and lipid metabolism diseases in general is disclosed.

There are no known literature references disclosing the imidazoles of this invention, their use as ACAT inhibitors, or their use in the treatment of atherosclerosis.

The compounds of this invention are very potent ACAT inhibitors. As shown by the data presented below in Table 6, the compounds of this invention inhibit ACAT activity in vitro with at least ten times the potency of any ACAT inhibitors described in the current literature. As shown by the data presented below in Table 8, the compounds of this invention cause a reduction in the serum cholesterol level in cholesterol-fed hamsters. The compounds of this invention are thus expected to be useful in pharmaceutical formulations for the treatment of atherosclerosis. The compounds of this invention have been shown to lower serum cholesterol, and this invention should not be construed as limited to any particular antihypercholesterolemic mechanism of action.

#### Summary of the Invention

5

10

25

30

35

40

45

50

The present invention provides novel compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing such imidazoles, and therapeutic methods for their use as antihypercholesterolemic agents.

This invention provides compounds of Formula (I):

is 0 or 2.

R 2 N X -A -N -R 6

wherein

R1 and R2

are selected independently from H,  $C_1$ - $C_8$  alkyl, provided that when  $R^1$  is H, then  $R^2$  cannot be H and when  $R^1$  is  $C_1$ - $C_8$  alkyl, then  $R^2$  cannot be  $C_1$ - $C_8$  alkyl,  $C_3$ - $C_8$  branched alkyl,  $C_3$ - $C_7$  cycloalkyl,  $C_4$ - $C_{10}$  cycloalkylalkyl,  $C_7$ - $C_{14}$  araalkyl, 2-, 3- or 4-pyridinyl, 2-thlenyl, 2-furanyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  alkyl,  $C_3$ - $C_8$  branched alkyl,  $C_3$ - $C_8$ 0,  $C_$ 

R<sup>1</sup> and R<sup>2</sup> can also be taken together as

10

5

15

where L or O,  $O(CH_2)_{m+1}O$ , or  $(CH_2)_m$  where m is 0-4;

 $R^3$ 

is H, C<sub>1</sub>-C<sub>6</sub> alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl, CH<sub>3</sub>, CH<sub>3</sub>O, or

R<sup>4</sup>

is straight chain C<sub>1</sub>-C<sub>8</sub> alkyl optionally substituted with F; C<sub>3</sub>-C<sub>8</sub> branched alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>4</sub>-C<sub>10</sub> cycloalkylalkyl, C<sub>7</sub>-C<sub>14</sub> araalkyl where the aryl group is optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>; C<sub>3</sub>-C<sub>6</sub> alkenyl or alkynyl, C<sub>1</sub>-C<sub>3</sub> perfluoroalkyl, phenyl optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-C<sub>4</sub> alkyl,C<sub>1</sub>-C<sub>4</sub> alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup> or NCOR7; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy,

25

20

NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>; 2-, 3- or 4-pyridinyl, pyrimidinyl, or biphenyl;

 $R^5$ is H, C<sub>1</sub>-C<sub>6</sub> alkyl, or benzyl;  $R^6$ 

30

is H, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> branched alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> alkenyl or alkynyl, phenyl optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR7:

R7 and R8

are selected independently from H or C<sub>1</sub>-C<sub>4</sub> alkyl;

35 Χ is  $S(O)_r$ , O,  $NR^5$ ,  $CH_2$ ;

Α

is  $C_2$ - $C_{10}$  alkyl,  $C_3$ - $C_{10}$  branched alkyl,  $C_3$ - $C_{10}$  alkenyl, or  $C_3$ - $C_{10}$  alkynyl;

Υ is O, S, H<sub>2</sub>;

Ζ is NHR4, OR4, or R4;

is 0-2,

or a pharmaceutically acceptable salt thereof.

Preferred are compounds of Formula (I) wherein:

R1 and R2

R1 and R2

are selected independently from C<sub>1</sub>-C<sub>8</sub> alkyl, provided that when R<sup>1</sup> is C<sub>1</sub>-C<sub>8</sub> alkyl, then R<sup>2</sup> cannot be C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> branched alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>4</sub>-C<sub>10</sub> cycloalkylalkyl, C<sub>7</sub>-C<sub>14</sub> araalkyl, 2-, 3-, or 4-pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 2 groups selected from F, Cl, Br, OH, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> branched alkyl,  $CH_3S(O)_r$ ,  $NO_2$ ,  $CF_3$ , or  $NR^7R^8$ ; or

can also be taken together as

50

45

5

10

20

25

35

40

where L is O,  $O(CH_2)_{m+1}O$ , or  $(CH_2)_m$  where m is 0-4. More preferred are compounds of Formula (I) wherein:

 $R^3$ is H, CH3, phenyl;

 $R^6$ is H, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> branched alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, phenyl optionally substituted with 1 to 3 groups selected from CH<sub>3</sub>, CH<sub>3</sub>O, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, or di(C<sub>1</sub>-C<sub>4</sub>)alkylamino; or benzyl optionally substituted with 1 to 3 groups selected from CH<sub>3</sub>, CH<sub>3</sub>O, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, or di(C<sub>1</sub>-C<sub>4</sub>)alkylamino;

Χ is S(O)r, CH<sub>2</sub>;

is C<sub>2</sub>-C<sub>10</sub> alkyl, C<sub>4</sub>-C<sub>9</sub> branched alkyl.

More specifically preferred because of their biological activity are compounds of Formula (I) wherein:

R<sup>1</sup> and R<sup>2</sup> are selected independently from C<sub>1</sub>-C<sub>8</sub> alkyl, provided that when R<sup>1</sup> is C<sub>1</sub>-C<sub>8</sub> alkyl, then R<sup>2</sup> cannot be C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> branched alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>4</sub>-C<sub>10</sub> cycloalkylalkyl, C<sub>7</sub>-C<sub>14</sub> araalkyl, 2-, 3-, or 4-pyridinyl, 2-thienyl, or phenyl optionally substituted with 1 to 2 groups selected from F, Br, Cl, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> branched alkyl, CH<sub>3</sub>O, CH<sub>3</sub>S(O)<sub>r</sub>, NO<sub>2</sub>, CF<sub>3</sub>, or di(C<sub>1</sub>-C<sub>4</sub>)alkylamino; or

R<sup>1</sup> and R<sup>2</sup> can also be taken together as 30

45

50

where L is O or OCH<sub>2</sub>O;

 $\mathbb{R}^3$ 

 $R^4$ is  $C_1$ - $C_8$  alkyl,  $C_3$ - $C_8$  branched alkyl,  $C_3$ - $C_7$  cycloalkyl,  $C_4$ - $C_{10}$  cycloalkylalkyl,  $C_7$ - $C_{14}$ araalkyl, phenyl substituted with 1 to 3 groups selected from CH₃, F, Cl, CH₃O, CN; or benzyl optionally substituted with 1 to 3 groups selected from CH<sub>3</sub>, CH<sub>3</sub>O, F, Cl, or CN;

 $R^6$ is C<sub>1</sub>-C<sub>8</sub> alkyl or phenyl optionally substituted with 1 to 3 groups selected from CH<sub>3</sub>, CH<sub>3</sub>O, F, Cl, or CN;

Α is C<sub>4</sub>-C<sub>9</sub> alkyl;

Χ is  $S(0)_r$ ;

55 is O, H<sub>2</sub>.

Specifically preferred are:

N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-phenylurea

```
N'-(2,4-difluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]-N-heptylurea
         N-butyl-N'-(2,4-difluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]urea
         N'-(2,4-dimethoxyphenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea
         N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-methylurea
5
         N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-propylurea
         N'-(2,4-difluorophenyl)-N-[5-[4,5-diphenyl)-1H-imidazol-2-yl)sulfonyl]pentyl]-N-heptylurea
         N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-(3-fluorophenyl)-N-heptylthiourea
         N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-(3-fluorophenyl)-N-heptylurea
         N'-(2,4-difluorophenyl)-N-heptyl-N-[5-(4-phenyl-1H-imidazol-2-ylthio)pentyl]urea
10
         N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-(2,4,6-trifluorophenyl)thiourea
         N'-(2,6-dichlorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea
         N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-(1-methylethyl)urea
         N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-2,4-difluoro-N-heptylbenzeneacetamide
         N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-propylthiourea
15
         N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-octylurea
         N'-cyclohexyl-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea
         N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-yl)sulfinyl]pentyl]-N-heptylurea
         N'-(2,4-difluorophenyl)-N-[2-(4,5-diphenyl-1H-imidazol-2-ylthio)ethyl]-N-heptylurea
         N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylbutanamide
         N-[5-(4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
20
         N-[5-[4,5-bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
         N'-(2,4-difluorophenyl)-N-[5-(4,5-dipropyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea
         N-[5-[4,5-bis(4-fluorophenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
         N-[5-(1H-dibenz[2,3:6,7]oxedino[4,5-d]imidazol-2-ylthio)pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
         N-[5-[4,5-bis(2-thienyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
25
         N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylpentanamide
         N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl[1,1'-biphenyl]-4-acetamide
         N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-(2,4,6-trifluorophenyl)urea
         N-[5-[4,5-bis(2-pyridinyl]-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl]-N-heptylurea
         N'-(2,4-difluorophenyl)-N-[6-(4,5-diphenyl)-1H-imidazol-2-yl)hexyl]-N-heptylurea
30
         N-[5-[4,5-bis(4-methylphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
         N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylbutanamide
         N-[5-[4,5-bis(4-hydroxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
         N-[5-[4,5-bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylcyclohexaneacetamide
35
         N-[5-[4,5-bis(3-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
         N-[5-[4,5-bis(2-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
         N'-[1,1'-biphenyl)-4-yl]-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea
         N-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-octylurea
         Propyl [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate
         (Phenylmethyl) [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate
40
         Phenyl [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate
         (2-Methylpropyl) [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate
         Ethyl [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate
         Octyl [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate
         N-[5-[4,5-bis[4-(dimethylamino)phenyl]-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
45
         N-[5-(4,5-dicyclohexyl-1H-imidazol-2-ylthio)pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea)
         (4-fluorophenyl)[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate
         N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-octyl-N-phenylurea
         N-[5-(1H,9H-dibenz[4,5:8,9][1,3]dioxonino[6,7-d]imidazol-2-ylthio)-pentyl-N'-(2,4-difluorophenyl)-N-
    heptylurea
50
         N'-(4-cyanophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea
         N-(2,4-difluorophenyl)-N'-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]urea
         N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-2,4-difluoro-N-heptylbenzeneacetamide
         Phenyl [5-[4,5-bis(4-dimethylamino)phenyl)-1H-imidazol-2-ylthio]pentyl]heptylcarbamate
55
         or pharmaceutically acceptable salts thereof.
```

#### Detailed Description of the Invention

#### Synthesis

5

The novel compounds of Formula (I) may be prepared using the reactions and techniques described in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and suitable for the transformation being effected. It is understood by those skilled in the art of organic synthesis that the functionality present on the imidazole and other portions of the molecule must be compatible with the reagents and reaction conditions proposed. Not all compounds of Formula (I) falling into a given class may be compatible with some of the reaction conditions required in some of the methods described. Such restrictions to the substituents which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternative methods described must then be used.

The compounds of Formula (I) wherein X is O, S, CH2 or NH can be prepared by the route shown in Scheme 1. The esters of Formula (3) wherein X is O or S can be prepared by converting the requisite 4imidazolin-2-one (1) where X is O, or 4-imidazolin-2-thione (1) where X is S, into the corresponding alkali metal salt by addition of a base such as sodium hydride, and the salt is alkylated with a compound of the formula M-(A')CO<sub>2</sub>R, wherein R is CH<sub>3</sub> or C<sub>2</sub>H<sub>5</sub>, M is a halogen or a tosylate group, and A' is a moiety having one less methylene group than A, in a polar solvent such as N,N-dimethylformamide. Alternatively, the esters of Formula (3) where X is S may be prepared by direct alkylation of the requisite 4-imidazolin-2thione with M-(A')CO<sub>2</sub>R, without the addition of a suitable base, in a polar solvent such as N,Ndimethylformamide at a temperature from ambient temperature to the reflux temperature of the solvent. The esters of Formula (3) wherein X is NH can be prepared by the reaction of the requisite 2-aminoimidazole of Formula (2) with a compound of the formula M-(A')CO<sub>2</sub>R wherein R, M, and A' are as defined above, in a suitable solvent such as N,N-dimethylformamide. Compounds of Formula (2) wherein R<sup>3</sup> is H are preferentially alkylated at a ring nitrogen atom. Therefore, in order to prepare compounds of Formula (I) wherein X is NH and R3 is H, it is usually necessary to protect the ring nitrogen atom. The protecting group is preferably stable under basic conditions and easily removed under acidic conditions, e.g., a silyl or trityl group. The protected 2-aminoimidazole can then be used to prepare esters of Formula (3) wherein R3 is a protecting group. The protecting group can be removed at any suitable stage in the synthetic sequence for the preparation of the compounds of Formula (I) wherein X is NH and R<sup>3</sup> is H.

The esters of Formula (3) are hydrolyzed to the corresponding carboxylic acids of formula (4) by methods which are well known in the chemical literature. For example, the hydrolysis can be accomplished by reaction with an alkali metal hydroxide in aqueous or organic solvents such as water, alcohols, ethers or mixtures thereof, followed by acidification with a mineral acid. The methods used to prepare compounds of formula (4) are substantially similar to the methods described in U.S. 4,654,358, U.S. 4,460,598 and in U.S. 4,900,744. Compounds of Formula (4) wherein R¹ and R² are phenyl or substituted phenyl, R³ is H, X is S, A¹ is (CH₂)<sub>n-1</sub> and n is 8 to 21 are claimed as antihypercholesterolemic compounds in U.S. 4,900,744.

The amides of Formula (5) are prepared by coupling the carboxylic acids of Formula (4) with a primary amine by amide bond forming reactions which are well known in the chemical literature. One method of amide bond formation is to use a coupling reagent which generates a reactive intermediate such as a mixed anhydride or active ester. Examples of such coupling agents are disubstituted carbodiimides, N,N'-carbonyldiimidazole, diphenylphosphoryl azide, and the like. For example, the coupling can be carried out with a disubstituted carbodiimide such as dicyclohexylcarbodiimide in an appropriate solvent such as methylene chloride, acetonitrile, toluene, or N,N-dimethylformamide. Nucleophilic hydroxy compounds such as 1-hydroxy-1H-benzotriazole, which form highly active esters, may be added to catalyze the reaction.

There are several alternate approaches to the preparation of the amides of Formula (5). For example, the boron trifluoride etherate catalyzed reaction of the carboxylic acids of Formula (4) with a primary amine, with azeotropic removal of water, affords the amides of Formula (5). Another approach is to convert the carboxylic acids of Formula (4) to the corresponding acid chloride using thionyl chloride, oxalyl chloride or the like and then to react the acid chloride with a primary amine in the presence of a base such as triethylamine to afford the amides of Formula (5). Alternatively, the esters of Formula (3) can be directly converted to the amides of Formula (5) by ester aminolysis in the presence of strong alkali metal catalysts such as sodium amide, sodium hydride, sodium methoxide, Grignard reagents or butyllithium, or in the presence of milder catalysts such as 2-pyridone, boron tribromide, or dimethylaluminum amides.

The amines of Formula (6) can be prepared by reduction of the corresponding amides of Formula (5) by a variety of methods well known to those skilled in the art. For example, reagents such as lithium aluminum hydride, diborane, sodium bis(2-methoxyethoxy)aluminum hydride (Red-A1®), and diisobutylaluminum hydride can be used to reduce an amide to an amine. Such reactions are typically conducted in an appropriate anhydrous aprotic solvent such as ether, toluene or tetrahydrofuran at a temperature from room temperature to the boiling point of the solvent for a period of 2-48 hours.

Alternatively amines of Formula (6), wherein X is NH can be prepared by the route shown in Scheme 2. The primary amines (9) can be prepared by reacting 2-bromoimidazoles of Formula (8) with an appropriately elaborated diamine under neat, thermal conditions or in appropriate solvent such as N,N-dimethyl-formamide, toluene, acetonitrile or tetrahydrofuran, at or below the boiling point of the solvent.

35

40

45

50

# Scheme 2

5 
$$R^1$$
 $R^2$ 
 $R^3$ 
 $R^3$ 
 $R^4$ 
 $R^3$ 
 $R^4$ 
 $R^4$ 

The secondary amines of Formula (6) wherein X is NH can be prepared by direct alkylation of the primary amines of Formula (9) with an appropriately substituted alkyl halide. Or, the secondary amines (6) are prepared by acylation of the primary amines of Formula (9) with an acid chloride or activated carboxylic acid derivative to give the amide of Formula (10) and reduction of the amide (10) to the amines (6) by well known methods previously described.

The compounds of Formula (7) where Y is O and Z is NR<sup>4</sup>, OR<sup>4</sup> R<sup>4</sup> are prepared by the reaction of the secondary amines (6) with the requisite isocyanates, chloroformates, acid chlorides or activated carboxylic acid derivatives in an appropriate solvent such as hexane, toluene, diethyl ether, methylene chloride or tetrahydrofuran at a temperature at or below the boiling point of the solvent.

The amines of Formula (7), wherein Y is H<sub>2</sub> are prepared by reaction of the corresponding ureas or amides of Formula (7) wherein Y is O, with a reducing agent such as lithium aluminum hydride or other such reagents in an appropriate anhydrous aprotic solvent such as hexane, toluene, diethylether or tetrahydrofuran at temperatures at or below the boiling point of the solvent.

As shown in Scheme 3, the thioureas of Formula  $(\underline{12})$  wherein X is S, O or NH and Z is NHR<sup>4</sup> can be prepared in an analogous manner by the reaction of the secondary amines of Formula  $(\underline{6})$  with the requisite isothiocyanate. Alternatively, the thioureas or thioamides where Z is R<sup>4</sup> of Formula  $(\underline{12})$  can be prepared from the ureas or amides of Formula  $(\underline{7})$  by the reaction with Lawesson's reagent or diphosphorus pentasulfide in an appropriate solvent such as toluene.

55

40

45

### Scheme 3

5

$$R^{1}$$
 $R^{2}$ 
 $R^{3}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{3}$ 
 $R^{4}$ 

As shown in Scheme 4, alternatively the amides of Formula (5) can be prepared by the alkylation of (1) or (2) with compounds of the formula M-(A')CONHR<sup>6</sup> wherein M is a halogen or tosylate group, as, described for compounds of Formula (3), Scheme 1.

### Scheme 4

30

35 R1 N OF R1 N NH<sub>2</sub> NH<sub>2</sub> 
$$X - A - CONH - R$$

40 1 2

Alternatively, compounds of Formula (7), where X is O, S, or NH can be prepared by the route shown in Scheme 5. The compounds of Formula (13) can be prepared from a lactone or an hydroxyalkylcarboxylic ester and an appropriate amine, neat or in an inert solvent such as N,N-dimethylformamide at ambient or elevated temperatures. The amines of Formula (14) are prepared by reduction of the corresponding amide of Formula (13) by a variety of well known methods, as illustrated above. The compounds of Formula (15) are prepared by the reaction of the secondary amine (14) with the requisite isocyanates, chloroformates, acid chlorides or activated carboxylic acid derivatives as described for the preparation of compounds of Formula (7), Scheme 1.

The compound of Formula (16) can be prepared by conversion of the hydroxy group to a halogen moiety by a variety of well known methods. Examples of these methods are phosphorous tribromide, phosphorous oxychloride, thionyl chloride, or triphenylphosphine and carbon tetrabromide. Or, compounds of Formula (16) where M is a tosylate or similar functionality, can be prepared from toluene sulfonyl chloride and triethylamine, in an appropriate aprotic solvent such as methylene chloride, tetrahydrofuran or toluene.

The compounds of Formula  $(\underline{7})$  can be prepared by converting the requisite 4-imidazolin-2-one  $(\underline{1})$  where X is O, or 4-imidazoline-2-thione  $(\underline{1})$  where X is S into the corresponding alkali metal salt by addition of a base such as sodium hydride, and alkylating with the compounds of Formula  $(\underline{16})$  in a polar aprotic

solvent such as N,N-dimethylformamide at an appropriate temperature.

#### Scheme 5

5

7, A Is (CH<sub>2</sub>)<sub>n-1</sub>

The compounds of Formula (7) wherein X is CH<sub>2</sub> are prepared by the route shown in Scheme 6. The compounds of Formula (18) are prepared by converting the requisite imidazoles of Formula (17) where R³ is alkyl or an appropriate protecting group, into the corresponding alkali metal salt, by addition of a base such as n-butyl lithium, and alkylating with an appropriate alkyl halide in a solvent such as tetrahydrofuran under an inert atmosphere and reduced temperatures. The compounds of Formula (19) are prepared from compounds of Formula (18) by reaction with an appropriately substituted amine, in an inert solvent such as toluene, acetonitrile, tetrahydrofuran or N,N-dimethylformamide, at a temperature at or below the boiling point of the solvent. The imidazole compounds of Formula (20) are prepared by the reaction of the secondary amines of Formula (19) with the requisite isocyanate, chloroformate, acid chloride or other activated carboxylic acid derivative as previously described. Or, the imidazole compounds of Formula (20) can be prepared by reacting the alkali metal salt of compounds of Formula (17) with the elaborated compounds of Formula (16) in analogous conditions described above. The compounds of Formula (7) wherein X is CH<sub>2</sub> and R³ is H, are prepared by deprotecting compounds of Formula (20), where R³ is a protecting group. For example, when R³ is a silyl protecting group, removal with tetrabutylammonium fluoride in tetrahydrofuran at reflux, affords compounds of Formula (7) where X is CH<sub>2</sub>.

Likewise, compounds of Formula (7) wherein X is O, S, NH or CH<sub>2</sub> and Y is H<sub>2</sub> may be prepared by reacting compounds similar to compounds of Formula (18) with an appropriately functionalized secondary amine, HNCH<sub>2</sub> ZR<sup>6</sup>, in a solvent such as toluene, acetonitrile, tetrahydrofuran, or N,N-dimethylformamide at a temperature at or below the boiling point of the solvent.

50

45

30

### Scheme 6

The linked phenyl compounds of Formula  $(\underline{24})$  are prepared as shown in Scheme 7. The linked bis-benzaldehyde compounds of Formula  $(\underline{21})$  are prepared by bis alkylation of an appropriately functionalized dihaloalkyl, with a substituted salisaldehyde, using an alkali base, such as sodium hydride in an inert solvent, such as N,N-dimethylformamide. The  $\alpha$ -hydroxyketones of Formula  $(\underline{22})$  are prepared by standard literature benzoin forming reaction conditions, Walter S. Ide, Johannes S. Buck, Organic Reactions, Vol. IV, p. 269, utilizing potassium cyanide in ethanol:water, at reflux.

The imidazoles of Formula (23) are prepared by methods well known in the literature, Klaus Hoffman, The Chemistry of Heterocyclic Compounds, Imidazoles, Part I, by condensing the  $\alpha$ -hydroxyketone compounds of Formula (22) with thiourea, or ammonium thiocyanate, or an appropriately substituted thiourea in a suitable solvent such as N,N-dimethylformamide, ethanol or hexanol, at a temperature at or below the boiling point of the solvent.

The compounds of Formula  $(\underline{24})$  are prepared by alkylating the alkali metal salt of imidazole  $(\underline{23})$  with the compound of Formula  $(\underline{16})$ , as described previously to give the compounds of Formula  $(\underline{24})$  directly or with compound of formula  $M(A')CO_2R$  when R is  $CH_3$  or  $C_2H_5$ , M is halogen or a tosylate group and A' is a moiety having one less methylene group than A, as described in Scheme 1.

50

40

45

# Scheme 7

30

The compounds of Formula  $(\underline{1})$ , Scheme 8, wherein X is S are available from commercial sources or can be prepared by methods as described above.

# Scheme 8

Alternatively, the compounds of Formula (1) where X is S, Scheme 8, can be prepared from the corresponding 4-imidazolin-2-ones of Formula (1) where X is O, Org. Syn. Coll., Vol. II, 231, by reaction with Lawesson's reagent or diphosphorus pentasulfide in a suitable solvent such as toluene.

As shown in Scheme 9, the 2-aminoimidazoles of Formula  $(\underline{2})$  can be prepared by the reaction of the appropriately substituted  $\alpha$ -aminoketones of Formula  $(\underline{27})$  with cyanamide  $(\underline{28})$ . Compounds of Formula  $(\underline{2})$ 

can be used in the preparation of compounds of Formula (I) as previously described in Scheme 1.

### Scheme 9

As shown in Scheme 10, the compounds of Formula (I) wherein X is  $S(O)_r$  and r is 1 or 2 can be prepared by the oxidation of the compounds of Formula (29) by methods which are well known in the chemical literature. For example, the oxidation of (29) with one equivalent of a peracid such as m-chloroperoxybenzoic acid in a suitable solvent such as methylene chloride at a low temperature affords primarily the sulfoxides of Formula (30), and the oxidation of (29) with an oxidant such as potassium hydrogen persulfate, or Oxone®, in a suitable solvent such as methanol affords the sulfones of Formula (31).

### Scheme 10

Alternatively, compounds of Formula (7) where  $R^3$  is not H, Scheme 11, can be prepared by direct alkylation of compounds of Formula (7) when R is H, in the presence or absence of a base such as potassium carbonate, pyridine, sodium hydride, triethylamine, or potassium t-butoxide in an appropriate solvent such as N,N-dimethylformamide, glyme, tetrahydrofuran, pyridine or methylene chloride.

## Scheme 11

5

10

15

30

35

40

45

50

55

Preparation of pharmaceutically suitable salts of Formula (I) can be carried out in accordance with well known techniques for forming salts. Physiologically acceptable salts include acid addition salts, e.g., hydrochloric, sulfuric, acetic, trifluoroacetic, succinic, citric, and benzene sulfonic acid salts.

The compounds of this invention and their preparation can be further understood by the following examples, which exemplify but do not constitute a limitation of the invention. In these examples, unless otherwise indicated, all temperatures are in degrees centigrade and parts and percentages are by weight.

#### **EXAMPLE 1**

#### Preparation of N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea

Part A. To a solution of 4,5-diphenyl-2-imidazolethiol (25.2 g, 0.1 mol) in N,N-dimethylformamide (250 ml) was added, dropwise, a solution of ethyl 5-bromopentanoate (23.73 mL, 31.35 g, 0.15 mol) in N,N-dimethylformamide (80 mL), and the reaction mixture was stirred at reflux under nitrogen for 18 hours. The reaction mixture was cooled, poured into 5% sodium bicarbonate and ice, and then extracted with ethyl acetate. The combined organic extracts were washed sequentially with 5% sodium bicarbonate, water, saturated sodium chloride solution, dried over magnesium sulfate, and concentrated under vacuum. The residue was chromatographed with 7:3 hexane-ethyl acetate, and the resulting solid was recrystallized from acetonitrile and triturated with hexane to give 5-(4,5-diphenyl-1H-imidazol-2-ylthio)-pentanoic acid ethyl ester (25.95 g, 0.068 mol) as a white solid, mp 87-89°. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>)  $\delta$  7.55-7.15(m,11H), 4.0(q,2H,J=8Hz), 2.9(t,2H,J-7Hz), 2.3(t,2H,J=7Hz), 1.9-1.6(m,4H), 1.2(t,3H,J=8Hz).

Additional esters which can be used as intermediates in the preparation of compounds of Formula (I) are prepared similarly as taught in U.S. 4,900,744.

Part B. To a solution of 5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentanoic acid ethyl ester (7.6 g, 0.02 mol) in ethanol (200 mL), was added dropwise a solution of sodium hydroxide (7.6 g) in water (200 mL), and the reaction mixture was stirred at reflux under nitrogen for 3 hours. The reaction mixture was concentrated to half the original volume and then extracted with ether. The ether extracts were discarded. The reaction mixture was acidified to pH 1 with 1 N hydrochloric acid and extracted with ether, and the combined organic extracts were dried over magnesium sulfate and concentrated under vacuum. The resulting solid was recrystallized from acetonitrile and triturated with hexane to give 5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentanoic acid (3.88 g, 0.011 mol) as a white solid, mp 190-195°. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>)  $\delta$  12.6(s,1H), 7.6-7.1(m,10H), 3.3-3.1(m,2H), 2.3-2.1(m,3H), 1.8-1.6(m,4H).

Additional acids which can be used as intermediates in the preparation of compounds of Formula (I) are prepared similarly and are claimed in U.S. 4,900,744.

Part C, Method 1. To a solution of 5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentanoic acid (2.0 g, 0.0057 mol) in N,N-dimethylformamide (25 mL) was added 1-hydroxybenzotriazole hydrate (0.93 g, 0.0069 mol) followed by a solution of heptylamine (1.10 mL, 0.86 g, 0.0074 mol) in N,N-dimethylformamide (10 mL). The reaction mixture was cooled to 0° and dicyclohexylcarbodiimide (1.42 g, 0.0069 mol) was added portionwise as a solid. The reaction mixture was stirred for 2 hours at 0° and then stirred for 48 hours at ambient temperature. The solids were filtered and washed with N,N-dimethylformamide. The filtrate was concentrated and the residue was chromatographed with 1:1 hexane-ethyl acetate. The resulting solid was recrystallized from acetonitrile and triturated with hexane to give 5-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-heptylpentanamide (2.21 g, 0.0049 mol) as a white solid, mp 104-106°. ¹H NMR (CDCl<sub>3</sub>)  $\delta$ 

11.6(s,1H), 7.6-7.1(m,10H), 6.1-6.0(m,1H), 3.1-2.8(m,4H), 2.2(t,2H,J=7Hz), 1.9-1.7(m,2H), 1.7-1.5(m,2H), 1.4-1.1(m,10H), 0.9(t,3H,J=8Hz).

Part C, Method 2. To a solution of 5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentanoic acid (2.0 g, 0.0057 mol) in toluene (35 ml) was added heptylamine (1.63 ml., 1.27 g, 0.011 mol) and then boron trifluoride etherate (1.35 mL., 1.56 g, 0.011 mol) and the reaction mixture was stirred at reflux for 120 hours using a Dean-Stark moisture trap. The reaction mixture was cooled, extracted with 0.1 N NaOH, 0.1 N HCl, and water, and the combined organic extracts were dried over magnesium sulfate and concentrated under vacuum. The residue was chromatographed and worked-up as described in Part C, Method 1, to give 5-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-heptylpentanamide (2.35 g, 0.005 mol) as a white solid.

Part D. To a solution of lithium aluminum hydride, (1.52 g, 0.04 mol) in dry tetrahydrofuran (50 mL) was added, dropwise, a solution of 5-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-heptylpentanamide(4.04 g, 0.009 mol) in tetrahydrofuran (25 mL) and the reaction mixture was stirred at reflux for 18 hours. The reaction mixture was cooled to 0°, quenched by the slow and careful sequential addition of water (1.52 mL), 15% sodium hydroxide (4.56 mL), and water (4.56 mL), and then stirred at 0° for 30 minutes. The solution was then dried over magnesium sulfate and concentrated under vacuum, and the residue was chromatographed with a gradient of 1:0 to 3:1 to 1:1 ethyl acetate-methanol. The resulting yellow oil was triturated with cold hexane to give N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanamine as a white solid. A solution of this amine (0.80 g, 0.0018 mol) in ether (20 mL) was treated with a sufficient amount of ethereal HCl (about 25 mL) to cause complete precipitation of the amine as the hydrochloride salt. The reaction mixture was stirred for 15 minutes, and the supernatant liquid was decanted to afford a gummy solid, which was triturated with hot acetonitrile and then with cold hexane to give N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanamine hydrochloride (0.82 g, 0.0017 mol) as a white solid, mp 187-190°. ¹H NMR (CDCl<sub>3</sub>) δ 9.3(s,2H), 7.7-7.3(m,10H), 3.7-3.5(m,2H), 3.0-2.7(m,4H), 2.0-1.2(m,16H), 0.9(t,3H,J=8Hz).

Part E. To a solution of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanamine (1.0 g, 0.0024 mol) in hexane (50 mL) was added, dropwise, a solution of 2,4-difluorophenylisocyanate (0.296 mL, 0.388 g, 0.0025 mol) in hexane (25 mL), and the reaction mixture was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated under vacuum and the residue was chromatographed with 7:3 hexane-ethyl acetate to give the title compound (0.86 g, 0.0015 mol) as a white solid, mp 96-98°. ¹H NMR (CDCl<sub>3</sub>) δ 10.8(s,1H), 7.7-7.1(m,14H), 3.4(t,2H,J=7Hz), 3.2(t,2H,J=7Hz), 3.0(t,2H,J=7Hz), 1.9-1.4-(m,16H), 0.9(t,3H,J=8Hz).

### EXAMPLE 2

5

10

15

20

30

#### 35 Preparation of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-phenylurea

To a solution of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanamine (1.0 g, 0.0024 mol) in hexane (50 mL) was added, dropwise, a solution of phenylisocyanate (0.27 mL, 0.298 g, 0.0025 mol) in hexane (25 mL) and the reaction mixture was stirred at ambient temperature for 4 hours. The reaction mixture was concentrated under vacuum and the residue was chromatographed with 6:4 hexane-ethyl acetate to give the title compound (0.5 g, 0.009 mol) as a yellow amorphous solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  11.0-(s,1H), 7.7-6.9(m,14H), 6.4(s,1H), 3.4(t,2H,J=7Hz), 3.2(t,2H,J=7Hz), 3.0(t,2H,J=7Hz), 1.9-1.1(m,16H), 0.9-(t,3H,J=8Hz).

#### 45 EXAMPLE 3

50

55

#### Preparation of N'-(2,4-difluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]-N-heptylurea

Part A. To a solution of 8-(4,5-diphenyl-1H-imidazol-2-ylthio)octanoic acid (8.44 g, 0.02 mol) in methylene chloride (100 mL) at 0° was added, portionwise as a solid, dicyclohexylcarbodiimide (4.12 g, 0.02 mol), and the reaction mixture was stirred at 0° for 30 minutes. To this reaction mixture was added, dropwise, heptylamine (2.96 mL, 2.3 g, 0.02 mol) and the reaction mixture was stirred at reflux for 72 hours. The reaction mixture was cooled, and the solids were filtered and washed with chloroform. The filtrate was concentrated under vacuum and the residue was chromatographed with a gradient of 7:3 to 1:1 hexane-ethyl acetate. The resulting solid was recrystallized from acetonitrile and triturated with hexane to give 8-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-heptyloctanamide (3.28 g, 0.0067 mol) as a white solid, mp 119-120°.  $^{1}$ H NMR (DMSO-d<sub>6</sub>)  $^{\delta}$  12.5(s,1H), 7.8-7.1(m,10H), 3.2-2.9(m,4H), 2.0(t,2H,J=7Hz), 1.75-1.0-(m,21H), 1.0-0.8(m,3H).

Part B. To a solution of lithium aluminum hydride (0.96 g, 0.025 mol) in dry tetrahydrofuran (30 mL) was added, dropwise, a solution of 8-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-heptyloctanamide (2.82 g, 0.0057 mol) in tetrahydrofuran (15 mL) and the reaction mixture was stirred at reflux for 18 hours. The reaction mixture was cooled to 0°, quenched by the slow and careful sequential addition of water (0.96 mL), 15% sodium hydroxide (2.88 mL), and water (2.88 mL), and then stirred at 0° for 30 minutes. The solution was then dried over magnesium sulfate and concentrated, and the residue was chromatographed with 1:1 hexane:ethyl acetate and then with a gradient of 1:0 to 3:1 to 1:1 ethyl acetate-methanol to give 8-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-heptyl-1-octanamine (1.07 g, 0.0022 mol) as a white solid, mp 87-89°. <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  7.6-7.2(m,11H), 3.1(t,2H,J=7Hz), 2.7-2.5(m,2H), 1.8-1.1(m,25H), 0.9-(t,3H,J=8Hz).

Part C. To a solution of 8-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-heptyl-1-octanamine (0.5 g, 0.001 mol) in hexane (25 mL) was added, dropwise, a solution of 2,4-difluorophenylisocyanate (0.15 mL, 0.194 g, 0.00125 mol) in hexane (10 mL), and the reaction mixture was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated under vacuum and the residue was chromatographed using 8:2 hexane-ethyl acetate to give a solid which was triturated with cold ethyl acetate and then hexane to give the title compound (0.18 g, 0.00028 mol) as a white solid, mp 89-91 °. ¹H NMR (DMSO-d<sub>6</sub>)  $\delta$  12.5(s,1H)-,7.9(s,1H), 7.5-7.1(m,10H), 3.3-3.1(m,5H), 1.8-1.2(m,17H), 0.9(t,3H,J=8Hz).

#### **EXAMPLE 4**

5

10

15

20

25

30

35

40

45

50

55

#### Preparation of N-butyl-N'-(2,4-difluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]urea

Part A. To a solution of 8-(4,5-diphenyl-1H-imidazol-2-ylthio)octanoic acid (4.4 g, 0.0125 mol) in methylene chloride (65 mL) at 0° was added, portionwise as a solid, dicyclohexylcarbodiimide (2.3 g, 0.011 mol) and the reaction mixture was stirred at 0° for 30 minutes. To this reaction mixture was added, dropwise, a solution of butylamine (1.24 mL, 0.92 g, 0.012 mol) in methylene chloride (15 mL) and the reaction mixture was stirred at reflux for 18 hours. The reaction mixture was cooled, and solids were filtered and washed with methylene chloride. The filtrate was concentrated under vacuum and the residue was chromatographed with a gradient of 7:3 to 1:1 hexane-ethyl acetate. The resulting solid was recrystallized from acetonitrile and triturated with hexane to give N-butyl-8-(4,5-diphenyl-1H-imidazol-2-ylthio)octanamide (1.43 g, 0.003 mol) as a white solid, mp 136-137°. ¹H NMR (DMSO-d<sub>6</sub>)  $\delta$  12.5(s,1H), 7.8-7.7(m,1H), 7.7-7.1(m,10H), 3.2-2.9(m,4H), 2.0(t,2H,J=7Hz), 1.8-1.1(m,14H), 0.9(t,3H,J=8Hz). Part B. To a solution of lithium aluminum hydride (0.46 g, 0.012 mol) in dry tetrahydrofuran (15 mL) was added, dropwise, a solution of N-butyl-8-(4,5-diphenyl-1H-imidazol-2-ylthio)octanamide(1.20 g, 0.0027

added, dropwise, a solution of lithium aluminum hydrode (0.46 g, 0.012 mol) in dry tetrahydrofuran (15 mL) was added, dropwise, a solution of N-butyl-8-(4,5-diphenyl-1H-imidazol-2-ylthio)octanamide(1.20 g, 0.0027 mol) in tetrahydrofuran (8 mL) and the reaction mixture was stirred at reflux for 18 hours. The reaction mixture was cooled to 0 °C and quenched by the slow and careful sequential addition of water (0.46 mL), 15% sodium hydroxide (1.38 mL), and water (1.38 mL) and then the reaction mixture was stirred at 0 ° for 30 minutes. The solution was dried over magnesium sulfate and concentrated under vacuum, and the residue was chromatographed with 1:1 hexane-ethyl acetate and then with a gradient of 1:0 to 8:2 to 1:1 ethyl acetate-methanol. The resulting solid was triturated with hexane to give N-butyl-8-(4,5-diphenyl-1H-imidazol-2-ylthio)octanamine (0.45 g, 0.001 mol) as a white solid, mp 75-78 °.  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  7.6-7.1-(m,10H), 3.1(t,2H,J=7Hz), 2.5(t,2H,J=7Hz), 1.7-1.0(m,16H), 0.9(t,3H,J=8Hz).

Part C. To a solution of N-butyl-8-(4,5-diphenyl-1H-imidazol-2-ylthio)octanamine (0.2 g, 0.00045 mol) in hexane (15 mL) was added, dropwise, a solution of 2,4-difluorophenylisocyanate (0.065 mL, 0.085 g, 0.00055 mol) in hexane (5 mL) and the reaction mixture was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated under vacuum and the residue was chromatographed with 7:3 hexane-ethyl acetate and the resulting solid was recrystallized from acetonitrile and triturated with hexane to give the title compound (0.138 g, 0.00023 mol) as a white solid, mp 114-115°. <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  8.1-7.9(m,1H), 7.6-7.2(m,11H), 6.95-6.75(m,2H), 6.5-6.4(m,1H), 3.4-3.1(m,6H), 1.8-1.3(m,16H), 1.0-(t,3H,J=8Hz).

#### **EXAMPLE 5**

#### Preparation of N'-(2,4-dimethoxyphenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea

To a solution of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanamine (0.75 g, 0.0017 mol), prepared according to the procedure of Example 1, Part D, in hexane (40 mL) was added, dropwise, a solution of 2,4-dimethoxyphenylisocyanate (0.358 g, 0.002 mol) in hexane (20 mL) and the reaction mixture

was stirred at ambient temperature for 4.5 hours. The reaction mixture was concentrated under vacuum and the residue was chromatographed with 7:3 hexane-ethyl acetate. The resulting solid was triturated with hexane to give the title compound (0.83 g, 0.0014 mol) as a glassy solid.  $^1H$  NMR (CDCl<sub>3</sub>)  $\delta$  7.7-7.1(m,10H), 6.8-6.1(m,3H), 3.8(s,3H), 3.7(s,3H), 3.45(s,1H), 3.4-3.3(m,2H), 3.2(t,2H,J=7Hz), 3.0(t,2H,J=7Hz), 1.8-1.1-(m,16H), 0.9(t,3H,J=8Hz).

#### **EXAMPLE 6**

10

#### Preparation of N'-(2,4-difluorophenyl)-N-heptyl-N-[5-(1-methyl-4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]urea

To a solution of potassium carbonate (0.056 g, 0.00042 mol) in dry tetrahydrofuran (10 mL) was added, portionwise as a solid, N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea (0.25 g, 0.00042 mol) and the reaction mixture was stirred at ambient temperature for 10 minutes. To this reaction mixture was added, dropwise, methyl iodide (0.039 mL, 0.0895 g, 0.00063 mol) and the reaction mixture was stirred for 18 hours at ambient temperature. The reaction mixture was then treated with N,N-dimethylformamide (1.0 mL) and methyl iodide (0.1 mL) and the reaction mixture was stirred at reflux for an additional 24 hours. The reaction mixture was cooled, poured into water and extracted with ethyl acetate. The combined organic extracts were dried over magnesium sulfate and concentrated under vacuum. The residue was chromatographed with 3:7 hexane-ethyl acetate to give the title compound (0.13 g, 0.00022 mol) as a yellow oil.  $^1$ H NMR (CDCl<sub>3</sub>)  $\delta$  8.1-8.0(m,1H), 7.5-7.1(m,10H), 6.9-6.7(m,2H), 6.4(s,1H), 3.5(s,3H), 3.4-3.2(m,5H), 1.9-1.2(m,17H), 0.9(t,3H,J=8Hz).

#### **EXAMPLE 7**

#### 5 Preparation of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-methylurea

To a solution of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanamine (0.30 g, 0.0007 mol) in hexane (15 mL) was added methylisocyanate (0.06 mL, 0.057 g, 0.001 mol) and the reaction mixture was stirred at ambient temperature for 18 hours. The reaction mixture was concentrated under vacuum and the residue was chromatographed with 1:1 hexane-ethyl acetate. The resulting oil was triturated with hexane to give the title compound (0.23 g, 0.00047 mol) as a white solid, mp 93-96°. <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  7.6-7.2-(m,11H), 4.35-2.7(m,9H), 1.9-1.2(m,16H), 0.9(t,3H,J=8Hz).

#### **EXAMPLE 8**

35

50

55

#### Preparation of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-propylurea

To a solution of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanamine (0.36 g, 0.0008 mol) in hexane (15 mL) was added propylisocyanate (0.094 mL, 0.085 g, 0.001 mol), and the reaction mixture was stirred at ambient temperature for 4 hours. The reaction mixture was then treated with additional propylisocyanate (0.094 mL, 0.085 g, 0.001 mol) and stirred at ambient temperature overnight and then at reflux for 72 hours. The reaction mixture was concentrated under vacuum and the residue was chromatographed using 2:8 hexane-ethyl acetate. The resulting oil was triturated with hexane to give the title compound (0.8 g, 0.00015 mol) as a white solid, mp 78-80°. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.6-7.2(m,10H), 4.4-(t,1H,J=7Hz), 3.4-2.9(m,8H), 1.9-1.1(m,19H), 1.0-0.75(m,6H).

#### **EXAMPLE 9**

#### Preparation of N'-(2,4-difluorophenyl)-N-[2-(4,5-diphenyl-1H-imidazol-2-ylthio)ethyl]-N-propylurea

Part A. To a solution of bromoacetylchloride (25.51 mL, 48.67 g, 0.31 mol) in methylene chloride (200 mL) at -15° was added, dropwise, a solution of propylamine (24,62 mL, 17.7 g, 0.3 mol) in methylene chloride (100 mL) and the reaction mixture was stirred at 0° for 30 minutes and then stirred at ambient temperature for 30 minutes. The reaction mixture was poured into water and then extracted with methylene chloride. The combined organic extracts were dried over magnesium sulfate and concentrated under vacuum. The residue was distilled to give bromo-N-propylacetamide as a clear liquid, bp 138-142°.  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  7.1(s,1H), 3.9(d,2H,J = 6Hz), 3.3(m,2H), 1.6(m,2H), 0.9(t,3H,J = 7Hz).

Part B. A portion of sodium hydride, 60% in mineral oil (0.4 g, 0.01 mol), was washed twice with hexane (10 mL) and the hexane was replaced with N,N-dimethylformamide (100 mL). To this solution was added, portionwise as a solid, sodium iodide (0.4 g, 0.003 mol) and then, dropwise, a solution of diphenylimidazole (2.52 g, 0.01 mol) in N,N-dimethylformamide (10 mL) followed by the dropwise addition of a solution of bromo-N-propylacetamide (1.80 g, 0.01 mol) in N,N-dimethylformamide (10 mL). The reaction mixture was stirred at reflux for 18 hours, then cooled and poured, carefully, into ice water, and then extracted with ethyl acetate. The combined organic extracts were backwashed with brine, dried over magnesium sulfate and concentrated under vacuum. The residue was chromatographed using 1:1 hexane-ethyl acetate and the resulting solid was recrystallized from acetonitrile to give 2-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-propylacetamide as a white solid, mp 183-185°. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 12.6-(s,1H), 8.3(s,1H), 7.5-7.1(m,10H), 3.8(s,2H), 3.0(q,2H,J=7.5Hz), 1.4(sextet, 2H,J=9Hz), 0.8(t,3H,J=6Hz). Part C. Employing the method of Example 1, Part D, but using 2-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-propylacetamide, N-[2-(4,5-diphenyl-1H-imidazol-2-ylthio)ethyl]-1-propanamine (0.28 g, 0.00083 mol) was obtained as an oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.9-7.6(m,2H), 7.5-7.1(m,10H), 3.1(s,4H), 2.6(t,2H,J=6Hz), 1.4-(sextet, 2H,J=12Hz), 0.8(t,3H,J=9Hz).

Part D. Employing the method of Example 1, Part E, but using N-[2-(4,5-diphenyl-1H-imidazol-2-ylthio)-ethyl]-1-propanamine, the title compound (0.20 g, 0.00045 mol) was obtained as a white solid, mp 189-190°. <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  11.6-11.2(s,1H), 7.8-7.6(s,1H), 7.6-6.9(m,10H), 6.8-6.6(m,2H), 3.8(t,2H,J=7Hz), 3.4(t,2H,J=6.5Hz), 3.2(t,2H,J=6Hz), 1.8-1.6(m,4H), 1.0(t,3H,J=7.5Hz).

**EXAMPLE 118** 

5

10

15

20

25

30

35

40

45

50

55

Preparation of N-[5-(4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]-pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea

Part A. A solution of  $\gamma$ -valerolactone (25.0 g, 0.249 mol) in toluene (50 mL) and n-heptylamine (35.96 g, 0.312 mol) was heated to reflux for 18 hours under a nitrogen atmosphere. The reaction mixture was allowed to cool to ambient temperature, diluted with ethyl acetate (300 mL), washed with 1 N aqueous HCl (50 mL), water, brine, dried over magnesium sulfate and concentrated to give a white solid. The product was crystallized from ethyl ether:hexane to give N-heptyl-5-hydroxypentanamide (41.8 g, 0.194 mol) as white plates, mp 55-6°. ¹H NMR (CDCl<sub>3</sub>)  $\delta$  6.06(bs,1H), 3.61(t,2H), 3.24(q,2H), 3.19(bs,1H), 2.19-(t,2H), 1.80-1.23(m,14H), 0.866(t,3H).

Part B. To a solution of lithium aluminum hydride (6.7 g, 0.176 mol) in dry tetrahydrofuran (300 mL), a solution of N-heptyl-5-hydroxypentanamide (19.0 g, 0.088 mol) in dry tetrahydrofuran (100 mL) under a nitrogen atmosphere was added dropwise. The reaction mixture was heated to reflux for 18 hours, allowed to cool to room temperature and was poured slowly into a stirred mixture of 10% agueous sodium sulfate (400 mL) and ice (200 mL). The resulting slurry was filtered through a bed of Celite® and the filtrate was extracted with ethyl acetate (2 x 500 mL). The combined organic layer was washed with water, brine, dried over magnesium sulfate and concentrated to give a viscous yellow oil. The product was crystallized from hexane to give N-(5-hydroxypentyl)-N-heptylamine (15.2 g, 0.075 mol) as a white powder, mp 47-8°. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.63(t,2H), 2.63(q,4H), 2.39(bs,2H), 1.66-1.24(m,16H), 0.905(t,3H). Part C. To a solution of N-(5-hydroxypentyl)-N-heptylamine (11.65 g, 0.0578 mol) in methylene chloride (75 mL) under a nitrogen atmosphere cooled to  $0^{\circ}$ , 2,4-difluorophenylisocyanate (8.97 g, 0.0578 mol) was added slowly. The reaction mixture was stirred for 1 hour, poured into 1 N aqueous HCl (200 mL) and was extracted with ethyl acetate (300 mL). The combined organic layer was washed with water, brine, dried over magnesium sulfate and was concentrated to give N'-(2,4-difluorophenyl)-N-heptyl-N-5hydroxypentylurea as a pale yellow oil (20.0 g, 0.056 mol). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.03 (m,1H), 6.88-6.59-(m,2H), 6.45(bs,1H), 3.68(t,2H), 3.33(m,4H), 1.81-1.22(m,16H), 0.907(t,3H).

Part D. To a solution of N'-(2,4-difluorophenyl)-N-heptyl-N-5-hydroxypentylurea (15.0 g, 0.042 mol) and carbon tetrabromide (16.75 g, 0.051 mol) in methylene chloride (350 mL) under a nitrogen atmosphere at ambient temperature, a solution of triphenylphosphine (13.24 g, 0.051 mol) in methylene chloride (100 mL) was added slowly. The reaction mixture stirred for 3 hours and was concentrated in vacuo to give crude viscous oil. The product was purified by flash chromatography on silica gel (400 mL) eluting with hexane:ethyl acetate (90:10 v:v) to give N-(5-bromopentyl)-N'-(2,4-difluorophenyl)-N-heptylurea as a viscous colorless oil (17.5 g, 0.042 mol).  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  8.14-8.00(m,1H), 6.92-6.79(m,2H), 6.35-(bs,1H), 3.49-3.25(m,6H), 1.99-1.26(m,16H), 0.915(t,3H).

Part E. To a suspension of sodium hydride (0.88 g, 60% mineral oil dispersion, 0.0022 mol) (washed free of mineral oil with hexane) in N,N-dimethylformamide (15 mL) under a nitrogen atmosphere, cooled to

 $0^{\circ}$ , a solution of 4,5-[bis-(4-methoxyphenyl)-1H-imidazol]-2-thione (0.63 g, 0.002 mol) in N,N-dimethylformamide (5 mL) was added slowly. The reaction mixture was stirred for 2 hours and then a solution of N-(5-bromopentyl)-N'-(2,4-difluorophenyl)-N-heptylurea (0.845 g, 0.002 mol) in N,N-dimethylformamide (3 mL) was added. The reaction mixture was allowed to warm to ambient temperature, stirred an additional 2 hours, poured into water (50 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic extracts were washed with water, brine, dried over magnesium sulfate and concentrated to give a viscous oil. The product was purified by flash chromatography on silica gel (100 mL) eluting with hexane:ethyl acetate (70:30 v:v) to give the title compound as a pure yellow foam (0.98 g, 0.0015 mol). <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  10.15(bs,1H), 7.87-7.76(m,1H), 7.51(d,2H), 7.3(d,2H), 6.86-6.6(m,6H), 6.42(d,1H), 3.8(s, 6H), 3.4(t,2H), 3.26(t,2H), 2.99(t,2H), 1.84-1.25(m,16H), 0.89(t,3H).

#### **EXAMPLE 191**

5

10

15

20

25

30

50

#### Preparation of N-(2,4-difluorophenyl)-N'-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]urea

Part A. A mixture of 5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentanoic acid (4.0 g, 0.011 mol) and urea (1.36 g, 0.023 mol) was heated to 179-180° for 5 hours. The cooled reaction mixture was partitioned in sodium carbonate (5%) and extracted with chloroform. The organic layers were washed with saturated sodium chloride solution then dried over magnesium sulfate and concentrated under vacuum. The residue was chromatographed with 9:1 ethyl acetate-methanol to give 5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentanamide (0.73 g, 0.002 mol) as a white solid, mp 136-138°.  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  10.65(s,1H), 7.7-7.2-(m,10H), 5.9(s,1H), 5.4(s,1H), 3.0(t,2H,J=7.4Hz), 2.3(t,2H,J=8Hz), 2.0-1.6(m,4H).

Part B. Employing the method of Example 1, Part D, using 5-(4,5-diphenyl-1H-imidazol-2-ylthio)-pentanamide (2.0 g, 0.0057 mol), 5-(4,5-diphenyl-1H-imidazol-2-ylthio)-1-pentanamine (0.32 g, 0.00095 mol) was obtained as a tan solid, mp 111-113 $^{\circ}$ . <sup>1</sup>H NMR (DMSO-d<sub>6</sub>)  $\delta$  7.5-7.2(m,12H), 3.1-(t,2H,J=7.2Hz), 2.5(t,2H,J=6.2Hz), 1.8-1.3(m,7H).

Part C. A solution of 5-(4,5-diphenyl-1H-imidazol-2-ylthio)-1-pentanamine (0.34 g, 0.001 mol) and 2,4-difluorophenylisocyanate (0.24 mL, 0.31 g, 0.002 mol) in toluene (10 mL) was stirred at ambient temperature for 120 hours. The solution was concentrated under vacuum to give a residue (0.53 g) which was chromatographed with 1:1 hexane-ethyl acetate. The resulting solid was triturated with cold acetonitrile to give the title compound (0.13 g, 0.0026 mol) as a white solid, mp 187-198°. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>)  $\delta$  12.5(s,1H), 8.2-8.0(m,2H), 7.5-7.1(m,11H), 7.0-6.9(m,1H), 6.6-6.5(m,1H), 3.2-3.0(m,4H), 1.8-1.3(m,6H).

#### 5 EXAMPLE 207

### Preparation of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-octyl-N-phenylurea

To a solution of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]benzeneamine (0.41 g, 0.001 mol) in toluene (25 mL) was added n-octylisocyanate (0.23 g, 0.0015 mol). The reaction mixture was stirred at reflux for 18 hours and then the solvent was removed under vacuum. The residue (1.0 g) was chromatographed with 7:3 hexane-ethyl acetate. The resulting solid was triturated with hexane to give the title compound (0.32 g, 0.00056 mol) as a white solid, mp 74-76°. <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  11.8(s,1H), 7.75-7.1- (m,15H), 4.3(t,1H,J=6.0Hz), 3.8(t,2H,J=7.0Hz), 3.0(quintet,4H,J=6.0Hz), 1.9-0.90(m,18H), 0.8- (t,3H,J=7.0Hz).

#### **EXAMPLE 209**

# Preparation of N-[5-[4,5-bis(4-hydroxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea

To a stirred solution of N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea (0.78 g, 0.0012 mol) in methylene chloride (30 mL) cooled to -78 $^{\circ}$  under a nitrogen atmosphere, 1M boron tribromide in methylene chloride (3.6 mL) was added. The reaction mixture stirred for 1 hour at 0 $^{\circ}$ , was poured over ice (100 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic layer was washed with 10% aqueous NaHCO $_{3}$  (50 mL), water, brine, dried over magnesium sulfate, and concentrated in vacuo to give the crude oil. The product was purified by flash chromatography on silica gel (100 mL) eluting with hexane:ethyl acetate (40:60 v:v) to give a white foam,

mp 110-12° (0.5 g, 0.00008 mol). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>)  $\delta$  12.22 (bs,1H), 9.55(bs,1H), 9.32(bs,1H), 7.92(s,1H), 7.45-6.6(m,11H), 3.24(m,4H), 3.06(t,2H), 1.77-1.17(m,16H), 0.88(t,3H).

#### **EXAMPLE 211**

5

10

15

20

25

30

35

40

45

50

Part A. To a suspension of sodium hydride (washed free of mineral oil with hexane) (2.45 g, 80% oil dispersion, 0.081 mol) in dry N,N-dimethylformamide (50 mL) under a nitrogen atmosphere, cooled to 0°, a solution of salisaldehyde (10.0 g, 81.9 mmol) in dry N,N-dimethylformamide (10 mL) was added slowly. The reaction mixture was stirred at 0° for 2 hours and diiodomethane (11.3 g, 0.041 mol) was added. The reaction mixture was allowed to warm to ambient temperature for 18 hours and then was warmed to 60° for 20 hours. The reaction was allowed to cool to ambient temperature, poured into 1 N aqueous HCl (100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic extract was washed with water, brine, dried over magnesium sulfate and concentrated to give a solid. The product was purified by flash chromatography on silica gel (300 mL) eluting with methylene chloride (100%) to give 2,2'-(methylenedioxy)-bis-(2-benzaldehyde) as a white crystalline solid, mp 131 to 3° (5.1 g, 0.0199 mol).  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  10.47(s, 2H), 7.87(d,2H), 7.68-7.54(m,2H), 7.21(d,2H), 7.15(t,2H), 6.02(s, 2H).

Part B. A mixture of 2,2'-(methylenedioxy)-bis-(2-benzaldehyde) (5.0 g, 0.0195 mol), potassium cyanide (0.63 g, 0.0975 mol) in ethanol (75 mL) and water (50 mL) was heated to reflux for 6 hours. The reaction mixture was allowed to cool to ambient temperature, was concentrated in vacuo and the resultant aqueous residue was partitioned between ethyl acetate and water. The organic layer was washed with water, brine, dried over magnesium sulfate and concentrated to give a viscous oil. The product was purified by flash chromatography on silica gel (250 mL) eluting with hexane:ethyl acetate (80:20 v:v) to give 13-hydroxy-dibenzo[d,h][1,3]-dioxonino-12(13H)-one as a crystalline solid, mp 129-30° (2.5 g, 0.0975 mol). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>)  $\delta$  7.49(t,2H), 7.29-7.08(m,6H), 6.40(d,1H), 5.97(d,1H), 5.92(d,1H), 5.24-(d,1H).

Part C. A solution of 13-hydroxy-dibenzo[d,h][1,3]-dioxonino-12(13H)-one (2.0 g, 0.0078 mol), thiourea  $(0.82~\rm g, 0.0108~\rm mol)$  and hexanol (25 mL), equipped with a column of 4°A sieves and a condenser, was heated to 160° for 20 hours under a nitrogen atmosphere. The reaction mixture was allowed to cool to ambient temperature and was diluted with ethyl ether (100 mL) to give a solid. The solid was washed with ethyl ether and dried to give N-(1H,9H-dibenz-[4,5:8,9][1,3]dioxonino-[6,7-d]imidazol)-2-thione as a white crystalline powder (1.6 g, 0.00539 mol), mp >250°. ¹H NMR (DMSO-d<sub>6</sub>)  $\delta$  12.5(s,2H), 7.43-7.08-(m,8H), 6.2-5.0(bd,2H).

Part D. Employing the method of Example 118, Part E, but using N-(1H,9H-dibenz-[4,5:8,9][1,3]-dioxonino-[6,7-d]imidazol)-2-thione, the title compound was isolated as a white foam, mp 65-70 ° (0.85 g, 0.00134 mol).  $^1H$  NMR (CDCl<sub>3</sub>)  $\delta$  10.35-10.10(bs,1H), 7.56(m,1H), 7.30-6.95(m,10H), 6.4(d,1H), 5.70-5.20-(bs,2H), 3.40-3.19(m,4H), 3.08(t,2H), 1.85-1.23(m,16H), 0.88(t,3H).

### **EXAMPLE 212**

 $\frac{\text{Preparation of N'-[5-(1H-dibenz[2,3:6,7]oxedino[4,5-d]imidazol-2-ylthio)pentyl]-N-(2,4-difluorophenyl)-N-hep-tylurea}{\text{tylurea}}$ 

Employing the method of Example 118, Part E, but using 1H-dibenz[2,3:6,7]oxedino[4,5-d]imidazol)-2-thione, the title compound was isolated as a white powder, mp 82-7 $^{\circ}$  (0.36 g, 0.00059 mol). <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  9.75-8.5(bs, 2H), 7.84-7.59(m,3H), 7.43-7.05(m,6H), 5.13-6.53(m,3H), 3.43-3.13(m,6H), 1.75-1.20-(m,16H), 0.88(t,3H).

Additional ureas, which are listed in Tables 1 and 2, were prepared or could be prepared analogously according to the procedures listed above.

5 10		9a N (HC) - 8			n R <sup>6</sup> mp°C	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub> amorphous solid	8 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub> 89-91	8 (CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub> 114-115	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub> glassy solid	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub> oil	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub> 93-96	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub> 78-80	2 (CH <sub>2</sub> ) <sub>2</sub> CH <sub>3</sub> 189-190	10 (CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	5 CH2CH3	3 (СН2)8СН3
20	Table 1	ξ. Σ.	-6 - -√ -√ -√ -√ -√ -√		R4	2,4-diFC <sub>6</sub> H <sub>3</sub>	C6H5	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diCH3OC6H3	2,4-diFC <sub>6</sub> H <sub>3</sub>	CH <sub>3</sub>	n-C <sub>3</sub> H <sub>7</sub>			2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>
30					Ex. $\frac{10.81}{10.82}$ $\frac{10.82}{10.82}$	1 С6И5 С6И5 И	2 C6H5 C6H5 H	3 C6H5 C6H5 H	4 C6H5 C6H5 H	5 C6H5 C6H5 H	6 C6H5 C6H5 CH3	7 C6H5 C6H5 H	8 С6И5 С6И5 И	9 C6H5 C6H5 H	10 С6Н5 С6Н5 Н	11 С6Н5 С6Н5 Н	12 С6Н5 С6Н5 Н
35 40				:	Ü N												
<b>4</b> 5																	

5	inued)		n R <sup>6</sup> mp°C	3 (CH <sub>2</sub> ) <sub>10</sub> CH <sub>3</sub>	10	∞	S	5	5 (	5 (	5 (	∞	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	2	5 (СН <sub>2</sub> ) <sub>6</sub> СН <sub>3</sub>	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	5 (СН2) 6СН3	5 (СН2) 6СН3	5 (СН <sub>2</sub> ) <sub>6</sub> СН <sub>3</sub>	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	8 (СН2)3СН3
15	Table 1 (continued)		R 4	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	$2,4-diFC_6H_3$	2,4-diFC6H3	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diFC <sub>6</sub> H3	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diFC <sub>6</sub> H3	$2,4$ -diFC $_6$ H $_3$	2,4-diFC <sub>6</sub> H3	2,4-diFC <sub>6</sub> H3	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	$2,4-diFC_6H_3$	2,4-diFC <sub>6</sub> H <sub>3</sub>	3-FC6H4	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>
25	<b>L</b>		$\frac{R^2}{R}$ R <sup>3</sup>	С645 Н	сенз н	C6H5 CH3	C6H5 n-C3H7	C6H5 n-C6H13	C6H5 CH2CH=CH2	C6H5 CH2C6H5	C6H5 C6H5	C6H5 C6H5	C6H5 4-FC6H4	C6H5 4-CH3C6H4	C6H5 4-CH30C6H4	C6H5 4-CF3C6H4	C6H5 4-C1C6H4	C6H5 3-FC6H4	C6H5 2-FC6H4	С6Н5 3-СН30С6Н4	С6И5 3-СИ30С6И4	C6H5 2-CF3C6H4	C6H5 4-FC6H4
30		Ex.	No. R1	13 C <sub>6</sub> H <sub>5</sub>	14 C6H5	15 C <sub>6</sub> H <sub>5</sub> (	16 C6H5	17 C6H5	18 C <sub>6</sub> H <sub>5</sub> (	19 C <sub>6</sub> H <sub>5</sub> (		21 C <sub>6</sub> H <sub>5</sub> (	22 C <sub>6</sub> H <sub>5</sub> (	23 C <sub>6</sub> H <sub>5</sub> (	24 C6H5 (	25 C <sub>6</sub> H <sub>5</sub> (	26 C <sub>6</sub> H <sub>5</sub> (	27 C <sub>6</sub> H <sub>5</sub> (	28 C <sub>6</sub> H <sub>5</sub> (	29 C <sub>6</sub> H <sub>5</sub> (	30 C <sub>6</sub> H <sub>5</sub> (	31 C <sub>6</sub> H <sub>5</sub> (	32 C <sub>6</sub> H <sub>5</sub> (
35																							
40 45																							
50																							
55																							

																				126			
5			) du																	124-126			
10			<u>જ</u> ી	(CH2)3CH3	(CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	(CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	(CH <sub>2</sub> ) <sub>5</sub> CH <sub>3</sub>	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH <sub>2</sub> )6CH <sub>3</sub>	(CH <sub>2</sub> )6CH <sub>3</sub>	(CH2)6CH3	(сн2)есн3	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	(СН2) 6СН3	(сн2) есн3	(сн2)есн3	(сн2) есн3	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH2)6CH3
			⊏I	∞	∞	∞	2	ω	2	2	2	ည	2	ß	4 5	2	2	Ŋ	2	S	S	Ŋ	2
15	Table 1 (continued)		R4	2,4-diFC <sub>6</sub> H3	2,4-diFC <sub>6</sub> H3	2,4-diFC <sub>6</sub> H3	CeHs	2-CF3C6H4	3-CF3C6H4	4-CF3C6H4	2-CH3C6H4	3-CH3C6H4	4-CH3C6H4	3-C2H5C6H4	3-(CH3)2CHC6H4	2-BrC <sub>6</sub> H4	3-BrC <sub>6</sub> H4	4-BrC <sub>6</sub> H4	2-FC <sub>6</sub> H4	3-FC <sub>6</sub> H4	4-FC <sub>6</sub> H4	3-C1C <sub>6</sub> H4	4-n-C4H9C6H4
20 25	Table		<sub>R</sub> 3	2-FC6H4		4-CH30C6H4	4-CH30C6H4													_	_		
30			$\frac{R^1}{R^2}$ R	C6H5 C6H5 2	C6H5	$C_{6}H_{5}$	C <sub>6</sub> H <sub>5</sub>	CeH5 CeH5 H	645 C645 H	645 C645 H	645 C645 H	645 C645 H	645 C645 H	645 C645 H	645 C645 H	6 <sup>H</sup> 5 C <sub>6</sub> H5 H	6H5 C6H5 H	6H5 C6H5 H	C6H5 C6H5 H	C6H5 C6H5 H	C6H5 C6H5 H	55 C6H5 C6H5 H	6H5 C6H5 H
35		E.	No.	33 C	34 C	35 C	36 C	37 C	38 C	39 C	40 C	41 C	42 C	43 C	44 C	45 C	20 05	51 C	25 C	53 C	54 C	25 C	56 C <sub>6</sub> H <sub>5</sub>
40																							
<b>4</b> 5																							
50																							
55																							

			J. dw								90-92	•						78-80					
5			<mark>8</mark> 6	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(сн2) есн3	(сн2)есн3	(сн2)есн3	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	$(CH_2)_6 CH_3$	$(CH_2)_6CH_3$	(CH2)6CH3	(CH2)6CH3	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$
10			⊏l	Ŋ	2	2	Ŋ	ည	r,	2	Ŋ	വ	2	2	2	Ŋ	ស	2	Ŋ	ည	5	2	S
15	ntinued)		R4	-CH30C <sub>6</sub> H4	4-CH3CH202CC6H4	2,3-diCH <sub>3</sub> C <sub>6</sub> H <sub>3</sub>	2,5-diCH <sub>3</sub> C <sub>6</sub> H <sub>3</sub>	2,6-diCH <sub>3</sub> C <sub>6</sub> H <sub>3</sub>	2,4-diCH <sub>3</sub> C <sub>6</sub> H <sub>3</sub>	2,3-diClC <sub>6</sub> H <sub>3</sub>	liC1C <sub>6</sub> H <sub>3</sub>	2,4-diClC <sub>6</sub> H <sub>3</sub>	liC1C <sub>6</sub> H <sub>3</sub>	2,3-diFC <sub>6</sub> H <sub>3</sub>	2,5-diFC <sub>6</sub> H <sub>3</sub>	$2,4,6$ -triClC $_6$ H $_2$	$2,4,5$ -tri $C1C_6H_2$	2,4,6-triFC <sub>6</sub> H2	2,4,5-triFC <sub>6</sub> H2	3,4,5-triCH30C <sub>6</sub> H2	2,4,6-triCH3C6H2	4-C1,2-CH3C6H3	4-C1,2,5-diCH3C6H2
20	Table 1 (continued)		<b>&amp;</b> I	4-CH <sub>3</sub>	4-CH <sub>3</sub>	2,3-d	2,5-d	2,6-d	2,4-0	2,3-4	2,6-d	2,4-	2,5-0	2,3-0	2,5-0	2,4,6	2,4,5	2,4,6	2,4,5	3,4,5	2,4,6	4-C1,	4-C1,
25																							
30		•	$\frac{R_1}{2}$ $\frac{R_2}{2}$ $R_3$	7 C6H5 C6H5 H	58 C <sub>6</sub> H <sub>5</sub> C <sub>6</sub> H <sub>5</sub> H	59 C <sub>6</sub> H <sub>5</sub> C <sub>6</sub> H <sub>5</sub> H	60 C6H5 C6H5 H	61 C6H5 C6H5 H	62 C6H5 C6H5 H	63 C <sub>6</sub> H <sub>5</sub> C <sub>6</sub> H <sub>5</sub> H	64 C6H5 C6H5 H	65 C <sub>6</sub> H <sub>5</sub> C <sub>6</sub> H <sub>5</sub> H	66 C <sub>6</sub> H <sub>5</sub> C <sub>6</sub> H <sub>5</sub> H	67 С6Н5 С6Н5 Н	68 C <sub>6</sub> H <sub>5</sub> C <sub>6</sub> H <sub>5</sub> H	69 С6И5 С6И5 И	70 C6H5 C6H5 H	71 C6H5 C6H5 H	72 C6H5 C6H5 H	73 C6H5 C6H5 H	74 C6H5 C6H5 H	75 C6H5 C6H5 H	76 C6H5 C6H5 H
35		Ë	No.	2	iñ	ß	9	9	9	9	9	9	9	9	9	9	7	7	7	7	7	7	7
40																							
45																							
50																							
55																							

			J om									68-70									95-97		
5			R6	(сн2) есн3	(CH <sub>2</sub> )6CH <sub>3</sub>	(CH <sub>2</sub> )6CH <sub>3</sub>	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	(сн2) есн3	(сн2) есн3	$(CH_2)_6CH_3$		(CH2)6CH3	(CH <sub>2</sub> )6CH <sub>3</sub>	$(CH_2)_6CH_3$	(сн2) есн3	(сн2) есн3	(сн2)есн3	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	(сн2) 6СН3	(сн2) есн3	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>
10																							
				5	2 5	5	5	5	5	2	5	5	2	5	2	2	ა	S	2	2	5	2	2
15	tinued)			C6H3	йсн <sub>3</sub> с <sub>6</sub> н <sub>2</sub>	3C6H3	5H3	30C6H3	3C6H3	.6H3				14	-6H4		7	_	7	idinyl			
20	<u> Table 1</u> (continued)		R4	4-C1,3-CF3C6H3	4-C1,2,6-c	3-C1,4-CH3	3-C1,4-FC	5-C1,2-CH <sub>2</sub>	2-C1,5-CF3	4-F,2-CH3(	4-N02C6H4	4-CNC6H4	4-NH2C6H4	4-CH3NHC6H4	4-(CH3)2NC6H4	4-HOC6H4	2-pyridinyl	3-pyridinyl	4-pyridinyl	2,6-pyrimidiny	C6H11	C <sub>5</sub> H <sub>9</sub>	n-C6H13
25	T a																						
30			R <sup>2</sup> R <sup>3</sup>	C6H5 H	C6H5 H	C6H3 H	C6H5 H	C6H5 H	C <sub>6</sub> H <sub>5</sub> H	C <sub>6</sub> H <sub>5</sub> H	C6H5 H	C6H5 H	C645 H	C6H5 H	C6H5 H	С645 И	C <sub>6</sub> H <sub>5</sub> H	C <sub>6</sub> H <sub>5</sub> H	C6H5 H	C6H5 H	C6H5 H	C <sub>6</sub> H <sub>5</sub> H	C6H5 H
35		Ex.	No. R1	77 C6H5	78 C <sub>6</sub> H <sub>5</sub>	79 C6H5	80 C <sub>6</sub> H <sub>5</sub>	81 C <sub>6</sub> H <sub>5</sub>	82 C6H5	83 C6H5	84 C6H5	85 C <sub>6</sub> H <sub>5</sub>	86 C <sub>6</sub> H <sub>5</sub>	87 C <sub>6</sub> H <sub>5</sub>	88 C <sub>6</sub> H <sub>5</sub>	89 C6H5	90 C <sub>6</sub> H <sub>5</sub>	91 C <sub>6</sub> H <sub>5</sub>	92 C <sub>6</sub> H <sub>5</sub>	93 C <sub>6</sub> H <sub>5</sub>	94 C <sub>6</sub> H <sub>5</sub>	95 C <sub>6</sub> H <sub>5</sub>	96 C <sub>6</sub> H <sub>5</sub>
40																							
<b>4</b> 5																							
50																							
55																							

5			mp°C	oil(a)								84-86		oil(b)			75-80				82-84	,	
10			Re	$(CH_2)_6CH_3$	(CH2)6CH3	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	(CH2)6CH3	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	(CH2)6CH3	(CH2)6CH3
			디	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	æ	∞
15 20	Table 1 (continued)		R <sup>4</sup>	n-CgH17	n-C <sub>3</sub> H <sub>7</sub>	CF <sub>3</sub>	сн2сн=снсн3	сн2сн=сн2	сн2сн=снсн2сн3	сн2с≡ссн3	n-C4H9	сн(сн3)2	CF2CF3	2,4-diFC <sub>6</sub> H <sub>3</sub>	n-C <sub>3</sub> H <sub>7</sub>								
25	<u> </u>		<u>83</u>	<b>x</b>	=	Ŧ	Ŧ	=	<b>=</b>	I	Ξ	Ŧ	Ŧ	I	Ŧ	Ŧ	Ŧ	Ŧ	¥	×	Ŧ	<b>=</b>	Ŧ
30	Table		R2	C <sub>6</sub> H <sub>5</sub>	C6H5	C <sub>6</sub> H <sub>5</sub>	C6H5	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C6H5	C6H5	C <sub>6</sub> H <sub>5</sub>	2-pyridinyl	3-pyridinyl	4-pyridinyl	2-thienyl	С645СН2	C6H5(CH2)2	C6H5(CH2)5	4-FC6H4	4-FC <sub>6</sub> H4	4-FC6H4
35			립	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	100 С <sub>6</sub> Н5	101 C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	104 C <sub>6</sub> H <sub>5</sub>	105 C <sub>6</sub> H <sub>5</sub>	106 C <sub>6</sub> H <sub>5</sub>	2-pyridinyl	108 3-pyridinyl	4-pyridinyl	.10 2-thienyl	С6И5СИ2	12 C6H5(CH2)2	С645(СН2)5	14 4-FC <sub>6</sub> H4	15 4-FC <sub>6</sub> H <sub>4</sub>	116 4-FC <sub>6</sub> H4
40		Ŗ.	No.	46	98	66	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116
45																							
50																							
55																							

5			mp C		55-59				63-65(c)														
10			R6	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	(CH2)6CH3	(CH2)6CH3	(CH <sub>2</sub> )6CH <sub>3</sub>	$(CH_2)_6CH_3$	(CH <sub>2</sub> )6CH <sub>3</sub>	(CH <sub>2</sub> )6CH <sub>3</sub>	(CH <sub>2</sub> )6CH <sub>3</sub>	(CH <sub>2</sub> )6CH <sub>3</sub>	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)7CH3	(сн2)8сн3
			디	2	5	œ	œ	2	2	æ	œ	Ŋ	8	2	2	S	Ŋ	Ŋ	æ	œ	2	4	9
15	ed)		<b>+</b> (	2,4,6-triFC <sub>6</sub> H <sub>2</sub>	$2,4-diFC_6H_3$	$2,4-diFC_6H_3$		2,4,6-triFC <sub>6</sub> H <sub>2</sub>	2,4-diFC <sub>6</sub> H3	2,4-diFC <sub>6</sub> H <sub>3</sub>	_	2,4,6-triFC <sub>6</sub> H <sub>2</sub>		$2,4-diFC_6H_3$	$2,4-diFC_6H_3$	2,4-diFC <sub>6</sub> H3	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diCH30C <sub>6</sub> H3	2,4-diCH <sub>3</sub> C <sub>6</sub> H <sub>3</sub>	2,4,6-triFC <sub>6</sub> H <sub>2</sub>	4	,4,6-triFC <sub>6</sub> H <sub>2</sub>	2,4-diCH30C <sub>6</sub> H3
20	Table 1 (continued)		R3 R4	H 2,4,6	H 2,4-d	H 2,4-d	H n-C3H7	H 2,4,6	H 2,4-d	H 2,4-d	H n-C3H7	H 2,4,6	н снз	H 2,4-di	H 2,4-d	H 2,4-d	H 2,4-d	H 2,4-di	H 2,4-di	Н 2,4,6-	H 4-FC <sub>6</sub> H4	H 2,4,6-	H 2,4-di
25	Table 1				5H4	5H4	5H4	5H4	44	44	44	44	2NHC6H4	44	5 <b>H</b> 4	C644	2C6H4	•	er		44	=	et et
30			<u>8</u> 2	4-FC6H4	4-CH30C6H4	4-СН30С6Н4	4-CH30C6H4	4-СН30С6Н4	4-CH3C6H4	4-CH3C6H4	4-CH3C6H4	4-CH3C6H4	4-(CH3);	4-NO2C6H4	4-CH3SC6H4	4-CH <sub>3</sub> S0(	4-CH3S02C6H4	4-C1C6H4	4-BrC6H4	4-FC6H4	4-CF3C6H4	$2-C1C_6H_4$	3-C1C6H4
35			ఠ	17 4-FC <sub>6</sub> H4	.8 4-СН <sub>3</sub> 0С <sub>6</sub> Н4	19 4-СН30С6Н4	20 4-CH30C6H4	21 4-CH <sub>3</sub> 0C <sub>6</sub> H <sub>4</sub>	22 4-CH3C6H4	23 4-CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	24 4-CH3C6H4	25 4-CH3C <sub>6</sub> H4	26 4-(CH3)2NC6H4	27 4-NO <sub>2</sub> C <sub>6</sub> H4	28 C <sub>6</sub> H <sub>5</sub>	29 C <sub>6</sub> H <sub>5</sub>	30 C <sub>6</sub> H <sub>5</sub>	31 4-C1C <sub>6</sub> H4	32 4-BrC <sub>6</sub> H4	33 C <sub>6</sub> H <sub>5</sub>	34 4-CF3C6H4	35 2-C1C <sub>6</sub> H4	36 3-C1C <sub>6</sub> H4
40		×	ۏ	117	118	119	120	121	721	123	124	125	971	127	128	129	130	131	132	133	134	135	136
<b>4</b> 5		<b>.</b>		1			1	1	1	7	1	1	1	1	1	7	7	7	1			1	
50																							
55																							

5			J, dw	25-57 (d)																			
10			Re	(CH2)6CH3	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH <sub>2</sub> ) <sub>7</sub> CH <sub>3</sub>	(CH2)6CH3	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(сн2) есн3	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH <sub>2</sub> ) <sub>7</sub> CH <sub>3</sub>	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>
				5	5	5	9	2	2	8	8	ß	9	4	5	5	2	S	9	ß	2	œ	2
15 20	Table 1 (continued)		R4	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	n-C3H7	C6H11	2,4-diFC <sub>6</sub> H3	2,4-diFC <sub>6</sub> H3	n-C3H7	2,4,6-triFC <sub>6</sub> H <sub>2</sub>	2,4,6-triFC <sub>6</sub> H <sub>2</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	2,4-diCH30C6H3	2,4-diFC <sub>6</sub> H <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	2,4-diCH <sub>3</sub> C <sub>6</sub> H <sub>3</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>
	ا ا		<u>83</u>	<b>=</b>	Ŧ	I	I	Ŧ	x	I	I	Ŧ	=	I	<b>=</b>	<b>=</b>	x	Ŧ	I	I	I	I	I
25 30	Tab		R <sup>2</sup>	4-C1C <sub>6</sub> H <sub>4</sub>	3-C1C6H4	4-nC4H9C6H4	C <sub>6</sub> H <sub>5</sub>	3-pyridinyl	3-pyridinyl	3-pyridinyl	3-pyridinyl	3-pyridinyl	3-pyridinyl	2-thienyl	2-thienyl	2-thienyl	4-pyridinyl	4-pyridinyl	4-pyridinyl	2-pyridinyl	C <sub>6</sub> H <sub>5</sub>	4-FC6H4	C <sub>6</sub> H <sub>5</sub>
35		Ex.	No. R1	137 4-C1C6H4	138 4-FC <sub>6</sub> H <sub>4</sub>	139 4-nC4H9C6H4	140 3,4-diClC <sub>6</sub> H <sub>3</sub>	141 C <sub>6</sub> H <sub>5</sub>	142 C <sub>6</sub> H <sub>5</sub>	143 C <sub>6</sub> H <sub>5</sub>	144 C <sub>6</sub> H <sub>5</sub>	145 4-FC <sub>6</sub> H <sub>4</sub>	146 4-CH30C6H4	147 C <sub>6</sub> H <sub>5</sub>	148 4-FC6H4	149 4-CH30C6H4	150 C <sub>6</sub> H <sub>5</sub>	151 4-FC <sub>6</sub> H4	152 4-CH30C6H4	153 C <sub>6</sub> H <sub>5</sub>	154 3-F, 4-C1C6H3	155 4-CH30C6H4	156 4-FC <sub>6</sub> H4
40																							
<b>4</b> 5																							
55																							

		J. CHI				oil(e)																
5 10		9 <u>8</u>	(сн2)есн3	(СН2) 6СН3	(CH <sub>2</sub> ) <sub>5</sub> CH <sub>3</sub>	(CH2)6CH3	(CH2)6CH3	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH2)6CH3	(сн2)есн3	(сн2) 6сн3	(СН2) 6СН3	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(сн2)есн3	(сн2) 6сн3	(сн2) есн3	(сн2) есн3	(сн2)есн3	(CH <sub>2</sub> ) <sub>6</sub> СH <sub>3</sub>	(СН2) <mark>5СН</mark> 3
			2	œ	6	2	2	œ	5	2	œ	æ	2	ω	œ	œ	2	2	œ	2	7	6
15	Table 1 (continued)		2,4-diFC <sub>6</sub> H3	2,4-diCH30C6H5	C <sub>6</sub> H <sub>5</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diCH30C6H3	2,4-diFC <sub>6</sub> H <sub>3</sub>	n-C3H7	2,4-diFC <sub>6</sub> H3	.2,4-diFC <sub>6</sub> H3	C <sub>6</sub> H <sub>5</sub>	2,4-diFC <sub>6</sub> H3	2,4-diFC <sub>6</sub> H3	n-C <sub>3</sub> H <sub>7</sub>	$2,4-diCH_3OC_6H_3$	2,5-diClC <sub>6</sub> H <sub>3</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diFC <sub>6</sub> H3	2,4-diCH30C <sub>6</sub> H3	n-C3H7	n-C <sub>3</sub> H <sub>7</sub>
20	<u> </u>	2	I	I	=	×	×	Ŧ	×	I	I	I	<b>=</b>	=	Ŧ	I	Ŧ	Ŧ	Ŧ	Ŧ	I	Ŧ
25	<u> Tab</u>	R2	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>		±	<b>=</b>	I	Ŧ	I	<b>=</b>	<b>=</b>	CH <sub>3</sub>	CH <sub>3</sub>	CH <sub>3</sub>	CH <sub>3</sub>	CH <sub>3</sub>	n-C4H9	n-C4H9	n-C4H9	n-C4H9	n-C8H17
30					.6H3																	
35	Ĕ.	No. R1			159 3,4-diCH30C6H3	160 C <sub>6</sub> H <sub>5</sub>	161 C <sub>6</sub> H <sub>5</sub>	162 C <sub>6</sub> H <sub>5</sub>	163 C <sub>6</sub> H <sub>5</sub>	164 4-FC <sub>6</sub> H4	165 4-CH30C <sub>6</sub> H4	166 C <sub>6</sub> H <sub>5</sub>	167 C <sub>6</sub> H <sub>5</sub>	168 C <sub>6</sub> H <sub>5</sub>	169 C <sub>6</sub> H <sub>5</sub>	170 C <sub>6</sub> H <sub>5</sub>	171 4-FC6H4	172 C <sub>6</sub> H <sub>5</sub>	173 C <sub>6</sub> H <sub>5</sub>	174 C6H5	175 C <sub>6</sub> H <sub>5</sub>	176 C <sub>6</sub> H <sub>5</sub>
40																						
<b>4</b> 5																						
55																						

		•						
Ē.			aple	Table 1 (continued)				
No.	R1	R2	2	R4		Re	J. dw	
177	C <sub>6</sub> H <sub>5</sub>	n-C8H17	工	$2,4-\mathrm{diClC}_6\mathrm{H}_3$	4	(CH2)7CH3		
178	C6H5	C5H9	<b>=</b>	$2,4-diFC_6H_3$	æ	(CH2)6CH3		
179	C <sub>6</sub> H <sub>5</sub>	C5H9	=	2,4,5-triClC <sub>6</sub> H <sub>2</sub>	2 5	(CH2)6CH3		
180	4-CH30C6H4	C6H11	Ŧ	C6H5	5	(CH <sub>2</sub> )8CH <sub>3</sub>		
181	C <sub>6</sub> H <sub>5</sub>	C6H11-CH2	I	2,4-diFC <sub>6</sub> H <sub>3</sub>	S	(CH2)6CH3		
182	C <sub>6</sub> H <sub>5</sub>	C6H11-(CH2)2	=	$2,4-diFC_6H_3$	2	(CH2)6CH3		
183	CH <sub>3</sub>	CH <sub>3</sub>	Ξ	$2,4-diFC_6H_3$	2	(CH2)6CH3		
184	CH <sub>3</sub>	CH <sub>3</sub>	=	n-C <sub>3</sub> H <sub>7</sub>	æ	(CH2)6CH3		
185	n-C4Hg	n-C4Hg	Ξ	2,4,6-triFC <sub>6</sub> H <sub>2</sub>	80	(CH2)6CH3		
186	=	Ŧ	<b>=</b>	2,4-diFC <sub>6</sub> H <sub>3</sub>	2	(CH2)6CH3	oil(f)	
187	<b>=</b>	I	<b>=</b>	$2,4-diFC_6H_3$	<b>∞</b>	(CH2)6CH3		
188	(СН3)2СН	(сн3)5сн	=	$2,4-diFC_6H_3$	ა	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	91-93	
189	C <sub>6</sub> H <sub>5</sub>	C6H5	=	2,4-diFC <sub>6</sub> H <sub>3</sub>	2	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	144-146	
190	C <sub>6</sub> H <sub>5</sub>	C6H5	=	2,4-diFC <sub>6</sub> H <sub>3</sub>	5	(CH <sub>2</sub> ) <sub>2</sub> CH <sub>3</sub>	68-70	
191	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	<b>=</b>	2,4-diFC <sub>6</sub> H <sub>3</sub>	2	I	187-189	
192	C <sub>6</sub> H <sub>5</sub>	C6H5	=	$(C_6H_4)(C_6H_5)$	5	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	119-121	
193	снзсн2сн2	сн3сн2сн2	=	2,4-diFC <sub>6</sub> H <sub>3</sub>	5	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	78-80	
194	2-pyridinyl	2-pyridinyl	<b>=</b>	$2,4-diFC_6H_3$	2	$(CH_2)_6CH_3$	80-83 (HCl salt)	salt)
195	3-CH30C6H4	$3-CH_30C_6H_4$	=	$2,4-diFC_6H_3$	သ	(CH2)6CH3	100-102	
196	2-CH30C6H4	2-CH30C6H4	I	$2,4-diFC_6H_3$	2	(CH2)6CH3	(b)	

50		40 45	35	30	25	20	15	10	5
					Table 1 (continued)	ned)			
	Ë.								
	No.	RI	R <sup>2</sup>	2	R4	n R6		J. dw	
	197	4-(CH3)2NC6H4	4-(CH3)2NC6H4	Ŧ	2,4-diFC6H3	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	6СН3	(h) 02-89	
	198	4-(CH3)2NC6H4	4-(CH3)2NC6H4	Ŧ	2,4-diFC6H3	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	6CH <sub>3</sub>	142-145 (HC	salt)
	199 (	C6H11	C6H11		2,4-diFC6H3	5 (CH <sub>2</sub> )	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	55-58(i)	•
	200	C6H5	4-(CH3)2NC6H4		2,4-diFC <sub>6</sub> H <sub>3</sub>	5 (CH <sub>2</sub> )	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	oi1(j)	
	201	2-furanyl	2-furanyl		2,4-diFC <sub>6</sub> H <sub>3</sub>	5 (CH <sub>2</sub> )	(CH2)6CH3	liq(k)	
	202	4-CH306H4	4-CH30C <sub>6</sub> H4		CH <sub>2</sub> (CH <sub>3</sub> ) <sub>2</sub>	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	6СН3	011(1)	
	203	4-(t-C4H9)C6H4	4-(t-C4H9)C6H4		2,4-diFC <sub>6</sub> H <sub>3</sub>	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	6СН3	78-80 (m)	
	204	4-CH30C6H4	4-CH30C <sub>6</sub> H4		2,4-diFC <sub>6</sub> H <sub>3</sub>	5 CH <sub>3</sub>		65-75 (n)	
	202	4-(CH3)2NC6H4	4-(CH3)2NC6H4		СН(СН3)2	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	6СН3	70-72(0)	
	206	C6H5	C <sub>6</sub> H <sub>5</sub>	I	(CH <sub>2</sub> ) <sub>7</sub> CH <sub>3</sub>	5 2,4,6	2,4,6-triFC6H2	oil(P)	
	207	C6H5	C <sub>6</sub> H <sub>5</sub>	I	(CH <sub>2</sub> ) <sub>7</sub> CH <sub>3</sub>	5 C <sub>6</sub> H <sub>5</sub>	! !	74-76	
	208	C6H5	C <sub>6</sub> H <sub>5</sub>	Ŧ	(CH2)7CH3	5 2,4,6	-triFC <sub>6</sub> H <sub>2</sub>	99-101	
	209	4-HOC <sub>6</sub> H4	4-HOC <sub>6</sub> H <sub>4</sub>	×	2,4-diFC <sub>6</sub> H <sub>3</sub>	5 (CH <sub>2</sub> )	(сн <sub>2</sub> ) <sub>6</sub> сн <sub>3</sub>	110-112	
	210	(сн3)5сн	(сн3)2сн	<b>=</b>	сн(сн3)2	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	6СН3	oil(q)	
	211	С644-2-ОСН20	211 С6Н4-2-ОСН20-2'-С6Н4 н	×	2,4-diFC <sub>6</sub> H <sub>3</sub>	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	6СН3	65-70	
	212	C6H40C6	Н4	×	2,4-diFC <sub>6</sub> H3	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	6СН3	82-87	
	213	n-C <sub>3</sub> H <sub>7</sub>	n-C <sub>3</sub> H <sub>7</sub>	=	n-C3H7	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	6СН3		
	214	2-pyridinyl	2-pyridinyl	=	С6Н11	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	6СН3		
	215	3-pyridinyl	3-pyridinyl	=	2,4-diCH30C6H3	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	6СН3		
	216	216 4-pyridinyl	4-pyridinyl	×	2,4,6-triFC <sub>6</sub> H <sub>2</sub> 5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	5 (CH <sub>2</sub> )	6СН3		

			Jedu																				
5			n Re	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	3 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	3 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	3 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	3 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	5 (CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	5 (CH <sub>2</sub> ) <sub>8</sub> CH <sub>3</sub>	CH <sub>3</sub>	5 C <sub>6</sub> H <sub>5</sub>	5 3-FC6H4	5 (CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>									
10			-	٠,	٠,	٠.,	٠,	٠.,	• ,		٠,	۵,	ц,	(-,	(*)	w	۵	u,	u,	ц,	u)	L.	L)
15	<u> Table 1</u> (continued)		R4	3-FC6H4	СН(СН3)2	C6H5	(CH2)7CH3	2,6-diClC <sub>6</sub> H <sub>3</sub>	CH3	$(C_6H_4)(C_6H_5)$	2,4-diFC6H3	C6H11	C6H5	2,4-diFC6H3	C6H11	2,4-diFC6H3	C6H11	$2,4-diFC_6H_3$	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	(CH <sub>2</sub> ) <sub>7</sub> CH <sub>3</sub>
20	Table 1		હ્યા	I	<b>=</b>	I	I	I	I	<b>±</b>	CH <sub>3</sub>	CH <sub>3</sub>	CH3	I	Ŧ	I	×	×	Ŧ	×	I	СН2СН3	C <sub>6</sub> H <sub>5</sub>
25	,			2-CH30C <sub>6</sub> H4	3-CH30C6H4	С6Н11	4-(CH3)2NC6H4	2-furanyl	4-(t-C4Hg)C6H4	2-thienyl	4-HO-C6H4	(сн₃)2сн	С645-СН2	44		4-CH3C6H4	$4-(CH_3)_2NC_6H_4$	=======================================	(СН3)2СН	=	(сн3) 5сн	(СН3)2СН	4-CH30C6H4
30			<u>س</u>	2-CI	3-0	C <sub>6</sub> H <sub>J</sub>	4-(	2-fı	,H4 4-(1	2-t	4-H(	<u>5</u>	H90	1-5,-Cel	0C6H4	4-C	4-((	C6H11		4 C6H11			4-C
35			R1	2-CH30C6H4	218 3-CH30C6H4	219 C <sub>6</sub> H <sub>11</sub>	220 C <sub>6</sub> H <sub>5</sub>	2-furanyl	222 4-(t-C4H9)C6H4	2-thienyl	224 4-HO-C <sub>6</sub> H4	225 (СН3) <sub>2</sub> СН	226 C <sub>6</sub> H5-CH2	C6H4-2-0CH20-2'-C6H4	C6H4	229 4-CH <sub>3</sub> 0C <sub>6</sub> H <sub>4</sub>	230 4-CH <sub>3</sub> 0C <sub>6</sub> H <sub>4</sub>	231 4-CH <sub>3</sub> 0C <sub>6</sub> H <sub>4</sub>	232 4-CH <sub>3</sub> 0C <sub>6</sub> H <sub>4</sub>	233 4-(CH3)2NC6H4	234 4-(CH3)2NC6H4	235 C <sub>6</sub> H <sub>11</sub>	236 C <sub>6</sub> H <sub>5</sub>
40		Ë.	No.	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236
45																							
50																							
55																							

			O du																					
5			R6	C6H5	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	$(CH_2)_6CH_3$	(CH2)6CH3	(CH2)6CH3	C <sub>6</sub> H <sub>5</sub>	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	C6H5
10			CI	2	2	2	2	5	2	2	2	5	2	2	2	က	œ	2	Ŋ	2	5	က	œ	2
15	tinued)		R4	(CH <sub>2</sub> ) <sub>7</sub> CH <sub>3</sub>	n-C3H7	C6H11	2,4-diCH30C6H3	2,4,6-triFC <sub>6</sub> H <sub>2</sub>	3-FC <sub>6</sub> H4	СН(СН3)2	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>7</sub> CH <sub>3</sub>	n-C <sub>3</sub> H <sub>7</sub>	C6H11	C <sub>6</sub> H <sub>5</sub>	2,4-diFC <sub>6</sub> H3	C6H11	(CH2)7CH3	n-C3H7	C6H11	C <sub>6</sub> H <sub>5</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	C6H11	(CH2)7CH3
20	Table 1 (continued)		R3	CH <sub>2</sub> C <sub>6</sub> H <sub>5</sub>	I	=	I	×	×	Ŧ	Ŧ	I	×	×	I	I	<b>=</b>	<b>±</b>	I	Ŧ	×	<b>=</b>	<b>=</b>	x
25 30	Tab		$\frac{R^2}{R}$	4-(CH3)2NC6H4	C6H11	(сн3) 2сн	4-CH3SC6H4	4-CH3SC6H4	4-CH3SO2C6H4	4-CH3SC6H4	4-CH3SOC6H4	4-CH3SO2C6H4	4-CH30C6H4	4-CH30C6H4	4-CH30C6H4	4-CH30C6H4	4-CH30C6H4	4-CH30C6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4
35		Ex.	$\frac{No. R^1}{}$	237 C <sub>6</sub> H <sub>5</sub>			240 4-CH3SC6H4		1502C6H4	243 C <sub>6</sub> H <sub>5</sub>	244 C <sub>6</sub> H <sub>5</sub>	245 C <sub>6</sub> H <sub>5</sub>	246 4-CH30C6H4	247 4-CH30C6H4					252 4-(CH3)2NC6H4	253 4-(CH <sub>3</sub> ) <sub>2</sub> NC <sub>6</sub> H <sub>4</sub>	254 4-(CH <sub>3</sub> ) <sub>2</sub> NC <sub>6</sub> H <sub>4</sub>	255 4-(CH <sub>3</sub> ) <sub>2</sub> NC <sub>6</sub> H <sub>4</sub>	256 4-(CH3)2NC6H4	257 4-(CH <sub>3</sub> )2NC <sub>6</sub> H <sub>4</sub>
40			_																					
<b>4</b> 5																								
55																								

## Footnotes to Table 1 <sup>1</sup>H NMR (CDC<sub>13</sub>) $\delta$ 11.6(s,1H), 7.7-7.1(m,10H). 5 4.4(t,1H,J=5Hz), 3.4(t,2H,J=6.7Hz), 3.2-2.9(m,5H), 1.8-1.0(m,29H), 1.0-0.8(m,7H). (b) $^{1}\text{H}$ NMR (CDC1<sub>3</sub>) $\delta$ 8.79-7.63(m,7H), 7.29-7.12(m,2H), 6.87-6.73 (m, 2H), 6.44 (bs, 1H), 3.34-3.08 (m, 6H), 10 1.83-1.18(m,16H), 0.86(t,3H). (c) $^{1}$ H NMR (CDCl<sub>3</sub>) $\delta$ 10.6-10.0(bs,1H), 7.80(m,1H),7.35-7.00(m,8H), 6.8-6.57(m,2H) 6.4(bs,1H), 15 3.89(t,2H), 3.25(t,2H), 3.00(t,2H) 2.33(s,3H), 2.32(s,3H), 1.79-1.29(m, 16H), 0.88(t, 3H). (d) 1<sub>H NMR</sub> (CDCl<sub>3</sub>) δ 11.1-11.0(bs,1H), 7.64(m,1H), 7.5(d,2H), 7.27(m,6H), 6.75(m,1H), 6.53(m,1H), 6.33(bs,1H), 3.45(t,2H), 20 3.26(t,2H), 2.98(t,2H), 1.82-1.25(m,16H), 0.90(t,3H). (e) $^{1}\text{H}$ NMR (CDCl<sub>3</sub>) $\delta$ 10.8-10.7(m,1H), 8.0-7.2(m,7H), 6.9-6.6 (m, 2H), 6.0-5.9 (m, 1H), 3.4 (t, 2H, J=6.6Hz), 25 3.3(t,2H,J=7.6Hz), 3.0(t,2H,J=6.5Hz), 1.9-1.2(m,18H), 0.9(t,3H,J=7.2Hz). (f) $^{1}$ H NMR (CDCl<sub>3</sub>) $\delta$ 10.4-10.1(m,1H), 8.0-7.8(m,1H), 30 7.2-6.9(m, 2H), 6.9-6.75(m, 2H), 6.5-6.4(m, 1H), 3.4-3.2(m, 4H), 3.0(t,2H,J=7Hz), 1.9-1.1(m,19H), 0.9(t,3H,J=8Hz).(g) <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) $\delta$ 12.17(bs,1H), 7.94(bs,1H), 7.43-6.77 (m,11H), 3.57 (s,3H), 3.24 (m,4H), 3.19 (s,3H), 35 3.07(t,2H), 1.76-1.18(m,16H), 0.85(t,3H). (h) <sup>1</sup>H NMR (CDCl<sub>3</sub>) $\delta$ 10.03-9.55(bs,1H), 7.86(m,1H), 7.58-7.20(bm, 4H), 6.82-6.61(m,6H), 6.42(bs,1H), 40 3.30-3.21(m,2H), 2.94(bs,14H), 1.78-1.26(m,16H), 0.88(t,3H). (i) $^{1}\text{H}$ NMR (CDCl<sub>3</sub>) $\delta$ 9.50-9.18(bs,1H), 7.97(m,1H), 6.80 (m, 2H), 6.41 (bs, 1H), 3.31 (m, 4H), 2.86 (t, 2H), 2.68-2.37 (m, 2H), 1.91-1.13 (m, 36H), 0.89 (t, 3H). 45 (j) $^{1}$ H NMR (CDCl<sub>3</sub>) $\delta$ 10.2-9.8(bs,1H), 7.85(m,1H), 7.70-7.16(m,7H), 6.75(m,1H), 6.89(d,3H), 6.39(bs,1H), 3.38(t,2H), 3.25(t,2H), 3.01(t,2H), 2.95(s,6H),

55

50

1.85-1.25(m, 16H), 0.9(t, 3H).

## Footnotes to Table 1 (continued)

- (k)  $^{1}$ H NMR (CDC1<sub>3</sub>)  $\delta$  10.35-10.15(bs,1H), 7.95(m,1H), 7.50-7.36(m,2H), 6.98-6.69(m,4H), 6.49-6.38(m,3H), 3.35(t,2H), 3.25(t,2H), 3.05(t,2H), 1.79-1.27(m,16H), 0.90(t,3H).
- (1)  $^{1}$ H NMR (CDC1<sub>3</sub>)  $\delta$  7.47(d,4H), 6.84(d,4H), 4.12(d,1H), 3.84(m,1H), 3.80(s,6H), 3.33(t,2H), 3.07(t,2H), 2.96(t,2H), 1.8-1.24(m,16H), 1.08(d,6H), 0.90(t,3H).
- (m)  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  10.15-10.0(bs,1H), 7.82(m,1H), 7.53(m,2H), 7.31(m,6H), 6.73(m,1H), 6.61(m,1H), 3.4(t,2H), 3.26(t,2H), 3.00(t,2H), 1.82-1.49(m,12H), 1.33(bs,22H), 0.9(t,3H).
- (n)  $^{1}$ H NMR (CDC1<sub>3</sub>)  $^{5}$  10.8-10.76(bs,1H), 7.70(m,1H), 7.15(m,2H), 7.31(m,2H), 6.82(m,4H), 6.73(m,1H), 6.58(m,1H), 6.40(bs,1H), 3.8(s,6H), 3.46(t,2H), 3.01(s,3H), 2.94(t,2H), 1.78-1.44(m,6H).
- (o)  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  7.56-7.33(bs,4H), 6.67(d,4H), 4.11(d,1H), 3.89(m,1H), 3.3(t,2H), 3.08(t,2H), 2.95(bs,14H), 1.84-1.25(m,16H), 1.1(d,6H), 0.9(t,3H).
- (p)  $^{1}$ H NMR (CDC1<sub>3</sub>)  $^{6}$  7.7-6.9(m,14H), 4.1(t,1H,J=5.4Hz), 3.8-3.65(m,2H), 3.1-2.9(m,4H), 1.9-1.0(m,18H), 0.85(t,3H,J=6.7Hz).
- (q)  $^{1}$ H NMR (DMSO-d<sub>6</sub>)  $\delta$  11.58(s,1H), 5.71(d,1H), 3.75(m,1H), 3.07(t,4H), 2.95-2.78(m,4H), 1.57-1.1(m,16H), 1.14(d,6H), 1.10(d,6H), 1.03(d,6H), 0.85(t,3H).

## **EXAMPLE 267**

5

10

15

20

25

30

35

40

Preparation of N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylthiourea

Employing the method of Example 1, Part E, using 2,4-dlfluorophenylisothiocyanate (0.14 g, 0.0008 mol), the title compound (0.19 g, 0.00031 mol) was obtained as a white solid, mp 116-118°.  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  9.5-9.4(s,1H), 7.8-7.1(m,11H), 7.0-6.7(m,3H), 3.8(t,2H,J=7.6Hz), 3.6(t,2H,J=7.8Hz), 3.1-(t,2H,J=7Hz), 1.9-1.1(m,18H), 0.9(t,3H,J=4Hz).

## O EXAMPLE 269

Preparation of N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylsulfinyl)pentyl]-N-heptylurea

To a solution of N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea (0.59 g, 0.001 mol) in methylene chloride (50 mL) cooled to -78° was added, dropwise, a solution of meta-chloroperbenzoic acid (0.286 g, 0.0017 mol) in methylene chloride (10 mL). The reaction mixture was stirred at -78° for 1 hour and then allowed to warm to ambient temperature. The reaction mixture was then cooled to 0° and then added, dropwise, was a solution of saturated sodium bisulfite. The layers were separated

and the organic layer was washed with saturated sodium bisulfite. The layers were separated and the sodium chloride solution, dried over magnesium sulfate, and concentrated under vacuum. The residue (0.76 g) was chromatographed with 1:1 hexane-ethyl acetate to give the title compound (0.43 g, 0.00071 mol) as a yellow solid, mp 77-79°. <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  8.1-7.9(m,1H), 7.6-7.2 (m,10H), 6.9-6.7(m,2H), 6.4-(d,1H,J=3.3Hz), 3.4-3.1(m,6H), 2.0-1.1(m,18H), 0.9(t,3H,J=6.4Hz).

## **EXAMPLE 272**

10

20

25

30

35

40

45

50

55

## Preparation of N'-(2,4-difluorophenyl)-N-[5-[(4,5-diphenyl-1H-imidazol-2-yl)sulfonyl]pentyl]-N-heptylurea

To a solution of N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea (0.11 g, 0.00019 mol) in methanol (5 mL) was added, portionwise as a solid, Oxone  $^{\text{TM}}$  (0.234 g, 0.00038 mol) and the reaction mixture was stirred at ambient temperature for 7 hours. The solids were filtered and washed with methanol. The filtrate was concentrated under vacuum and the residue was chromatographed with 6:4 hexane-ethyl acetate to give the title compound (0.06 g, 0.000096 mol) as a glassy, colorless solid, mp 66-68°.  $^{\text{1}}$ H NMR (CDCl<sub>3</sub>)  $\delta$  7.85-7.75(m,1H), 7.6-7.1(m,11H), 6.8-6.6(m,2H), 6.4(s,1H), 3.4(t,4H,J=10Hz), 3.25(t,2H,J=7Hz), 1.9-1.75(m,2H), 1.75-1.4(m,6H), 1.4-1.1(m,8H), 0.9(t,3H,J=8Hz).

## **EXAMPLE 329**

## Preparation of N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylamino)phenyl]-N-heptylurea

Part A. A solution of 2-bromo-4,5-diphenyl-1H-imidazole (3,5 g, 0.0117 mol) in 1,5-diaminopentane (20 mL) was heated to reflux for 48 hours. The reaction mixture was concentrated in vacuo to give a viscous oil which was taken up in methylene chloride (60 mL) and washed with 10% aqueous NaHCO<sub>3</sub>, water (2 x 50 mL), brine, dried over magnesium sulfate and concentrated in vacuo to give 5-(4,5-diphenyl-1H-imidazol-2-ylamino)aminopentane as a viscous oil (3.5 g, 0.0109 mol). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.55-7.09-(m,10H), 4.79-3.79(bs,3H), 3.14(t,2H), 2.59(t,2H), 1.79-1.22(m,6H).

Part B. To a solution of 5-(4,5-diphenyl-1H-imidazol-2-ylamino)aminopentane (1.7 g, 0.00531 mol) and triethylamine (0.58 g, 0.0058 mol) in methylene chloride cooled to 0° under a nitrogen atmosphere, heptanoyl chloride (0.788 g, 0.00531 mol) was added slowly. The reaction mixture was stirred for 1 hour at 0°, poured into water and extracted with methylene chloride (2 x 50 mL). The combined organic extract was washed with water, brine, dried over magnesium sulfate and concentrated to give N-[5-(4,5-diphenyl-1H-imidazol-2-ylamino)pentyl]heptanamide as a viscous oil. The product was purified by flash chromatography on silica gel (250 mL) eluting methylene chloride:methanol (95:5 v:v), to give an amber foam (1.3 g, 0.003 mol).  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  7.43-7.15(m,10H), 6.3(m,1H), 3.24-3.1(m,4H), 2.09-(t,2H), 1.6-1.16(m,14H), 0.84(t,3H).

Part C. Employing the method of Example 118, Part B, but using N-[5-(4,5-diphenyl-1H-imidazol-2-ylamino)pentyl]heptanamide, N-[5-(4,5-diphenyl-1H-imidazol-2-ylamino)pentyl]-N-heptylamine was obtained as an amber oil (1.00 g, 0.00238 mol).  $^1$ H NMR (CDCl<sub>3</sub>)  $\delta$ 7.56-6.85(m,10H), 3.23(m,2H), 2.49-(m,4H), 1.68-0.90(m,16H), 0.88(t,3H).

Part D. Employing the method of Example 118, Part C, but using N-[5-(4,5-diphenyl-1H-imidazol-2-ylamino)pentyl]-N-heptylamine, the title compound was obtained as a yellow foam (0.395 g, 0.000688 mol).  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  8.37-7.1(m,11H), 6.9-6.67(m,2H), 6.44(d,1H),4.53(bs,1H), 3.27(m,6H), 1.74-1.23-(m,16H), 0.89(t,3H).

## **EXAMPLE 330**

## Preparation of N'-(2,4-difluorophenyl)-N-[6-(4,5-diphenyl-1H-imidazol-2-yl)hexyl]-N-heptylurea

Part A. To a solution of 4,5-diphenyl-1-[(trimethylsilyl)ethoxymethyl]-1H-imidazole (2.5 g, 0.00734 mol) (B. Lipshutz, B. Huff, W. Hazen, Tetrahedron Letters, 29, 3411-14, 1988), in dry tetrahydrofuran (50 mL) cooled to -78° under a nitrogen atmosphere, n-butyl lithium in hexane (2.5 M, 0.00734 mol) was added slowly. The reaction mixture was stirred for 1 hour and 1,6-dibromohexane (2.68 g, 0.0011 mol) was added rapidly, stirred for 1/2 hour and was allowed to warm to ambient temperature and stirred for 2 additional hours. The reaction mixture was poured into water and extracted with ethyl acetate (2 x 50 mL). The combined organic layer was washed with water, brine, dried over magnesium sulfate and concentrated to give a viscous oil. The product was purified by flash chromatography on silica gel (250

5	mL) eluting with hexane:ethyl acetate (70:30 v:v) to give 6-bromo-1-(4,5-diphenyl-1-[(trimethylsilyl) ethoxymethyl]imidazol-2-yl)hexane as an oil (2.18 g, 0.00424 mol). $^1$ H NMR (CDCl $_3$ ) $\delta$ 7.53-7.16(m,10H 5.10(s,2H), 3.48(t,2H), 3.34(t,2H), 2.90(t,2H), 1.99-1.5(m,8H), 0.875(t,2H), 0.008(s,9H). Part B. A solution of 6-bromo-1-(4,5-diphenyl-1-[(trimethylsilyl)ethoxymethyl]-1H-imidazol-2-yl)hexan (1.0 g, 0.00195 mol) and n-heptylamine (0.45 g, 0.00389 mol) in acetonitrile (25 mL) was heated to 60 for 8 hours. The reaction mixture was poured into 10% aqueous sodium bicarbonate and extracted with ethyl acetate (2 x 50 mL). The combined organic extract was washed with water, brine, dried over
10	magnesium sulfate and concentrated to give N-[6-(4,5-diphenyl-1-[(trimethylsilyl)ethoxymethyl]-1+-imidazol-2-yl)hexyl]-N-heptylamine as a colorless viscous oil (1.04 g, 0.00189 mol). $^1$ H NMR (CDCl3) $^3$ 7.52 7.2(m,10H), 5.11(s,2H), 4.7-4.2(bs,1H), 3.3(t,2H), 2.93-2.70(m,6H), 1.95-1.34(m,18H), 0.93(t,3H), 0.86 (t,2H), 0.005(s,9H).
15	Part C. Employing the method of Example 118, Part C, but using N-[6-(4,5-diphenyl-1-[(trimethylsilyl) ethoxymethyl]-imidazole-2-yl)hexyl]-N-heptylamine, N'-(2,4-difluorophenyl)-N-[6-(4,5-diphenyl-1-[(trimethylsilyl)ethoxymethyl]-imidazole-2-yl)hexyl]-N-heptylurea was isolated as a viscous oil (1.40 g 0.00199 mol). $^1$ H NMR (CDCl <sub>3</sub> ) $\delta$ 8.12(m,1H), 7.53-7.16(m,10H), 6.88(m,2H), 6.48(d,1H), 5.1(s,2H), 3.33 (m,6H), 2.90(t,2H), 2.0-1.34(m,18H), 0.88(t,3H), 0.79(t,2H), 0.055(s,9H). Part D. To a solution of N'-(2,4-difluorophenyl)-N-[6-(4,5-diphenyl-1-[(trimethylsilyl)ethoxymethyl]-1H
20	imidazol-2-yl)hexyl]-N-heptylurea (0.60 g, 0.000853 mol) in dry tetrahydrofuran (10 mL) under a nitroge atmosphere, tetrabutylammonium fluoride (1M in tetrahydrofuran, 3.41 mL) was added and the reactio mixture was heated to reflux 7 hours. The reaction mixture was cooled, poured into water (50 mL) an extracted with ethyl acetate (2x50 mL). The combined organic layer was washed with water, brine, drie over magnesium sulfate and concentrated in vacuo. The product was purified by flash chromatograph on silica gel (75 mL) eluting hexane:ethyl acetate (60:40 v:v) to give the title compound as a colorles
25	glass (0.26 g, 0.000454 mol). <sup>1</sup> H NMR (CDCl <sub>3</sub> ) $\delta$ 9.5-9.0(bs,1H), 7.87(m,1H), 7.5-7.2(m,10H), 6.83-6.7 (m,2H), 6.4(d,1H), 3.28(m,4H), 2.67(t,2H), 1.75-1.26(m,18H), 0.88(t,3H).
30	
35	
40	
<b>4</b> 5	
50	
-	

5					Imp C										116-118	
10					ુ જી	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub> I	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>
					<b>c</b> l	2	വ	∞	ω	လ	8	æ	2	2	2	æ
15		Re	NHR4		≻-I	0	0	0	0	S	0	0	0	0	S	S
		 = = -	$\overline{}$		×I	0	0	0	0	0	0	0	0	0	S	S
20 25	Table 2	—×—(CH₂),N—R <sup>6</sup>	₩.		R4	2,4-diFC <sub>6</sub> H3	2,4-diCH30C <sub>6</sub> H3	2,4-diFC <sub>6</sub> H <sub>3</sub>	n-C3H7	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4,6-triFC <sub>6</sub> H <sub>2</sub>	2,4,6-triFC <sub>6</sub> H <sub>2</sub>	2,4-diFC <sub>6</sub> H3	2,4-diFC <sub>6</sub> H3	2,4-diFC <sub>6</sub> H <sub>3</sub>
30					<u>R3</u>	æ	<b>=</b>	<b>=</b>	=	<b>=</b>		C6H5	<b>=</b>	<b>=</b>	=	=
35					<u>R2</u>	C6H5	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C6H5	C6H5	C <sub>6</sub> H <sub>5</sub>	4-FC6H4	3-pyridinyl	C <sub>6</sub> H <sub>5</sub>	4-FC6H4
40					R <sub>1</sub>	-6 <sup>H</sup> 5	.6H5	.6H5	,6H5	.6H5	.6H5	.6H5	-FC6H4	,6H5	.6H5	FC6H4
45				E.	No.	258 (	259 (	260 0	261	262 0	263 0	264 0	265 4	266 C	267 C	268 4
50																

_			mp • C	77-79			89-99	•														
5 10			ુ જો	(CH2)6CH3	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH2)6CH3	(CH2)6CH3	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH2) 6CH3	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH2) 6CH3	(CH2) 6CH3	(CH <sub>2</sub> )8CH <sub>3</sub>	(CH2)5CH3	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH2)6CH3	(CH2)8CH3	(CH2)6CH3	(CH2)6CH3	(CH <sub>2</sub> ) 5CH <sub>3</sub>
15			디	ς.	80	Ŋ	Ŋ	80	80	Ŋ	r.	S	r2	∞	4	7	2	80	9	2	8	4
			<b>&gt;-</b> I	0	0	0	0	0	0	S	0	0	0	0	0	0	0	0	0	0	0	0
20	(pər		×I		So				202					Ŧ		H	NCH <sub>3</sub>		NCH <sub>2</sub> C <sub>6</sub> H <sub>5</sub>		NC3H7	NC3H7
25 30	Table 2 (continued)		R4	,4-diFC <sub>6</sub> H3	,4-diFC <sub>6</sub> H3	-C3H7	,4-diFC <sub>6</sub> H3	,4-diFC <sub>6</sub> H <sub>3</sub>	-C3H7	-C3H7	-C3H7	,4,6-triFC <sub>6</sub> H2	,4-diCH30C6H3	,4-diFC6H3	-C5H11	6H5	,4-diFC <sub>6</sub> H <sub>3</sub>	,4-diFC <sub>6</sub> H <sub>3</sub>	-C <sub>3</sub> H <sub>7</sub>	,4,6-triFC <sub>6</sub> H <sub>2</sub>	,4-diClC <sub>6</sub> H3	,4,5-triCH30C <sub>6</sub> H2
35			R3	н 5	н 2	I	н 5	Н 2	<b>=</b>	I	CH3 n	н 2	Н 2	н 2	<b>=</b>	CH <sub>3</sub> C	H 2	н 2	<b>=</b>	H 2	<b>H</b> 2	<b></b>
40			묎	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C6H5	CeH5	4-FC6H4	C6H5	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C6H5	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>
45	-		R1	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	4-FC <sub>6</sub> H4	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	с6Н5	C6H5	ceH <sub>5</sub>	c <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>
50		Ξ.	No.	569	270	271	272	273	274	275	576	277	278	279	780	281	282	283	284	282	786	287

5			MD €C		124-126	89-91	161-163																
10			<u>9</u>	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	$(CH_2)_6CH_3$	(CH2)6CH3	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	(CH2)6CH3	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	(CH2)6CH3	(CH2)6CH3	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(СН2) 6СН3	(СН2) 6СН3	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>
15			Œ!	2	2	5	5	2	2	2	2	2	2	5	2	2	2	5	S	2	٣	3	2
			<b>&gt;-</b> I	0	S	S	S	0	0	0	0	S	S	S	0	0	0	0	0	H2	H2	H2	S
20	nued)		×I	NC <sub>6</sub> H <sub>13</sub>	S	S	S	¥	CH <sub>2</sub>	So	205	0	Ŧ	CH2	0	¥	CH <sub>2</sub>	S0	202	0	Ŧ	CH <sub>2</sub>	0
25 30	Table 2 (continued)		R <sup>4</sup>	CH <sub>3</sub>	2,4,6-triFC <sub>6</sub> H <sub>2</sub>	(CH <sub>2</sub> ) <sub>2</sub> CH <sub>3</sub>	3-FC6H4	C6H11	$2,4-diCH_30C_6H_3$	2,4,6-triFC <sub>6</sub> H <sub>2</sub>	3-FC6H4	сн(сн3)2	C6H5	(CH <sub>2</sub> ) <sub>7</sub> CH <sub>3</sub>	2,6-diClC <sub>6</sub> H <sub>3</sub>	CH <sub>3</sub>	$(C_6H_4)(C_6H_5)$	2,4-diFC <sub>6</sub> H3	C6H11	C6H5	2,4-diFC <sub>6</sub> H <sub>3</sub>	C6H11	n-C <sub>3</sub> H <sub>7</sub>
35			R3	<b>=</b>	I	±	Ξ	I	<b>=</b>	Ŧ	Œ	Ξ	Ŧ	Ŧ	<b>=</b>	I				CH3	=	I	<b>=</b>
40			R <sup>2</sup>								4-CH	4-CH	4-CH;	4-CH <sub>2</sub>	$4-CH_30C_6H_4$	4-CH <sub>3</sub>	4-CH3	4-CH3	(CH3)		C6H5	4-CH30C6H4	C <sub>6</sub> H <sub>5</sub>
45				C <sub>6</sub> H <sub>5</sub>	C6H5	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	(сн3) 5сн	(сн3)5сн	4-CH30C6H4	4-CH30C6H4	4-CH30C6H4	4-CH30C6H4	4-CH30C6H4	299 4-CH30C6H4	4-CH30C6H4	$4-CH_30C_6H_4$	4-CH30C6H4	(сн3)5сн	(сн3)5сн	C6H5	306 4-CH30C6H4	C <sub>6</sub> H <sub>5</sub>
50		EX.	No.	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307

			mp • C																			
5			R6	(CH2)6CH3	$(CH_2)_6CH_3$	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH2)6CH3	(CH2)6CH3	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> )6CH <sub>3</sub>	(CH <sub>2</sub> )6CH <sub>3</sub>	$(CH_2)_6CH_3$	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	C <sub>6</sub> H <sub>5</sub>	(CH2)6CH3	(CH2)6CH3	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH2)6CH3	(CH2)3CH3	(CH2)8CH3
				5	2	2	ĸ	æ	2	2	2	2	5	m	ω	2	2	5	œ	œ	Ŋ	2
15			>-l ×l	NH S	CH <sub>2</sub> S	0 H <sub>2</sub>		CH <sub>2</sub> H <sub>2</sub>		502 0	O H	CH <sub>2</sub> 0	CH <sub>2</sub> S							0 H <sub>2</sub>		NH O
20	Table 2 (continued)		R4	6 <sup>H</sup> 11	H(CH <sub>3</sub> ) <sub>2</sub>	C6H5	,4-diFC <sub>6</sub> H3	6 <sup>H</sup> 11	СН2) 7СН3	-C3H7	6 <sup>H</sup> 11	н(сн <sub>3</sub> ) <sub>2</sub>	6H5	,4-diFC <sub>6</sub> H3	6H11	СН2) 7СН3	,4-diFC <sub>6</sub> H3	,4-diFC <sub>6</sub> H3	,4-diFC <sub>6</sub> H <sub>3</sub>	6 <sup>H</sup> 11	,4-diFC <sub>6</sub> H3	,4-diFC <sub>6</sub> H3
25 30	Table 2		<sub>ال</sub> ح	H	- -	±	Н 2	J	Ξ	Ξ	ı.	 	. T	H 2	<b>∵</b>			CH <sub>2</sub> C <sub>6</sub> H <sub>5</sub> 2		<u>ت</u>	н 2	н 2
35			<u>R</u> 2	(СН3) 2СН	C6H5	4-CH30C6H4	(сн3) 2сн	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-CH30C6H4	C6H5	C6H5	(СН3) 2СН	4-CH3SC6H4	4-CH3SOC6H4	4-CH3SO2C6H4	C <sub>6</sub> H <sub>5</sub>
40 45			<b></b> !	Н3)2СН	н3)2СН	C <sub>6</sub> H <sub>5</sub>	н3)2сн	(CH3)2NC6H4	(CH3)2NC6H4	(CH3)2NC6H4	(CH3)2NC6H4	(CH <sub>3</sub> ) <sub>2</sub> NC <sub>6</sub> H <sub>4</sub>	$4-(CH_3)_2NC_6H_4$	(CH3)2NC6H4	4-CH30C6H4	Н5	C <sub>6</sub> H <sub>5</sub>	(СН3)5СН	CH3SC6H4	сн <sub>3</sub> SOC <sub>6</sub> Н4	4-CH3S02C6H4	326 4-CH3SC <sub>6</sub> H4
		ĒX.	No. R1	308 (CI	309 (CI	310 C6	311 (CI	312 4-	313 4-	314 4-	315 4-	316 4-	317 4-	318 4-	319 4-(	320 C <sub>6</sub> H <sub>5</sub>	321 C <sub>6</sub> I	322 (CI	323 4-(	324 4-(	325 4-(	326 4-(
50																						

5			mp °C			foam	glass
10			<u>&amp;</u>	CH <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	$(CH_2)_6CH_3$	(сн2) есн3
			<b>c</b> i	2	2	2	2
15			<b>≻</b> I	H2	S	0	0
			×I	S	S	¥	CH <sub>2</sub>
20	ontinued)		R4	diFC <sub>6</sub> H <sub>3</sub>	diFC <sub>6</sub> H <sub>3</sub>	diFC <sub>6</sub> H <sub>3</sub>	$2,4-diFC_6H_3$
25	Table 2 (continued)			2,4-	2,4-	2,4-	2,4-
30	ĘĮ		찌	Ξ	x	Ŧ	<b>=</b>
35			O. I	45	45	45	H <sub>5</sub>
40			<sup>2</sup>	رو رو	رو د	<sub>9</sub> 5	<sub>S</sub>
45			No. R1	4-CH3SOC6H4	4-CH3S02C6H4	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>
50		Ex.	N N	327	328	329	330

**EXAMPLE 331** 

Preparation of 2,4-difluoro-N-[(5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl)]-N-heptylbenzeneacetamide

To a solution of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanamine (2.2 g, 0.005 mol), 1-hydroxybenzotriazole hydrate (0.81 g, 0.006 mol), and 2,4-difluorophenylacetic acid (1.12 g, 0.0065 mol) in

N,N-dimethylformamide (50 mL) at 0 ° was added, portionwise as a solid, dicyclohexylcarbodiimide (1.24 g, 0.006 mol). The reaction mixture was stirred at 0 ° for 2.5 hours, then at ambient temperature for 72 hours. The solids were filtered and washed with chloroform. The filtrate was concentrated under vacuum and the residue (5.2 g) was chromatographed with 7:3 hexane-ethyl acetate. The resulting solid was triturated with hexane to give the title compound (2.59 g, 0.0044 mol) as a yellow oil,  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  7.6-7.0(m,11H), 6.8-6.5(m,2H), 3.7(d,2H,J=13.7Hz), 3.5(t,2H,J=6.4Hz), 3.4-3.0(m,3H), 2.9(t,2H,J=6.1Hz), 1.8-1.1(m,17H), 0.9(t,3H,J=6.6Hz).

#### **EXAMPLE 344**

10

15

25

30

35

40

45

PreparationofN-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-2,4-difluoro-N-heptylbenzeneethaneamine

To a solution of lithium aluminium hydride (1 N in tetrahydrofuran, 2 mL) in dry tetrahydrofuran (30 mL), a solution of N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-2,4-difluoro-N-heptylbenzeneacetamide (0.70 g, 0.00107 mol) in dry tetrahydrofuran (15 mL) was added slowly. The reaction mixture was heated to reflux for 5 hours and was then allowed to cool to ambient temperature. The reaction mixture was poured into a mixture of 10% aqueous sodium sulfate (150 mL) and ice (150 mL). The resultant emulsion was filtered through Celite® and the filtrate was extracted with ethyl acetate (3 x 100 mL). The organic layer was washed with water, brine, dried over magnesium sulfate and concentrated in vacuo to give a crude oil. The product was purified by flash chromatography on silica gel (100 mL) eluting methanol: methylene chloride (5.95 v:v) to give the title compound as a viscous colorless oil (0.46 g, 0.000723 mol). 

1 NMR (CDCl<sub>3</sub>) δ 9.2-9.15(bs,1H), 7.56-7.25(m,4H), 7.11(m,1H), 6.94-6.70(m,6H), 3.81(m,6H), 3.07(t,2H), 2.74-2.58(m,4H), 2.43(m,4H), 1.71(m,2H), 1.53-1.20(m,14H), 0.91(t,3H).

## **EXAMPLE 346**

Preparation of N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylcyclohexaneacetamide

- Part A. Employing the method of Example 118, Part C, but using 2-cyclohexane acetyl chloride, N-heptyl-N-(5-hydroxypentyl)cyclohexaneacetamide was obtained as an oil (1.5 g, 0.0046 mol). <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  3.70-3.61(m,2H), 3.37-3.18(m,4H), 2.03(d,2H), 1.97-1.08(m,26H), 1.02-0.86(m,4H).
  - <u>Part B.</u> Employing the method of Example 118, Part D, but using N-heptyl-N-(5-hydroxypentyl)-cyclohexaneacetamide, N-(5-bromopentyl)-N-heptylcyclohexane acetamide was isolated as an oil (1.3 g, 0.00334 mol).  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  3.47-3.39(m,2H), 3.36-3.18(m,4H), 2.17(d,2H), 1.96-0.86(m,30H).
  - <u>Part C.</u> Employing the method of Example 118, Part E, but using N-(5-bromopentyl)-N-heptylcyclohex-aneacetamide, the title compound was isolated as an oil (0.47 g, 0.00075 mol), <sup>1</sup>H NMR (DMSO-d<sub>6</sub>)  $\delta$  12.34(s,1H), 7.29(d,2H), 6.95(d,2H), 6.84(d,2H), 3.77(s,3H), 3.73(s,3H), 3.18(m,4H) 3.07(m,2H), 2.09(d,2H), 1.73-0.81(m,30H).
- Additional amides, which are listed in Table 3, were prepared or could be prepared analogously according to the procedures of Examples 331, 344 and 346.

55

5					R6 IMP°C	(СН <sub>2</sub> ) <sub>6</sub> СН <sub>3</sub> оі1	$(CH_2)_6CH_3 \text{ oil}^{(a)}$	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub> oil <sup>(b)</sup>	(CH2)6CH3 57-58	(СН2) <sub>6</sub> СН3 оі1 <sup>(с)</sup>	<sub>1</sub> 6СН3 оі1 <sup>(d)</sup>	$(CII_2)_6CH_3$ oil $^{(e)}$	$(CH_2)_6CH_3 \text{ oil}(f)$	$(CH_2)_6CH_3 \text{ oil}(9)$	$(CH_2)_6CH_3 \text{ oil}^{(h)}$	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub> oi1 <sup>(i)</sup>
10		),N—R <sup>6</sup>	₹		I I	S 0 5 (CH <sub>2</sub> )	S 0 5 (CH <sub>2</sub> )	S 0 5 (CH <sub>2</sub> )	S 0 5 (CH <sub>2</sub> )	S 0 5 (CH <sub>2</sub> )	S 0 5 (CH <sub>2</sub> )	S 0 5 (CII <sub>2</sub> )	S 0 5 (CH <sub>2</sub> )	S 0 5 (CH <sub>2</sub> )	S 0 5 (CH <sub>2</sub> )	S 0 5 (CH <sub>2</sub> )
15	Table 3	X—X—(CH <sub>2</sub> ),N—R <sup>6</sup>	` <del>-</del>		R4	CH2-2,4-diFC <sub>6</sub> H3	2CH3	CH2 (CH2) 2CH3	6H4) (C <sub>6</sub> H <sub>5</sub> )	H <sub>11</sub>	iFC <sub>6</sub> H <sub>3</sub>		6H11 :	2 <sup>CH3</sup> :	CH2-3,4-diClC6H3	6F5 .
25	<u>Tat</u>	£ 2	R <sup>2</sup>		اله اله	H CH2-2	н сн2сн2сн3	н сн <sub>2</sub> (с	н сн <sup>2</sup> (с	н сн <sub>2</sub> с6	H 2,4-d	H C6H5	H CH2-C6H11	Ŧ	<b>=</b>	<b>=</b>
30					R <sup>2</sup>	C6H5	C6H5	C6H5	C6H5	C6H5	C6H5	C <sub>6</sub> H <sub>5</sub>	(сн3) 2сн	4-CH30C6H4	4-СН30С <sub>6</sub> Н4	4-СН30С <sub>6</sub> Н4
35 40				×	No. R1	31 C <sub>6</sub> H <sub>5</sub>	32 C <sub>6</sub> H <sub>5</sub>	33 C <sub>6</sub> H <sub>5</sub>	34 C <sub>6</sub> H <sub>5</sub>	35 C <sub>6</sub> H <sub>5</sub>	36 C <sub>6</sub> H <sub>5</sub>	37 C <sub>6</sub> H <sub>5</sub>	38 (сн3)2сн	39 4-CH30C6H4	40 4-CH30C6H4	41 4-СН30С6Н4
45				M	Z!	ĸ	m	e e	m	m	m	M.	M	m'	ĸ	8
50																

			oi1(j)	oil(k)	oil	oi1(1)	_														
5			.2	.0	.2	.0	l io														
10		<b>8</b> 6	(CH2)6CH3	(СН2) 6СН3	$(CH_2)_6CH_3$	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(сн2) есн	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(сн2) 6СН3	(сн2) есн3	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH2)6CH3			(CH2)6CH3	CH <sub>2</sub> H <sub>2</sub> 3 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>
			5	2	5	2	2	2	2	2	5	2	Ŋ	S	2	5		2	2	2	m
		<b>≻</b> -I	0	H2	H2	0	0	0	0	0	H2	0	0	0	0	H2		0	0	0	£
15		×ı	S	S	S	S	S	S	3 CH <sub>2</sub>		S	0	CH <sub>2</sub> (	¥	S	0	CH <sub>2</sub>	₹	S	0	CH2
20	Table 3 (continued	₽ <b>₩</b>	CH2-2,4-diFC <sub>6</sub> H3	(сн2)2сн3	CH2-2,4-diFC <sub>6</sub> H3	CH2C6H11	CH2C6H11	n-C3H7	CH2-2, 4-diCH30C6H3	CH2-2,4,6-triFC6H2	CH2-3-FC6H4	СН(СН3)2	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>7</sub> CH <sub>3</sub>	2,6-diClC <sub>6</sub> H <sub>3</sub>	CH <sub>3</sub>	$CH_2(C_6H_4)(C_6H_5)$	2,4-diFC <sub>6</sub> H <sub>3</sub>	CH3 C6H11	CH <sub>3</sub> C <sub>6</sub> H <sub>5</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>
25	9	R3	_	_	_	_	_		_	_			_					CH3	<del>1</del> 3	H3	
30	<u>Tal</u>	R <sup>2</sup>	4-CH30C6H4	C6H5	4-CH30C6H4		4-CH30C <sub>6</sub> H4			4-pyridinyl	2-CH30C6H4	3-CH30C6H4	C6H11 1	4-(CH3)2NC6H4	2-furanyl	4-(t-C4Hg)C6H4 H	2-thienyl	4-HOC <sub>6</sub> H <sub>4</sub> (	(сн3)5сн (	42 -	'-C6H4 P
35 40		R1	4-CH30C6H4	C <sub>6</sub> H <sub>5</sub>	4-СН <sub>3</sub> ОС <sub>Б</sub> Н4	4-(CH3)2NC6H4	4-СН3ОС6Н4	1-C3H7	3-pyridinyl	4-pyridinyl	2-СН3ОС6Н4	3-CH30C6H4 3	26H11	,6H5	2-furanyl	1-(t-C4Hg)C6H4	-thieny	4-HOC6H4	(сн3) 2сн	359 С <sub>6</sub> Н <sub>5</sub> СН <sub>2</sub>	644-2-0CH20-2'-C6H4
	>		42 4	343 (	44 '	45 4	46 4	47 1	48	49 4	20 %	51	25 (	23	54 2	55 4	356 2	57 4	83	29 C	8
45	L		m	m	3	m	m	κ'n	8	S.	m.	W	Μ̈́.	<b>⇔</b> i	m	Ę,	m	m	<u>س</u>	ξ.	m
45																					
50																					

		mp°C																			
5		<sup>8</sup> 6	£	(CH2)6CH3	(CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	(сн) всн3	CH3	5 C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH2) 3CH3	5 C <sub>6</sub> H <sub>5</sub>	CH2)6CH3	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	CH2)6CH3	СН2)6СН3	(CH2)6CH3	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	CH2) 6CH3	CH <sub>2</sub> )6CH <sub>3</sub>	(сн2)есн3
10		<b>⊆</b> i	8	8	2	2	2	5	3 (	2	5	2	5 (	5 (	2 (	2	2	2	2	_	2 ((
		≻I	0		2 0	H2	0	0	0	0		0	0	0	0	0	0	0	0	0	0
		×I	S	0	CH <sub>2</sub>	H	S	0	至	₹	S	S	S	¥	Ë	S	Ŧ	3	S	8	S
15			C <sub>6</sub> H <sub>3</sub>		CH2-2,4-diFC6H3	-diFC <sub>6</sub> H3	C <sub>6</sub> H <sub>3</sub>	CH2-2, 4-diFC6H3	•	Н3	Н3	C6H3	CH2-2,4-diFC <sub>6</sub> H3	-diFC <sub>6</sub> H <sub>3</sub>	-diFC <sub>6</sub> H3	-diFC <sub>6</sub> H3	-diFC <sub>6</sub> H3	CH2-2,4-diFC <sub>6</sub> H3			21
20	Table 3 (continued	R4	2,4-diFC <sub>6</sub> H <sub>3</sub>	C6H11	CH <sub>2</sub> -2,4	CH2-2,4	2,4-diF	CH2-2,4	C6H11		(CH2)7CH3	2,4-diF	CH <sub>2</sub> -2, 4.	CH2-2,4	CH2-2,4.	CH2-2,4	CH2-2,4	CH2-2,4.	n-C3H7	$CH_2C_6H_{11}$	СН(СН3)5
25	Table 3	R3	=	<b>=</b>	I	=	I	Ŧ	I	CH <sub>2</sub> C <sub>6</sub> H <sub>5</sub>	C6H5	Ŧ	Ŧ	I	<b>=</b>	×	Ŧ	Ŧ	CH <sub>3</sub>	<b>=</b>	I
30 35		R <sup>2</sup>	4-CH3C6H4	4-(CH3)2NC6H4	C6H11			(СН3)2СН	6H4	4-CH30C6H4	4-(CH3)2NC6H4	(СН3)2СН	4-CH3SC6H4	4-CH3SOC6H4	4-CH3SO2C6H4	4-CH3SC6H4	4-CH3SOC6H4	4-CH3SO2C6H4	4-CH30C6H4	$4-CH_{3}0C_{6}H_{4}$	4-СН <sub>3</sub> 0С <sub>6</sub> Н4
40		$\frac{R1}{R}$	361 4-CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	4-CH30C6H4	363 4-CH30C6H4	4-СН3ОС6Н4	365 4-(CH3)2NC6H4	4-(CH3)2NC6H4	C6H40C	С6Н5	C <sub>6</sub> H <sub>5</sub>	3	371 4-CH3SC6H4	SOC6H4	S02C6H4			CeHs	377 4-СН30С6Н4	378 4-СН30С6Н4	379 4-СН30С6Н4
45	<u> </u>	No.	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379
50																					

		J. dw											
5		R6	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	H2)6CH3	(CH2)6CH3	C <sub>6</sub> H <sub>5</sub>	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	H2)6CH3	H2)6CH3	5 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	3 (CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	H2)6CH3	ЧS
10		⊊l	2 (C	3 (C	) (C	<sub>6</sub> C <sub>6</sub>	5 (C	2 (C	5 (CI	5 (C	3 (CI	) (C	5 C <sub>6</sub> H <sub>5</sub>
		<b>≻</b> I	0	S	0	0	0	0	#2	0	0		
15	ned	×I	S	S	S	S	<b>S</b> 05	S	S	S	20	S	205 (
20 25	Table 3 (continued	R4	CH <sub>2</sub> C <sub>6</sub> H <sub>5</sub>	CH2-2,4-diFC <sub>6</sub> H3	CH2C6H11	$(CH_2)_7CH_3$	n-C <sub>3</sub> H <sub>7</sub>	C6H11	СН(СН3)2	C <sub>6</sub> H <sub>5</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	C6H11	(CH <sub>2</sub> ) 7CH <sub>3</sub>
		<u></u>	<b>=</b>	×	<b>=</b>	=	=	<b>=</b>	×	Ŧ	=	Ŧ	<b>=</b>
<i>30</i>		<u>R</u> 2								4-(CH3)2NC6H4		4-(CH3)2NC6H4	4-(CH3)2NC6H4
40		Ex. <u>No.</u> R <sup>1</sup>	4-CH <sub>3</sub> OC <sub>6</sub> H <sub>4</sub>	1 4-CH30C6H4	2 4-CH30C6H4	3 4-CH30C6H4	4-(CH3)2NC6H4	5 4-(CH3)2NC6H4	5 4(CH <sub>3</sub> )2NC <sub>6</sub> H <sub>4</sub>	7 4-(CH3)2NC6H4	3 4-(CH3)2NC6H4	9 4-(СН3)2C6H4	390 4-(CH <sub>3</sub> ) <sub>2</sub> NC <sub>6</sub> H <sub>4</sub>
<b>4</b> 5	ı	N E	38(	38.	38.	38	38	38;	38(	38,	386	38	39(
50													

## Footnotes To Table 3

5

10

15

20

25

30

35

40

45

50

- (a)  ${}^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  11.7-11.6(bs,1H), 7.7-7.1(m,10H), 3.4(t,2H,J=7Hz), 3.3-3.2(m,2H), 2.9(t,2H,J=7Hz), 2.35-2.25(m,2H), 1.8-1.1(m,18H), 1.0-0.8(m,6H).
- (b) <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 11.8-11.7(bs,1H), 7.7-7.1(m,10H), 3.4(t,2H,J=6.6Hz), 3.2(t,2H,J=8.7), 2.9(t,2H,J=6.5Hz), 2.4-2.2(m,2H), 1.8-1.1(m,20H), 0.85(sextet, 6H,J=4.1Hz).
- (c)  ${}^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  7.6-7.1(m,11H), 3.4-2.9(m,6H), 2.2-2.1(m,2H), 1.8-1.0(m,27H), 0.9-0.8(m,3H).
- (d)  ${}^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  7.6-7.2(m,11H), 6.9-6.8(m,2H), 3.7-3.4(m,2H), 3.2-3.0(m,4H), 1.9-1.0(m,17H).
- (e)  ${}^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  7.6-7.1(m,16H), 3.6-3.4(m,2H), 3.3-2.9(m,4H), 1.9-1.0(m,16H), 0.9-0.8(m,3H).
- (f)  ${}^{1}$ H NMR (DMSO-d<sub>6</sub>)  $\delta$  11.64(bs,1H), 3.18(m,4H), 2.98-2.74(m,4H), 2.08(d,2H), 1.77-0.81(m,42H).
- (g)  $^{1}$ H NMR (DMSO-d<sub>6</sub>)  $\delta$  12.36(s,1H), 7.39(d,2H), 7.31(d,2H), 6.95(d,2H), 6.85(d,2H), 3.76(s,3H), 3.74(s,3H), 3.28-3.03(m,6H), 2.22(t,2H), 1.75-1.11(m,18H), 0.83(m,6H).
- (h)  $^{1}$ H NMR (DMSO-d<sub>6</sub>)  $\delta$  12.35(bs,1H), 7.62-7.17(m,7H), 6.95(d,2H), 6.85(d,2H), 3.8-3.66(m,8H), 3.35-3.02(m,6H), 1.78-1.14(m,16H), 0.85(m,3H).
- (1)  $^{1}$ H NMR (DMSO-d<sub>6</sub>)  $\delta$  12.33(bs,1H), 7.37(d,2H), 7.31(d,2H), 6.94(d,2H), 6.83(d,2H), 3.82(d,2H), 3.77(s,3H), 3.73(s,3H), 3.42-3.01(m,6H), 1.81-1.16(m,16H), 0.85(m,3H).
- (j)  $^{1}$ H NMR (DMSO-d<sub>6</sub>)  $\delta$  12.32(bs,1H), 7.43-6.8(m,11H), 3.78(s,3H), 3.73(s,3H), 3.65(s,2H), 3.35-3.01(m,6H), 1.77-1.16(m,16H), 0.87(m,3H).
- (k)  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  7.6-7.2(m,10H), 2.1(t,2H,J=7.4Hz), 2.5-2.3(m,7H), 1.8-1.6(m,2H), 1.5-1.2(m,18H), 0.9(quintet, 6H,J=5.1Hz).
- (1)  ${}^{1}$ H NMR (DMSO-d<sub>6</sub>)  $\delta$  12.12(s,1H), 7.31(d,2H), 7.20(d,2H), 6.70(d,2H), 6.63(d,2H), 3.18(m,4H), 3.03(m,2H), 2.91(s,6H), 2.87(s,6H), 2.08(d,2H), 1.64-0.82(m,30H).

#### **EXAMPLE 391**

## Preparation of cyclohexyl [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate

To a solution of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanamine (0.87 g, 0.002 mol) and sodium bicarbonate (5%, 1 mL) in toluene (10 mL) at 0° was added, dropwise, a solution of cyclohexylch-loroformate (0.32 g, 0.002 mol) in toluene (5 mL). The reaction mixture was allowed to warm to ambient temperature and stirred overnight. The solvent was removed under vacuum. The residue (1.0 g) was chromatographed with 7:3 hexane-ethyl acetate to give the title compound (0.61 g, 0.0011 mol) as a yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 11.1(bs,1H), 7.7-7.2(m,10H), 4.6(bs,1H), 3.3(t,2H,J=5.1Hz), 3.2(t,2H,J=7.5Hz), 3.0-(t,2H,J=5.2Hz), 1.9-1.2(m,26H), 0.9-0.8(m,3H).

## **EXAMPLE 401**

## 75 Preparation of phenyl N-[5-(4,5-bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylcarbamate

Part A. Employing the method of Example 118, Part B, but using phenyl chloroformate and triethylamine, phenyl, N-heptyl-N-(5-hydroxypentyl)carbamate was obtained as an oil (3.18 g, 0.00989 mol).  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  7.40-7.06(m,5H), 3.68-3.63(m,2H), 3.42-3.27(m,4H), 2.08-1.95(bs,1H), 1.75-1.26(m,16H), 0.90-(t,3H).

<u>Part B.</u> Employing the method of Example 118, Part C, but using phenyl N-heptyl-N-(5-hydroxypentyl)-carbamate, phenyl N-(5-bromopentyl)-N-heptylcarbamate was isolated as an oil (3.8 g, 0.0099 mol).  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  7.39-7.07(m,5H), 3.47-3.25(m,6H), 1.97-1.89(m,2H), 1.75-1.26(m,14H), 0.87(t,3H).

Part C. Employing the method of Example 118, Part D, but using phenyl N-(5-bromopentyl)-N-heptylcarbamate, the title compound was isolated as an oil (0.3 g, 0.000615 mol). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>)  $\delta$  11.07(s,1H), 7.35(m,2H), 7.18(t,1H), 7.05(d,2H), 3.31(m,2H), 3.20(m,2H), 2.95(m,3H), 2.8(m,1H), 1.67-1.06-(m,2H), 0.86(m,3H).

Additional carbamates, which are listed in Table 4, were prepared or could be prepared analogously according to the procedures of Examples 391 and 401.

30

20

25

35

40

45

50

					mp C	oil	oil(a)	oil(b)	oi1(c)	oil(d)	oil(e)	oil(f)	0j1(g)	oil( <b>h</b> )	011(1)	oil
5					<u>R</u> 6	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	(сн2) 6сн3	(сн2) есн3	(СН2) 6СН3	(сн2) есн3	(сн2) есн3	(сн2) есн3	(сн2) есн3	(сн2) есн3
10					<b>c</b> l	S.	ۍ آ	2	Ŋ	ເນ	Ŋ	Ŋ	ß	ις.	ß	2
		- F	OR4		>-1	0	0	0	0	0	0	0	0	0	0	0
15		-N <sub>2</sub> ) <sub>n</sub> N-	<b>\( \)</b>		×I	S	S	S	S	S	S	S	S	S	S	S
20	Table 4	X — (CH <sub>2</sub> ),N — R <sup>6</sup>	<b>-</b> 8-		R4	C6H11	C6H5	СН2СН(СН3)2	СН2СН3	(СН2) 7СН3	4-FC6H4	(CH <sub>2</sub> ) <sub>2</sub> CH <sub>3</sub>	CH <sub>2</sub> C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C6H5	C <sub>6</sub> H <sub>5</sub>
25		<u></u>	_		R3	Ŧ	Ŧ	æ	<b>=</b>	x	Ŧ	<b>=</b>	Ŧ	=	<b>=</b>	Ŧ
30		Г. д.			<u>R<sup>2</sup></u>	C6H5	C <sub>6</sub> H <sub>5</sub>	C6H5	C <sub>6</sub> H <sub>5</sub>	C6H5	4-(CH3)2NC6H4	4-CH30C6H4	(сн3)5сн			
35					<u>R1</u>									(CH3)2NC6H4	30C6H4	)2СН
40					[A]	C <sub>6</sub> H <sub>5</sub>	C6H5	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	C6H5	CeH5	C <sub>6</sub> H <sub>5</sub>	CeH5	4-(C	4-CH	(СН3
				Ë.	No.	391	392	393	394	395	396	397	398	399	400	401
45																
50																

			Je dw																			
5			શ્વ	CH3	C <sub>6</sub> H <sub>5</sub>	3-FC <sub>6</sub> H4	(CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	(CH <sub>2</sub> )6CH <sub>3</sub>	(CH <sub>2</sub> )6CH <sub>3</sub>	(CH <sub>2</sub> )6CH <sub>3</sub>	(CH2)6CH3	(CH2)6CH3	(CH2)6CH3	(CH <sub>2</sub> )6CH <sub>3</sub>	$(CH_2)_6CH_3$	(CH <sub>2</sub> )6CH <sub>3</sub>	(сн2)есн3	$(CH_2)_6CH_3$	(CH2)6CH3	$(CH_2)_6CH_3$	C <sub>6</sub> H <sub>5</sub>
10			⊑I	2	2	2	S	2	2	2	5	2	2	2	2	2	2	2	2	က	œ	2
			<b>≻</b> I	0	0	0	0	H2	0	0	0	0	0	0	0	0	#2	0	0	0	0	0
			×ı	S	0	CH <sub>2</sub>	¥	S	S	S	¥	CH2	S	¥	CH2	S	S	S	20	S	S	502
20	Table 4 (continued)		R4	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	CH2-2,4-diFC6H3	(CH <sub>2</sub> ) <sub>7</sub> CH <sub>3</sub>	(CH <sub>2</sub> ) <sub>7</sub> CH <sub>3</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	n-C3H7	C6H11	сн(сн3)2	C <sub>6</sub> H <sub>5</sub>	2,4-diFC <sub>6</sub> H3	C6H11	(CH <sub>2</sub> ) <sub>7</sub> CH <sub>3</sub>				
25	Table 4		હ્ય	Ŧ	Ŧ	×	I	Ŧ	x	±	Ŧ	Ŧ	C <sub>6</sub> H <sub>5</sub>	CH <sub>2</sub> CH <sub>3</sub>	CH2C6H5	CH <sub>3</sub>	I	I	I	æ	I	I
30 35			R <sup>2</sup>	C6H11	(сн3)5сн	(сн3)5сн	1-CH30C6H4	4-(CH3)2NC6H4	(сн3)5сн	4-CH3SC6H4	4-CH3SOC6H4	4-CH3SO2C6H4	4-CH <sub>3</sub> SC <sub>6</sub> H <sub>4</sub>	4-CH3SOC6H4	4-CH3SO2C6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4
40			$\frac{R_1}{R_1}$	4-(CH3)NC6H4	4-(CH3)NC6H4	C6H11	CeH5	C6H <sub>5</sub>	(сн3)2сн	4-CH3SC6H4	4-CH3SOC6H4	1-CH3SO2C6H4	C6H5			NC6H4	NC6H4	NC6H4	NC6H4	NC6H4	438 4-(CH3)2NC6H4	NC6H4
45		Ex.	No.	421	422	423	424 (	425	426	427	428	429	430 (	431	432	433	434	435	436	437	438	439
50																						

			J. Chi							
5			R6	(CH <sub>2</sub> )6CH <sub>3</sub>	(CH2)6CH3	(сн2) есн3	(сн2) есн3	(сн2) есн3	(сн2) есн3	C <sub>6</sub> H <sub>5</sub>
10			⊏I	5	2	2	ည	m	œ	2
				0					0	S
15			×I	S	S	S	20	S	502	S
20 25	Table 4 (continued		R4	n-C3H7	C6H11	СН(СН3)2	C <sub>6</sub> H <sub>5</sub>	2,4-diFC <sub>6</sub> H <sub>3</sub>	C <sub>6</sub> H <sub>11</sub>	(CH2)7CH3
25	Table		<del>ال</del> اع	I	I	CH3.	· =	<b>x</b>	I	×
30				6H4	6H4	6H4	6H4	6H4	6H4	.6H4
35			R2	4-CH <sub>3</sub> 0C	4-CH30C	4-CH30C	4-CH30C	4-CH30C	4-CH <sub>3</sub> 0C	4-CH30C6H4
40			No. R1	4-CH30C6H4	4-CH <sub>3</sub> 0C <sub>6</sub> H <sub>4</sub>	4-CH30C6H4	4-СН30С6Н4	4-CH30C6H4	4-CH30C6H4	4-CH30C6H4
45		<u>۳</u>	No.	440	441	442	443	444	445	446
50										
55										

## Footnotes To Table 4

5

10

15

20

25

30

35

40

45

50

- (a)  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  10.6(s,1H), 7.7-7.0(m,15H), 3.4(q,4H,J=4.7Hz),2.9(t,2H,J=5.8Hz), 1.8-1.2(m,16H), 0.95-0.75(m,3H).
- (b)  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  10.9(s,1H), 7.75-7.1(m,10H), 3.75(d,2H,J=6.3Hz), 3.3(t,2H,J=6.0Hz), 3.15(t,2H,J=7.5Hz), 3.0(t,2H,J=6.2Hz), 2.0-1.2(m,17H), 0.9(t,9H,J=3.2Hz).
- (c)  ${}^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  10.9(s,1H), 7.75-7.1(m,10H), 4.0(d,2H,J=6.8Hz), 3.4-2.95(m,6H), 1.9-1.1(m,19H), 1.0-0.8(m,3H).
- (d)  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  10.7(s,1H), 7.7-7.2(m,10H), 4.1 to 3.9(m,2H), 3.4-2.9(m,6H), 1.8-1.2(m,28H), 0.9-0.8(m,6H).
- (e)  ${}^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  10.4(s,1H), 7.7-6.8(m,14H), 3.5-2.9(m,6H), 1.9-1.1(m,16H), 1.0-0.8(m,3H).
- (f)  ${}^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  10.9(s,1H), 7.75-7.1(m,10H), 4.0(q,2H,J=6.9Hz), 3.3(t,2H,J=9.5Hz), 3.2(t,2H,J=7.5Hz), 3.0(t,2H,J=7.8Hz), 1.8-1.1(m,18H), 0.9(t,3H,J=7.2Hz).
- (g)  $^{1}$ H NMR (CDCl<sub>3</sub>)  $\delta$  10.5(s,1H), 7.7-7.2(m,15H), 5.05(s,2H), 3.3(q,2H,J=5.7Hz), 3.2(t,2H,J=7.4Hz), 3.0(q,2H,J=5.4Hz), 1.8-1.1(m,16H), 0.9(t,3H,J=6.4Hz).
- (h)  $^{1}$ H NMR (CDC1<sub>3</sub>)  $\delta$  10.0-9.8(bs,1H), 7.57-7.03(m,9H), 6.63(m,4H), 3.43-3.26(m,4H), 3.09-2.86(bs,14H), 1.81-1.25(m,16H), 0.89(t,3H).
- (i)  $^{1}$ H NMR (DMSO-d<sub>6</sub>)  $\delta$  12.34(s,1H), 7.39-7.22(m,6H), 7.19(t,1H), 7.06(d,2H), 6.94(d,2H), 6.84(d,2H), 3.77(s,3H), 3.72(s,3H), 3.40-3.20(m,4H), 3.09(m,2H), 1.75-1.17(m,16H), 0.84(m,3H).

5				읾	<b>(сн</b> 2) <sub>6</sub> сн3	(CH2)3CH3	(CH2)8CH3	C6H5	2,4-diFC <sub>6</sub> H <sub>3</sub>	(CH2)6CH3	(CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	CH3	C <sub>6</sub> H <sub>5</sub>	( <b>сн</b> 2) <sub>6</sub> сн3	(CH <sub>2</sub> ) <sub>3</sub> <sup>3</sup> H <sub>3</sub>
10				7	NH-2,4-diFC6H3 (CH2)6CH3	H-2,4-diFC6H3	NH-2,4-diFC6H3	СН2СН(СН3)2	СН2СН(СН3)2	СН2СН(СН3)2	0(сн2)7сн3	0(CH <sub>2</sub> ) <sub>7</sub> CH <sub>3</sub>	0(CH <sub>2</sub> ) <sub>7</sub> CH <sub>3</sub>	NHCH(CH <sub>3</sub> ) <sub>2</sub>	NHCH(CH3)2
15				_			2			2			2		~
20	Table 5	X-A-N-R <sup>6</sup>		<b>∀</b>	:H2CH(CH3)(CH2)3 (	CH2)3CH(CH3)CH2	CH2)3C(CH3)2CH2	$(CH_2)CH(C_5H_{11})(CH_2)_2$ 0	н(снз) (сн2)4	<b>Н2СН=СН(СН2)2</b>	СН2)3СН=СН(СН2)2 (	H2C≡C(CH2)2	CH2)3C≡C(CH2)2	$CH_2CH(CH_3)(CH_2)_3$	(сн <sub>2</sub> ) зсн (сн <sub>3</sub> ) сн <sub>2</sub>
		Z Z -E			U	CH <sub>2</sub> (	H		ပ	сн2 с		ပ	_	сн2 с	) ₩
30				×I	S	ວ	Z	0	S		J3 ME	H5 0	S	5	Z
		<u>r</u> gr		<u>س</u> ا	<b>=</b>	<b>=</b>	<b>=</b>	×	CH3	<b>=</b>	CH2CH	CH <sub>2</sub> C <sub>6</sub>	$C_6H_5$	<b>=</b>	<b>=</b>
35 40				R <sup>2</sup>	C <sub>6</sub> H <sub>5</sub>	C6H5	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub>	4-(CH3)2NC6H4 CH3	4-(CH3)2NC6H4	4-(CH3)2NC6H4 CH2CH3	4-(CH3)2NC6H4 CH2C6H5	4-CH30C6H4	4-CH30C6H4	4-CH30C6H4
45				No. R1 R2	-6H5	-6H5	.6H5	-6H5	1-(CH3)2NC6H4	1-(CH3)2NC6H4	1-(CH3)2NC6H4	1-(CH3)2NC6H4	1-CH30C <sub>6</sub> H4	1-СН30С6Н4	4-сн30с6н4
			×	اه	47 (	48 (	49 (	20 (	21 7	52 4	23 7	54 4	22 7	7 95	457 4
50			ш	Z	4	4	4	4	4	4	4	4	4	Þ	4

	45	<b>35</b>		30	25		15	10	5
				<b>⊢-</b> 1	Table 5 (continued				
×									
اف	R1	R <sup>2</sup>	હ્ય	×I	Ą	<b>≻</b> I	7		શ્વ
158	4-CH30C6H4	4-CH30C6H4	I	0	(СН2)3СН(СН3)2СН2	H2	<b>NHCH</b> (CH <sub>3</sub> ) <sub>2</sub>	2	( <b>сн</b> 2)8сн <sub>3</sub>
59	(сн3) 2сн	(сн3)5сн	I	S	(CH2)2CH(C5H11) (CH2)2	H <sub>2</sub> ) <sub>2</sub> 0	(CH <sub>2</sub> ) <sub>7</sub> CH <sub>3</sub>		C6H5
9	(CH <sub>3</sub> ) <sub>2</sub> CH	(сн3)2сн	CH3	CH <sub>2</sub>	СН(СН3) (СН2)4	S	(CH2)7CH3		2,4-diFC6H3
61	(сн3)5сн	(сн3)2сн	<b>=</b>	H	СН2СН=СН(СН2)2	H2	(CH2)7CH3		(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>
9	(сн3) 2сн	(СН3)2СН	±	0	(CH <sub>2</sub> ) <sub>3</sub> CH=CH(CH <sub>2</sub> ) <sub>2</sub>	0	0C <sub>6</sub> H <sub>5</sub>		$(CH_2)_3CH_3$
463	C6H11	C6H11	×	S	CH <sub>2</sub> C≡C(CH <sub>2</sub> ) <sub>2</sub>	S	0C <sub>6</sub> H <sub>5</sub>		CH <sub>3</sub>
164	C6H11	C6H11	C <sub>6</sub> H <sub>5</sub>	CH <sub>2</sub>	(CH2)3C≡C(CH2)2	#2	0C <sub>6</sub> H <sub>5</sub>		C <sub>6</sub> H <sub>5</sub>
9	C6H11	C6H11	I	¥	СН2СН(СН3) (СН2)3	0	NH(CH <sub>2</sub> )7CH <sub>3</sub>	<del>1</del> 3	$(CH_2)_6CH_3$
99	C6H11	C6H11	<b>=</b>	0	(сн2)3сн(сн3)сн2	S	NH(CH2)7CH3	<del>I</del> 3	$(CH_2)_3CH_3$
191	CeH5	4-CH30C6H4	<b>=</b>	S	(CH2)3C(CH3)2CH2	#2	NH(CH <sub>2</sub> )7CH <sub>3</sub>	H3	(СН2)8СН3
89	C <sub>6</sub> H <sub>5</sub>	4-CH30C6H4	Ŧ	СН2	(CH2)2CH(C5H11)(CH2)2	H2)2 0	CH <sub>2</sub> C <sub>6</sub> H <sub>5</sub>		C6H5
691	CeH5	4-CH30C6H4	CH3	¥	СН(СН3) (СН2) 4	S	C <sub>6</sub> H <sub>5</sub>		2,4-diFC <sub>6</sub> H <sub>3</sub>
170	C <sub>6</sub> H <sub>5</sub>	4-CH30C6H4	Ŧ	0	СН2СН=СН(СН2)2	H <sub>2</sub>	CH <sub>2</sub> C <sub>6</sub> H <sub>5</sub>		$(CH_2)_{6}CH_3$
171	C <sub>6</sub> H <sub>5</sub>	4-(CH3)2NC6H4	Ŧ	S	(сн2) 3СН=СН(СН2) 2	0	0СН(СН3)5		(CH2)3CH3
172	C <sub>6</sub> H <sub>5</sub>	4-(CH3)2NC6H4	Ŧ	CH <sub>2</sub>	CH2C≡C(CH2)2	S	0СН(СН3)5		CH <sub>3</sub>
473	C <sub>6</sub> H <sub>5</sub>	4-(CH3)2NC6H4	C6H5	¥	(CH2)3C≡C(CH2)2	#2	0СН(СН3)2		C <sub>6</sub> H <sub>5</sub>
174	4-(CH3)2NC6H4	4-(CH3)2NC6H4	<b>±</b>	S	СН2СН(СН3) (СН2)3	0	СН2СН(СН3)2	2	$(CH_2)_3CH_3$
475	4-(CH3)2NC6H4	4-(CH3)2NC6H4	=	S	(CH <sub>2</sub> ) <sub>3</sub> CH(CH <sub>3</sub> )CH <sub>2</sub>	0	0(СН2)7СН3	æ	(СН2) ӨСН3
9/1	4-(CH3)2NC6H4	4-(CH3)2NC6H4	Ŧ	S	(CH <sub>2</sub> ) <sub>3</sub> C(CH <sub>3</sub> ) <sub>2</sub> CH <sub>2</sub>	0	NH-2,4-diFC6H3	FC <sub>6</sub> H <sub>3</sub>	(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>

5		<u>R</u>	(CH <sub>2</sub> )8 <sup>CH<sub>3</sub></sup>	$(CH_2)_6$ CH <sub>3</sub>	(CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	$(CH_2)_3$ CH3	$(CH_2)_{6}(H_3)$	$(CH_2)_6CH_3$
10		7	4-diFC <sub>6</sub> H <sub>3</sub>	2)2CH3	O CH2-2,4-diFC6H3	0 0-2,4-diFC <sub>6</sub> H <sub>3</sub>	0 CH2-CH(CH3)2	Ę.
15		<b>≻</b> I	2 0 NH-2,	0 NH(CH2)2CH3	0 CH2-2	0 0-2,4	0 CH2-C	0 сн2сн3
Table 5 (continued			(CH2)2CH(C5H11)(CH2)2 0 NH-2,4-diFC6H3	.H <sub>2</sub> )4	CH <sub>2</sub> ) <sub>2</sub>	(CH2)3CH=CH(CH2)2	12)2	:(CH2)2
25 <b>e</b> qe L		VΙ	(сн2) 2сн(	СН(СН3)(СН2)4	CH2CH=CH(CH2)2	(CH <sub>2</sub> ) <sub>3</sub> CH=	CH2C=C(CH2)2	(CH2)3C≡C(CH2)2
30		<del>الاع</del> ا×	S0	1 502 0	S	S S	S	S
35		R2	4-(CH3)2NC6H4 1	4-(CH3)2NC6H4 H	4-CH30C6H4C6H4 h	4-CH30C6H4 F	4-CH30C6H4 F	4-CH30C6H4 F
45		$\frac{R1}{R}$	477 4-(CH3)2NC6H4 4	-(CH3)2NC6H4	-CH30C6H4	-сн30с6Н4	-сн30с6н4	482 4-CH30C <sub>6</sub> H4
	<u>۳</u>	No.	477 4	478 4	479 4	480 4	481 4	482 4

## **Utility**

50

The compounds of the present invention are inhibitors of the enzyme acyl-CoA: cholesterol acyltransferase and are thus effective in inhibiting esterification and transport of cholesterol across the intestinal wall.

## A. Asssay of the Inhibition of Acyl-CoA: Cholesterol Acyltransferase (ACAT) in Hepatic Microsomes

The ability of the compounds to inhibit ACAT, the enzyme responsible for the intracellular synthesis of cholesteryl esters, was tested as follows. Male Sprague Dawley rats weighing 150-300 g, were fed rat chow ad libitum. The animals were fasted for twenty-four hours prior to being sacrificed by decapitation. The livers were perfused in situ with 50 ml of cold 0.25 M sucrose, excised, and homogenized in three volumes of 0.1 M phosphate buffer, pH 7.4, that contained 0.5 mM EDTA (ethylenediaminetetraacetic acid), 1.0 mM glutathione, 0.25 M sucrose and 20 mM leupeptin. Microsomes were obtained by differential centrifugation; the supernatant from an initial spin at 15,000 x g for 15 minutes was centrifuged at 105,000 x g for 1 hour to pellet the microsomes. The microsomes were suspended in homogenization buffer, reisolated by centrifugation, and stored at -70 °C. Microsomes were used within one month of preparation.

The control assay in a final volume of 200 µI consisted of 200 µg of microsomal protein, 75 µm <sup>14</sup> Coleoyl-CoA (10,000 dpm/nmol) in 0.1 M phosphate, pH 7.4, that contained 1 mM glutathione. Compounds were added in 5-10 µI of DMSO (dimethyl sulfoxide) and additional controls were run with DMSO only. All components, except the oleoyl-CoA, were preincubated for 15 min. at 37 °C prior to the initiation of the reaction by the addition of oleoyl-CoA. The assay was terminated after 10 min by the addition of 500 µI of hexane: isopropanol (3:2, v/v). 20,000 dpm of <sup>3</sup>H-cholesteryl oleate and 10 µg of unlabeled cholesteryl oleate and oleic acid were added as an internal standard and carriers, respectively. After allowing 10 min. for lipid extraction, the samples were centrifuged at 1,000 x g for 10 min. to separate the solvent layers. 200 µI of the top (hexane) layer containing the neutral lipids was spotted onto a Baker SI250-Pa silica gel TLC plate and the plate developed using a hexane: diethyl ether: acetic acid (170:30:1 v/v/v) mobile phase. The lipids were visualized by their interaction with iodine vapor and the cholesteryl ester spot was scraped into a scintillation vial and counted. The specific activity of ACAT in the control incubation averaged 260 pmol/min/mg microsomal protein. The inhibition of ACAT activity by the compounds is shown in Table 6; the data are expressed as the concentration at which ACAT activity is inhibited by 50% (IC<sub>50</sub>).

## B. Assay of the Inhibition of Cholesterol Esterification in Mammalian Cells

The esterification of cholesterol was determined in the murine macrophage-like cell line J774.A1. Cells were seeded in 35 mm wells at a density of 300,000 cells per well in 2 mls of Dulbecco's Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Cells were incubated at 37°C in an atmosphere of 5% CO2 and 93% humidity. After 24 hours the media was changed to 0.68 mls 10% FBS-DMEM containing 34 µg of acetylated human low density lipoprotein (ac-LDL) to increase the intracellular concentration of cholesterol and promote esterification. At 41 hours, various inhibitors were added to the cells in DMSO (10 µI/ml maximum). At 43 hours, the cells were pulsed with 0.1 mM <sup>14</sup>C-oleic acid (10,000 dpm/nmol) complexed with BSA (bovine serum albumin) to follow cholesterol ester formation. The experiment was terminated at 45 hours by washing the monolayers 3 times with 3 ml of Tris-buffered saline at 4°C. The lipids were extracted by incubating the monolayers with 1.5 ml of hexane: isopropanol (3:2, v/v) for 30 min. under gentle agitation. During this period, 10,000 dpm 3H-cholesteryl linoleate and 10 µg of cholesteryl oleate were added as an internal standard and carrier respectively. The organic solvent was removed and the cells were washed with an additional 1.0 ml of hexane: isopropanol which was combined with the original extract. The cells were allowed to dry overnight, digested with 1.5 ml of 0.2 N sodium hydroxide for 1 hour and an aliquot of the solubilized protein used for protein determination using the Lowry method. The organic extract was taken to dryness, the residue resuspended in 100 µl of chloroform and the lipids separated on silica gel impregnated glass fiber plates using a hexane: diethylether: acetic acid (170:30:1, v/v/v) solvent system. Individual lipids were visualized with iodine and the cholesteryl ester spot cut out and transferred to scintillation vials to determine the amount of radioactivity. The conversion of oleic acid to cholesteryl ester in control averaged 0.54 mmol/hour/mg protein and was increased upon the addition of ac-LDL to about 10.69 ± 0.69 mmol/hour/mg protein. The inhibition of esterification by the compounds is shown in Table 7; the data are expressed as the concentration at which ACAT activity is inhibited by 50% (IC<sub>50</sub>). It should be noted that many of the intermediates had inhibitory activity in the in vitro ACAT assay and in the macrophage assay. For example, N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanaminehydrochloride had IC50's of 100 nM and 6 µm in the in vitro ACAT and macrophage assay, respectively.

## C. Assay of Antihypercholesterolemic Activity in Cholesterol-fed Hamsters

Inhibition of ACAT activity in the gut reduces the absorption of cholesterol in cholesterol-fed animals. Hamsters weighing approximately 100 g, were maintained on a diet supplemented with 0.8% cholesterol. The treatment group received 1-100 mg/kg/day, p.o., of the test compound dissolved in 500  $\mu$ I of corn oil for a period of two weeks. The control group were pair-fed to the treatment group and were dosed with 500  $\mu$ I of the corn oil vehicle. At sacrifice, the hamsters were anesthetized with CO<sub>2</sub> and exsanguinated via cardiac puncture. Total serum cholesterol was determined on a Du Pont aca® IV. The data were expressed in terms of mg cholesterol per 100 ml of serum (mg %). The antihypercholesterolemic activity of the compound of Example 1 is shown in Table 8.

Table 6
Inhibition of <u>In Vitro</u> Hepatic ACAT Activity by Various Compounds

10	Compound of Example	In Vitro ACAT IC50 (nM)
	1	13
	2	23
15	3	8
	4	60
	5	12
	6	3,600
20	7	41
	8	10
	9	930
25	53	17
	64	30
	71	16
	85	60
30	94	10
	97	25
	105	20
35	107	1,000
	110	60
	114	40
40	118	170
40	122	80
	160	490
	186	2,850
45	188	20
	189	70
	190	30
50	191	400
	192	70

55

Table 6 (continued)

5	Compound of Example	In <u>Vitro</u> ACAT IC <sub>50</sub> (nM)
10	193	60
	195	40
	196	300
	197	119
15	198	40
	199	20
	200	710
20	201	200
20	204	500
	206	40
	207	9
25	208	20
	209	1,400
	212	60
30	267	58
30	269	8
	272	16
	289	30
35	290	140
	291	130
	329	3,500
40	330	280
40	331	25
	332	3
	333	30
45	334	160
	335	30
	338	30
50	339	700
50	340	200

Jable 6 (continued)

5	Compound of Example	<u>In Vitro</u> ACAT IC <sub>50</sub> (nM)
10	341	605
10	342	250
	343	300
	344	240
15	392	20
	393	35
	394	33
20	395	500
	396	10
	397	40
	398	9
25	399	120

Table 7

30

# Inhibition of Cholesterol Esterification <u>in Macrophage by Various Compounds</u>

35

	Compound of Example	Cholesterol Esterification IC <sub>50</sub> (µM)
40	1	1.0
	2	0.8
	3	17.5
45	4	4.6
	5	2.5
	6	3.8
50	7	7.5
	8	0.5

Table 7 (continued)

# Inhibition of Cholesterol Esterification in Macrophage by Various Compounds

10	Compound of Example	Cholesterol Esterification IC <sub>50</sub> (μΜ)
	9	11.2
15	53	0.4
	64	0.6
	71	1.9
20	85	3.1
	94	0.1
	97	0.7
25	105	0.3
25	107	2.3
	110	0.9
	114	3.5
30	118	0.1
	122	0.3
	160	1.6
35	186	6.2
	188	0.9
	189	2.2
	191	2.4
40	192	2.0
	193	2.7
	195	0.4
45	196	1.4
	197	0.1
	199	0.6
50	206	0.4
50	207	0.6

# Table 7 (continued)

# Inhibition of Cholesterol Esterification in Macrophage by Various Compounds

10	Compound of Example	Cholesterol Esterification IC <sub>50</sub> (µM)
	209	4.8
15	212	1.7
	267	6.1
	269	1.2
20	272	3.5
	289	2.5
	290	1.2
25	291	0.9
	329	3.4
	330	4.4
22	331	0.2
30	332	0.1
	333	1.6
	334	1.1
35	338	0.3
	339	0.2
	392	0.4
40	393	0.5
	394	0.5
	395	3.9
45	396	0.6
	397	0.8
	398	1.3

55

50

Table 8

Dose Response Evaluation of Example 1 in Hypercholesterolemic Hamsters Dose (mg/kg/day) Serum Cholesterol (mg %)a Decrease (%) Control Treated 400 ± 25 295 ± 12 26 1 3 381 ± 17 279 ± 16 27 10 371 ± 7 201 ± 12 46 30 368 ± 15 197 ± 11 46 100 400 ± 17 162 ± 8 60

a) Values are the mean ± SEM, n = 9-10 per group

## Dosage Forms:

5

10

15

The compounds of the present invention can be administered orally using any pharmaceutically acceptable dosage form known in the art for such administration. The active ingredient can be supplied in solid dosage forms such as dry powders, granules, tablets or capsules, or in liquid dosage forms, such as syrups or aqueous suspensions. The active ingredient can be administered alone, but is generally administered with a pharmaceutical carrier. A valuable treatise with respect to pharmaceutical dosage forms is Remington's Pharmaceutical Sciences, 16th Edition, 1980.

In the therapeutic use of intestinal ACAT inhibitors, the compounds utilized are administered to the patient at dosage levels of 1 to 28 g per day. For a normal male adult human of approximately 70 kg of body weight, this translates into a dosage of 14 to 400 mg per kilogram body weight per day. The dosage administered will, of course, vary depending upon known factors such as the age, health, and weight of the recipient; nature and extent of symptoms, kind of concurrent treatment, frequency of treatment, and the effect desired. Useful pharmaceutical dosage forms for administration of the compounds of this invention can be illustrated as follows:

#### **Tablets**

Tablets are prepared by conventional procedures so that the dosage unit is 500 milligrams of active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose and 10 milligrams of magnesium stearate.

## Capsules

40 Capsules are prepared by conventional procedures so that the dosage unit is 500 milligrams of active ingredient, 100 milligrams of cellulose and 10 milligrams of magnesium stearate.

## Syrup

45

50

	Wt. %
Active Ingredient	10
Liquid Sugar	50
Sorbitol	20
Glycerine	5
Flavor, Colorant and Preservative	as required
Water	as required

The final volume is brought up to 100% by the addition of distilled water.

## Aqueous Suspension

E	
_	

10

	Wt. %
Active Ingredient	10
Sodium Saccharin	0.01
Keltrol® (Food Grade Xanthan Gum)	0.2
Liquid Sugar	5
Flavor, Colorant and Preservative	as required
Water	as required

Xanthan gum is slowly added into distilled water before adding the active ingredient and the rest of the formulation ingredients. The final suspension is passed through a homogenizer to assure the elegance of 15 the final products.

## Resuspendible Powder

20

25

	Wt. %
Active Ingredient	50.0
Lactose	35.0
Sugar	10.0
Acacia	4.7
Sodium Carboxylmethylcellulose	0.3

Each ingredient is finely pulverized and then uniformly mixed together. Alternatively, the powder can be prepared as a suspension and then spray dried.

## Semi-Solid Gel

35

35		<b>W</b> t. %
	Active Ingredient	10
	Sodium Saccharin	0.02
	Gelatin	2
40	Colorant, Flavor and Preservative	as required
	Water	as required

Gelatin is prepared in hot water. The finely pulverized active ingredient is suspended in the gelatin solution and then the rest of the ingredients are mixed in. The suspension is filled into a suitable packaging container and cooled down to form the gel.

## Semi-Solid Paste

50

	Wt. %
Active Ingredient	10
Gelcarin® (Carrageenin gum)	1
Sodium Saccharin	0.01
Colorant, Flavor and Preservative	as required
Water	as required

Gelcarin® is dissolved in hot water (around 80 °C) and then the fine-powder active ingredient is suspended in this solution. Sodium saccharin and the rest of the formulation ingredients are added to the suspension while it is still warm. The suspension is homogenized and then filled into suitable containers.

## Emulsifiable Paste

10

15

20

	Wt. %
Active Ingredient	30
Tween® 80 and Span® 80	6
Keltrol®	0.5
Mineral Oil	63.5

All the ingredients are carefully mixed together to make a homogenous paste.

The term "consisting essentially of" in the present disclosure is intended to have its customary meaning; namely, that all specified materials and conditions are very important in practicing the invention but that unspecified materials and conditions are not excluded so long as they do not prevent the benefits of the invention from being realized.

The foregoing disclosure includes all the information deemed essential to enable those of skill in the art to practice the claimed invention. The cited publications and applications may provide further useful information.

#### Claims

## Claims for the following Contracting States: AT, BE, CH, DE, FR, GB, GR, IT, LI, LU, NL, SE

## 1. A compound of the formula

wherein


 $R^1$  and  $R^2$  are selected independently from H,  $C_1$ - $C_8$  alkyl, provided that when  $R^1$  is H, then  $R^2$ 

cannot be H and when  $R^1$  is  $C_1$ - $C_8$  alkyl, then  $R^2$  cannot be  $C_1$ - $C_8$  alkyl,  $C_3$ - $C_8$  branched alkyl,  $C_3$ - $C_7$  cycloalkyl,  $C_4$ - $C_{10}$  cycloalkylalkyl,  $C_7$ - $C_{14}$  araalkyl, 2-, 3- or 4-pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  alkyl,  $C_3$ - $C_8$  branched alkyl,  $C_3$ - $C_8$ 0, NO<sub>2</sub>,

CF<sub>3</sub>, or NR<sup>7</sup>R<sup>8</sup>; or

R<sup>1</sup> and R<sup>2</sup> can also be taken together as

55



5

10

15

where L is O,  $O(CH_2)_{m+1}O$ , or  $(CH_2)_m$  where m is 0-4;

 $\mathbb{R}^3$ 

 $R^4$ 

is H, C<sub>1</sub>-C<sub>6</sub> alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl, CH<sub>3</sub>, CH<sub>3</sub>O, or CF<sub>3</sub>;

is straight chain C<sub>1</sub>-C<sub>8</sub> alkyl optionally substituted with F; C<sub>3</sub>-C<sub>8</sub> branched alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>4</sub>-C<sub>10</sub> cycloalkylalkyl, C<sub>7</sub>-C<sub>14</sub> araalkyl where the aryl group is optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>; C<sub>3</sub>-C<sub>6</sub> alkenyl or alkynyl, C<sub>1</sub>-C<sub>3</sub> perfluoroalkyl, phenyl optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-C<sub>4</sub> alkyl,C<sub>1</sub>-C<sub>4</sub> alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup> or NCOR<sup>7</sup>; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H,

25

30

20

CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>; 2-, 3- or 4-pyridinyl, pyrimidinyl, or

biphenyl;

 $\mathbb{R}^5$  $R^6$ 

is H, C<sub>1</sub>-C<sub>6</sub> alkyl, or benzyl;

is H, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> branched alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> alkenyl or alkynyl, phenyl optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C1-C<sub>4</sub> alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy,  $NR^7R^8$ , or  $NCOR^7$ ;

35

40

45

are selected independently from H or C<sub>1</sub>-C<sub>4</sub> alkyl;

Χ is S(O)<sub>r</sub>, O, NR<sup>5</sup>, CH<sub>2</sub>;

Α is C2-C10 alkyl, C3-C10 branched alkyl, C3-C10 alkenyl, or C3-C10 alkynyl;

Υ is O, S,  $H_2$ ;

Ζ is NHR4, OR4, or R4;

is 0-2,

or a pharmaceutically acceptable salt thereof.

## 2. A compound of Claim 1 wherein

R<sup>1</sup> and R<sup>2</sup>


R7 and R8

are selected independently from  $C_1-C_8$  alkyl, provided that when  $R^1$  is  $C_1-C_8$  alkyl, then  $R^2$  cannot be  $C_1$ - $C_8$  alkyl,  $C_3$ - $C_8$  branched alkyl,  $C_3$ - $C_7$  cycloalkyl,  $C_4$ - $C_{10}$ cycloalkylalkyl, C<sub>7</sub>-C<sub>14</sub> araalkyl, 2-, 3-, or 4-pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 2 groups selected from F, Cl, Br, OH, C<sub>1</sub>-C<sub>4</sub> alkoxy,  $C_1$ - $C_4$  alkyl,  $C_3$ - $C_8$  branched alkyl,  $CH_3S(O)_r$ ,  $NO_2$ ,  $CF_3$ , or  $NR^7R^8$ ; or

R1 and R2

can also be taken together as

50



10

where L is O,  $O(CH_2)_{m+1}O$ , or  $(CH_2)_m$  where m is 0-4.

- 3. A compound of Claim 2 wherein
  - R<sup>3</sup> is H, CH<sub>3</sub>, phenyl;
  - is H, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> branched alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, phenyl optionally substituted with 1 to 3 groups selected from CH<sub>3</sub>, CH<sub>3</sub>O, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, or di(C<sub>1</sub>-C<sub>4</sub>)-alkylamino; or benzyl optionally substituted with 1 to 3 groups selected from CH<sub>3</sub>, CH<sub>3</sub>O, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, or di(C<sub>1</sub>-C<sub>4</sub>)alkylamino;
  - X is S(O)r,  $CH_2$ ;
  - A is  $C_2$ - $C_{10}$  alkyl,  $C_4$ - $C_9$  branched alkyl.

25

30

35

20

- 4. A compound of Claim 3, wherein R¹ and R² are selected independently from C₁-C<sub>8</sub> alkyl, C₃-C<sub>8</sub> branched alkyl, C₃-C<sub>7</sub> cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C<sub>7</sub>-C₁₄ araalkyl, 2-, 3-, or 4-pyridinyl, 2-thienyl, or phenyl optionally substituted with 1 to 2 groups selected from F, Br, Cl, C₁-C₄ alkyl, C₃-C<sub>8</sub> branched alkyl, CH₃O, CH₃S(O)<sub>r</sub>, NO₂, CF₃, or di(C₁-C₄)alkylamino; or
  - R<sup>1</sup> and R<sup>2</sup> can also be taken together as

45

50

40

where L is O or OCH2O;

- R<sup>3</sup> is H;
- $R^4$  is  $C_1$ - $C_8$  alkyl,  $C_3$ - $C_8$  branched alkyl,  $C_3$ - $C_7$  cycloalkyl,  $C_4$ - $C_{10}$  cycloalkylalkyl,  $C_7$ - $C_{14}$  araalkyl, phenyl substituted with 1 to 3 groups selected from  $CH_3$ , F, Cl,  $CH_3O$ , CN; or benzyl optionally substituted with 1 to 3 groups selected from  $CH_3$ ,  $CH_3O$ , C

CN;

- $R^6$  is  $C_1$ - $C_8$  alkyl or phenyl optionally substituted with 1 to 3 groups selected from  $CH_3$ ,  $CH_3O$ , F, Cl, or CN;
- A is  $C_4$ - $C_9$  alkyl;
- 55 X is  $S(O)_r$ ;
  - Y is O,  $H_2$ .

- 5. Compounds of claims 1 to 4, selected from N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea;
  - N'-(2,4-difluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]-N-heptylurea;
  - N-butyl-N'-(2,4-dlfluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]urea;
  - N'-(2,4-dimethoxyphenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea;
  - N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-methylurea;
  - N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-propylurea;
  - N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-(3-fluorophenyl)-N-heptylurea;
  - N'-(2,4-difluorophenyl)-N-[5-[(4,5-diphenyl-1H-imidazol-2-yl)sulfonyl])pentyl]-N-heptylurea;
  - N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-(1-methylethyl)urea;
  - N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-2,4-difluoro-N-heptylbenzeneacetamide;
  - N'-cyclohexyl-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea;
  - N'-(2,4-difluorophenyl)-N-[5-[(4,5-diphenyl-1H-imidazol-2-yl)sulfinyl]pentyl]-N-heptylurea;
  - N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylbutanamide;
  - N-[5-[4.5-bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea;
  - N-[5-[4,5-bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylcyclohexaneacetamide;
  - N-[5-[4,5-bis(2-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea; phenyl [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate;
  - N-[5-[4,5-bis[4-(dimethylamino)phenyl]-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea;
    - N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-octyl-N-phenylurea;
    - N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-2,4-difluoro-N-heptylbenzeneacetamide;
  - phenyl [5-[4,5-bis(4-(dimethylamino)phenyl)-1H-imidazol-2-ylthio]pentyl]heptylcarbamate;
  - and N-[5-(4,5-dicyclohexyl-1H-imidazol-2-ylthio)pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea.
- **6.** A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claims 1 to 5 and a pharmaceutically acceptable carrier.
- 7. A process for preparing a compound of Formula (I):

wherein

R<sup>1</sup> and R<sup>2</sup> are selected independently from H, C<sub>1</sub>-C<sub>8</sub> alkyl, provided that when R<sup>1</sup> is H, then R<sup>2</sup>

cannot be H and when  $R^1$  is  $C_1$ - $C_8$  alkyl, then  $R^2$  cannot be  $C_1$ - $C_8$  alkyl,  $C_3$ - $C_8$  branched alkyl,  $C_3$ - $C_7$  cycloalkyl,  $C_4$ - $C_{10}$  cycloalkylalkyl,  $C_7$ - $C_{14}$  araalkyl, 2-, 3- or 4-pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  alkyl,  $C_3$ - $C_8$  branched alkyl,  $C_3$ - $C_8$ 0,  $C_1$ - $C_2$ 0,  $C_3$ - $C_4$ 0,  $C_3$ - $C_8$ 0,  $C_1$ - $C_2$ 0,  $C_3$ - $C_8$ 0,  $C_3$ - $C_8$ 0,  $C_3$ - $C_8$ 0,  $C_3$ - $C_8$ 0,  $C_1$ - $C_9$ -

CF<sub>3</sub>, or NR<sup>7</sup>R<sup>8</sup>; or

R<sup>1</sup> and R<sup>2</sup> can also be taken together as

55

45

5

10

15

20

25

30

20

10

5

where L is O,  $O(CH_2)_{m+1}O$ , or  $(CH_2)_m$  where m is 0-4;

 $\mathbb{R}^3$ 

is H,  $C_1$ - $C_6$  alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl, CH<sub>3</sub>, CH<sub>3</sub>O, or CF<sub>3</sub>;

 $R^4$ 

 $R^6$ 

is straight chain  $C_1$ - $C_8$  alkyl optionally substituted with F;  $C_3$ - $C_8$  branched alkyl,  $C_3$ - $C_7$  cycloalkyl,  $C_4$ - $C_{10}$  cycloalkylalkyl,  $C_7$ - $C_{14}$  araalkyl where the aryl group is optionally substituted with 1 to 3 groups selected from  $C_1$ - $C_4$  alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN,  $CO_2H$ ,  $CF_3$ ,  $NO_2$ ,  $C_1$ - $C_4$  carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>;  $C_3$ - $C_6$  alkenyl or alkynyl,  $C_1$ - $C_3$  perfluoroalkyl, phenyl optionally substituted with 1 to 3 groups selected from  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN,  $CO_2H$ ,  $CF_3$ ,  $NO_2$ ,  $C_1$ - $C_4$  carboalkoxy, NR<sup>7</sup>R<sup>8</sup> or NCOR<sup>7</sup>; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from  $C_1$ - $C_4$  alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN,  $CO_2H$ ,  $CF_3$ ,  $NO_2$ ,  $C_1$ - $C_4$  carboalkoxy,  $NR^7R^8$ , or NCOR<sup>7</sup>; 2-, 3- or 4-pyridinyl, pyrimidinyl, or biphenyl;

25

R<sup>5</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, or benzyl;

30

is H,  $C_1$ - $C_8$  alkyl,  $C_3$ - $C_8$  branched alkyl,  $C_3$ - $C_7$  cycloalkyl,  $C_3$ - $C_8$  alkenyl or alkynyl, phenyl optionally substituted with 1 to 3 groups selected from  $C_1$ - $C_4$  alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C<sub>1</sub>- $C_4$  alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>;

35

40

45

 $R^7$  and  $R^8$  are selected independently from H or  $C_1-C_4$  alkyl;

X is  $S(O)_r$ , O,  $NR^5$ ,  $CH_2$ ;

A is  $C_2$ - $C_{10}$  alkyl,  $C_3$ - $C_{10}$  branched alkyl,  $C_3$ - $C_{10}$  alkenyl, or  $C_3$ - $C_{10}$  alkynyl;

Y is  $O, S, H_2$ ;

Z is  $NHR^4$ ,  $OR^4$ , or  $R^4$ ;

r is 0-2,

or a pharmaceutically acceptable salt thereof, comprising the steps of:

reacting a compound of the formula

$$\begin{array}{c|c}
R^1 & N \\
 &$$

50

55

where  $R^1$ ,  $R^2$ , X, A, and  $R^6$ , are as defined above, and  $R^3$  is as defined above, or a suitable protecting group, such as a silyl or a trityl group, with:

- i) an isocyanate of the formula,  $R^4-N=C=0$ , where  $R^4$  is as defined above, to yield a compound of Formula (I) above, where Y is O, and Z is  $NHR^4$ ; or
- ii) an isothiocyanate of the formula,  $R^4-N=C=S$ , where  $R^4$  is as defined above, to yield a compound of Formula (I) above, where Y is S, and Z is NHR<sup>4</sup>; or

iii) a chloroformate of the formula,

5

10

15

20

35

40

45

50

55

where R<sup>4</sup> is as defined above, to yield a compound of Formula (I) above where Y is O and Z is OR<sup>4</sup>; or

iv) an acid chloride of the formula,

or other activated carboxylic acid, where R<sup>4</sup> is as defined above, to yield a compound of Formula (I) above where Y is O and Z is R<sup>4</sup>.

- 8. A process of Claim 7, further comprising removing any protecting group on R<sup>3</sup>, to yield a compound of Formula (I), where R<sup>3</sup> is H.
  - 9. A process of Claim 7, further comprising reacting a compound of Formula (I) where Y is O with Lawesson's reagent or diphosphorous pentasulfide to yield a compound of Formula (I) where Y is S.
- 10. A process of Claim 7, further comprising reacting a compound of Formula (I) where Y is O with a reducing agent such as lithium aluminum hydride or sodium borohydride, to yield a compound of Formula (I) where Y is H<sub>2</sub>.
  - 11. A process of Claim 7, further comprising reacting a compound of Formula (I) where X is S with a suitable oxidizing agent to yield either the sulfoxide, SO, where r is 1, or the sulfone, SO<sub>2</sub>, where r is 2.
  - 12. A process of Claim 7, further comprising reacting a compound of Formula (I) where  $R^3$  is H with a suitable alkylating agent such as an alkyl halide, to yield a compound of Formula (I) where  $R^3$  is  $C_1$ - $C_6$  alkyl, allyl, or benzyl.
  - 13. A process comprising the steps of alkylating a compound of the formula,

wherein

R1 and R2

are selected independently from H,  $C_1$ - $C_8$  alkyl, provided that when R¹ is H, then R² cannot be H and when R¹ is  $C_1$ - $C_8$  alkyl, then R² cannot be  $C_1$ - $C_8$  alkyl,  $C_3$ - $C_8$  branched alkyl,  $C_3$ - $C_7$  cycloalkyl,  $C_4$ - $C_{10}$  cycloalkylalkyl,  $C_7$ - $C_{14}$  araalkyl, 2-, 3- or 4-pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  alkyl,  $C_3$ - $C_8$  branched alkyl,  $C_3$ - $C_8$ 0, NO2,

CF<sub>3</sub>, or NR<sup>7</sup>R<sup>8</sup>; or

R<sup>1</sup> and R<sup>2</sup> can also be taken together as

5

10

15

20

25

35

40

where L is O,  $O(CH_2)_{m+1}O$ , or  $(CH_2)_m$  where m is 0-4;

R<sup>3</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl, CH<sub>3</sub>, CH<sub>3</sub>O,

CF<sub>3</sub>, or an appropriate protecting group, such as a silyl or trityl group, and

X is O or S, with a compound of the formula,

$$M(A)-N-R^{\epsilon}$$

30 where

M is halide or tosylate,

A is  $C_2$ - $C_{10}$  alkyl,  $C_3$ - $C_{10}$  branched alkyl,  $C_3$ - $C_{10}$  alkenyl, or  $C_3$ - $C_{10}$  alkynyl;

is H, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> branched alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> alkenyl or alkynyl, phenyl optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>;

Y is O, S, or  $H_2$ , and

Z is NHR<sup>4</sup>, OR<sup>4</sup>, or R<sup>4</sup>,

to yield a compound of Formula (I):

*4*5

50

55

wherein

R1 and R2

are selected independently from H,  $C_1$ - $C_8$  alkyl,  $C_3$ - $C_8$  branched alkyl,  $C_3$ - $C_7$  cycloal-kyl,  $C_4$ - $C_{10}$  cycloalkylalkyl,  $C_7$ - $C_{14}$  araalkyl, 2-, 3- or 4-pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  alkyl,  $C_3$ - $C_8$  branched alkyl,  $C_1$ - $C_4$ 0, NO<sub>2</sub>,  $C_7$ - $C_8$ 0, or NR<sup>7</sup> R<sup>8</sup>; or

R<sup>1</sup> and R<sup>2</sup> can also be taken together as

10

15

20

25

30

35

40

55

 $R^4$ 

where L is O,  $O(CH_2)_{m+1}O$ , or  $(CH_2)_m$  where m is 0-4;

R<sup>3</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl, CH<sub>3</sub>, CH<sub>3</sub>O, or CF<sub>3</sub>;

is straight chain C<sub>1</sub>-C<sub>8</sub> alkyl optionally substituted with F; C<sub>3</sub>-C<sub>8</sub> branched alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>4</sub>-C<sub>10</sub> cycloalkylalkyl, C<sub>7</sub>-C<sub>14</sub> araalkyl where the aryl group is optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>; C<sub>3</sub>-C<sub>6</sub> alkenyl or alkynyl, C<sub>1</sub>-C<sub>3</sub> perfluoroalkyl, phenyl optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup> or NCOR<sup>7</sup>; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>; 2-, 3- or 4-pyridinyl, pyrimidinyl, or biphenyl;

R<sup>5</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, or benzyl;

is H, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> branched alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> alkenyl or alkynyl, phenyl optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy; F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>;

 $R^7$  and  $R^8$  are selected independently from H or  $C_1$ - $C_4$  alkyl;

X is  $S(O)_r$ , O,  $NR^5$ ,  $CH_2$ ;

A is  $C_2$ - $C_{10}$  alkyl,  $C_3$ - $C_{10}$  branched alkyl,  $C_3$ - $C_{10}$  alkenyl, or  $C_3$ - $C_{10}$  alkynyl;

Y is  $O, S, H_2$ ;

Z is NHR<sup>4</sup>, OR<sup>4</sup>, or R<sup>4</sup>;

r is 0-2,


and, optionally forming a pharmaceutically acceptable salt thereof.

- 14. A process of Claim 13 further comprising removing any protecting group on R3.
  - **15.** A process of Claim 13 further comprising reacting a compound of Formula (I) where Y is O with Lawesson's reagent or diphosphorous pentasulfide to yield a compound of Formula (I) where Y is S.
- 16. A process of Claim 13 further comprising reacting a compound of Formula (I) where Y is O with a reducing agent such as lithium aluminum hydride or sodium borohydride, to yield a compound of Formula (I) where Y is H<sub>2</sub>.
  - 17. A process of Claim 13, further comprising reacting a compound of Formula (I) where X is S with a suitable oxidizing agent to yield either the sulfoxide, SO, where r is 1, or the sulfone, SO<sub>2</sub>, where r is 2.
  - 18. A process of Claim 13 further comprising reacting a compound of Formula (I) where  $R^3$  is H with a suitable alkylating agent such as an alkyl halide, to yield a compound of Formula (I) where  $R^3$  is  $C_1$ - $C_6$

alkyl, allyl, or benzyl.

#### Claims for the following Contracting State: ES

# A process for preparing a compound of Formula (I):



wherein

10

15

20

30

35

R1 and R2 are selected independently from H, C<sub>1</sub>-C<sub>8</sub> alkyl, provided that when R<sup>1</sup> is H, then R<sup>2</sup>

cannot be H and when R1 is C1-C8 alkyl, then R2 cannot be C1-C8 alkyl, C3-C8 branched alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>4</sub>-C<sub>10</sub> cycloalkylalkyl, C<sub>7</sub>-C<sub>14</sub> araalkyl, 2-, 3- or 4pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> branched alkyl, CH<sub>3</sub>S(O)<sub>r</sub>, NO<sub>2</sub>,

CF<sub>3</sub>, or NR<sup>7</sup>R<sup>8</sup>; or

R<sup>1</sup> and R<sup>2</sup> can also be taken together as 25

40

45

50

 $R^4$ 

where L is O,  $O(CH_2)_{m+1}O$ , or  $(CH_2)_m$  where m is 0-4;

 $R^3$ is H, C<sub>1</sub>-C<sub>6</sub> alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl, CH<sub>3</sub>, CH<sub>3</sub>O,

is straight chain C<sub>1</sub>-C<sub>8</sub> alkyl optionally substituted with F; C<sub>3</sub>-C<sub>8</sub> branched alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>4</sub>-C<sub>10</sub> cycloalkylalkyl, C<sub>7</sub>-C<sub>14</sub> araalkyl where the aryl group is optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>; C<sub>3</sub>-C<sub>6</sub> alkenyl or alkynyl, C<sub>1</sub>-C<sub>3</sub> perfluoroalkyl, phenyl optionally substituted with 1 to 3 groups selected from  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>,  $C_1$ - $C_4$ carboalkoxy, NR7R8 or NCOR7; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>; 2-, 3- or 4-pyridinyl, pyrimidinyl, or biphenyl;

 $\mathbb{R}^5$ is H, C<sub>1</sub>-C<sub>6</sub> alkyl, or benzyl;

55  $R_{e}$ is H, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> branched alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> alkenyl or alkynyl, phenyl optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-

 $C_4$  alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>;

 $R^7$  and  $R^8$  are selected independently from H or  $C_1$ - $C_4$  alkyl;

X is  $S(O)_r$ , O,  $NR^5$ ,  $CH_2$ ;

A is  $C_2$ - $C_{10}$  alkyl,  $C_3$ - $C_{10}$  branched alkyl,  $C_3$ - $C_{10}$  alkenyl, or  $C_3$ - $C_{10}$  alkynyl;

Y is O, S,  $H_2$ ;

Z is  $NHR^4$ ,  $OR^4$ , or  $R^4$ ;

r is 0-2,

5

10

15

20

25

30

35

40

45

50

or a pharmaceutically acceptable salt thereof, comprising the steps of:

reacting a compound of the formula

$$\begin{array}{c|c}
R^1 & N \\
N & N \\
R^2 & N \\
R^3 & 6
\end{array}$$

where  $R^1$ ,  $R^2$ , X, A, and  $R^6$ , are as defined above, and  $R^3$  is as defined above, or a suitable protecting group, such as a silyl or a trityl group, with:

i) an isocyanate of the formula,  $R^4-N=C=0$ , where  $R^4$  is as defined above, to yield a compound of Formula (I) above, where Y is O, and Z is NHR<sup>4</sup>; or

ii) an isothiocyanate of the formula,  $R^4-N=C=S$ , where  $R^4$  is as defined above, to yield a compound of Formula (I) above, where Y is S, and Z is NHR<sup>4</sup>; or

iii) a chloroformate of the formula,

where R<sup>4</sup> is as defined above, to yield a compound of Formula (I) above where Y is O and Z is OR<sup>4</sup>; or

iv) an acid chloride of the formula,


or other activated carboxylic acid, where  $R^4$  is as defined above, to yield a compound of Formula (I) above where Y is O and Z is  $R^4$ .

# 2. A process of Claim 1 wherein

R¹ and R² are selected independently from  $C_1$ - $C_8$  alkyl, provided that when R¹ is  $C_1$ - $C_8$  alkyl, then R² cannot be  $C_1$ - $C_8$  alkyl,  $C_3$ - $C_8$  branched alkyl,  $C_3$ - $C_7$  cycloalkyl,  $C_4$ - $C_{10}$  cycloalkylalkyl,  $C_7$ - $C_{14}$  araalkyl, 2-, 3-, or 4-pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 2 groups selected from F, Cl, Br, OH,  $C_1$ - $C_4$  alkoxy,

C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> branched alkyl, CH<sub>3</sub>S(O)<sub>r</sub>, NO<sub>2</sub>, CF<sub>3</sub>, or NR<sup>7</sup>R<sup>8</sup>; or

R<sup>1</sup> and R<sup>2</sup> can also be taken together as



10

where L is O,  $O(CH_2)_{m+1}O$ , or  $(CH_2)_m$  where m is 0-4.

- 3. A process of Claim 2 wherein
  - R<sup>3</sup> is H, CH<sub>3</sub>, phenyl;
  - is H, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> branched alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, phenyl optionally substituted with 1 to 3 groups selected from CH<sub>3</sub>, CH<sub>3</sub>O, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, or di(C<sub>1</sub>-C<sub>4</sub>)-alkylamino; or benzyl optionally substituted with 1 to 3 groups selected from CH<sub>3</sub>, CH<sub>3</sub>O, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, or di(C<sub>1</sub>-C<sub>4</sub>)alkylamino;
  - X is S(O)r,  $CH_2$ ;
  - A is  $C_2$ - $C_{10}$  alkyl,  $C_4$ - $C_9$  branched alkyl.

25

20

- 4. A process of Claim 3, wherein R¹ and R² are selected independently from C₁-C<sub>8</sub> alkyl, C₃-C<sub>8</sub> branched alkyl, C₃-C<sub>7</sub> cycloalkyl, C₄-C<sub>10</sub> cycloalkylalkyl, C<sub>7</sub>-C<sub>14</sub> araalkyl, 2-, 3-, or 4-pyridinyl, 2-thienyl, or phenyl optionally substituted with 1 to 2 groups selected from F, Br, Cl, C₁-C₄ alkyl, C₃-C<sub>8</sub> branched alkyl, CH₃O, CH₃S(O)<sub>r</sub>, NO₂, CF₃, or di(C₁-C₄)alkylamino; or
  - R<sup>1</sup> and R<sup>2</sup> can also be taken together as

35

30

40

45

50

where L is O or OCH2O;

- R<sup>3</sup> is H
- $R^4$  is  $C_1$ - $C_8$  alkyl,  $C_3$ - $C_8$  branched alkyl,  $C_3$ - $C_7$  cycloalkyl,  $C_4$ - $C_{10}$  cycloalkylalkyl,  $C_7$ - $C_{14}$  araalkyl, phenyl substituted with 1 to 3 groups selected from  $CH_3$ , F, Cl,  $CH_3O$ , CN; or benzyl optionally substituted with 1 to 3 groups selected from  $CH_3$ ,  $CH_3O$ , C

CN;

- $R^6$  is  $C_1$ - $C_8$  alkyl or phenyl optionally substituted with 1 to 3 groups selected from  $CH_3$ ,  $CH_3O$ , F, Cl, or CN;
- A is C<sub>4</sub>-C<sub>9</sub> alkyl;
- X is  $S(O)_r$ ;
  - Y is O,  $H_2$ .

5. A process of claims 1 to 4, wherein the compounds prepared are selected from N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea;

N'-(2,4-difluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]-N-heptylurea;

N-butyl-N'-(2,4 difluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazo]-2-ylthio)octyl]urea;

N'-(2,4-dimethoxyphenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea;

N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl]-N'-methylurea;

N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-propylurea;

N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-(3-fluorophenyl)-N-heptylurea;

N'-(2,4-difluorophenyl)-N-[5-[(4,5-diphenyl-1H-imidazol-2-yl)sulfonyl])pentyl]-N-heptylurea;

N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-(1-methylethyl)urea;

N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-2,4-difluoro-N-heptylbenzeneacetamide;

N'-cyclohexyl-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea;

N'-(2,4-difluorophenyl)-N-[5-[(4,5-diphenyl-1H-imidazol-2-yl)sulfinyl]pentyl]-N-heptylurea;

N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylbutanamide;

N-[5-[4.5-bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2.4-difluorophenyl)-N-heptylurea;

N-[5-[4,5-bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylcyclohexaneacetamide;

N-[5-[4,5-bis(2-methoxyphenyl)-1H-imidazol-2-ylthio] pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea;

phenyl [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate;

N-[5-[4,5-bis[4-(dimethylamino)phenyl]-1 H-imidazol-2-ylthio] pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea;

N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-octyl-N-phenylurea;

N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio] pentyl]-2, 4-difluoro-N-heptylbenzene acetamide;

phenyl [5-[4,5-bis(4-(dimethylamino)phenyl)-1H-imidazol-2-ylthio]pentyl]heptyl]carbamate;

and N-[5-(4,5-dicyclohexyl-1H-imidazol-2-ylthio)pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea.

25

5

10

15

20

- **6.** A process of Claim 1 , further comprising removing any protecting group on R³, to yield a compound of Formula (I), where R³ is H.
- 7. A process of Claim 1, further comprising reacting a compound of Formula (I) where Y is O with Lawesson's reagent or diphosphorous pentasulfide to yield a compound of Formula (I) where Y is S.
  - 8. A process of Claim 1, further comprising reacting a compound of Formula (I) where Y is O with a reducing agent such as lithium aluminum hydride or sodium borohydride, to yield a compound of Formula (I) where Y is H<sub>2</sub>.

35

- 9. A process of Claim 1, further comprising reacting a compound of Formula (I) where X is S with a suitable oxidizing agent to yield either the sulfoxide, SO, where r is 1, or the sulfone, SO<sub>2</sub>, where r is 2.
- **10.** A process of Claim 1, further comprising reacting a compound of Formula (I) where R³ is H with a suitable alkylating agent such as an alkyl halide, to yield a compound of Formula (I) where R³ is C¹-C₆ alkyl, allyl, or benzyl.
  - 11. A process comprising the steps of alkylating a compound of the formula,

45

55

50

wherein

R<sup>1</sup> and R<sup>2</sup>

are selected independently from H,  $C_1$ - $C_8$  alkyl, provided that when  $R^1$  is H, then  $R^2$  cannot be H and when  $R^1$  is  $C_1$ - $C_8$  alkyl, then  $R^2$  cannot be  $C_1$ - $C_8$  alkyl,  $C_3$ - $C_8$  branched alkyl,  $C_3$ - $C_7$  cycloalkyl,  $C_4$ - $C_{10}$  cycloalkylalkyl,  $C_7$ - $C_{14}$  araalkyl, 2-, 3- or 4-

pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  alkyl,  $C_3$ - $C_8$  branched alkyl,  $CH_3$ S(O)<sub>r</sub>,  $NO_2$ ,  $CF_3$ , or  $NR^7$ R<sup>8</sup>; or

R<sup>1</sup> and R<sup>2</sup> can also be taken together as

5

10

15

where L is O,  $O(CH_2)_{m+1}O$ , or  $(CH_2)_m$  where m is 0-4;

 $R^3$  is H,  $C_1$ - $C_6$  alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl,  $CH_3$ ,  $CH_3O$ ,

CF<sub>3</sub>, or an appropriate protecting group, such as a silyl or trityl group, and

X is O or S.

with a compound of the formula,

25

$$M(A)-N-R^{\epsilon}$$

30

35

40

where

M is halide or tosylate,

A is  $C_2$ - $C_{10}$  alkyl,  $C_3$ - $C_{10}$  branched alkyl,  $C_3$ - $C_{10}$  alkenyl, or  $C_3$ - $C_{10}$  alkynyl;


is H, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> branched alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> alkenyl or alkynyl, phenyl optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>;

Y is O, S, or  $H_2$ , and

Z is NHR<sup>4</sup>, OR<sup>4</sup>, or R<sup>4</sup>,

to yield a compound of Formula (I):

45



55

50

wherein

R<sup>1</sup> and R<sup>2</sup> are selected independently from H, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> branched alkyl, C<sub>3</sub>-C<sub>7</sub> cycloal-kyl, C<sub>4</sub>-C<sub>10</sub> cycloalkylalkyl, C<sub>7</sub>-C<sub>14</sub> araalkyl, 2-, 3- or 4-pyridinyl, 2-thienyl, 2-furanyl,

phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  alkyl,  $C_3$ - $C_8$  branched alkyl,  $CH_3S(O)_r$ ,  $NO_2$ ,  $CF_3$ , or  $NR^7R^8$ ; or

R<sup>1</sup> and R<sup>2</sup> can also be taken together as

5

10

15

where L is O,  $O(CH_2)_{m+1}O$ , or  $(CH_2)_m$  where m is 0-4;

20 R<sup>3</sup>

is H,  $C_1$ - $C_6$  alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl,  $CH_3$ ,  $CH_3O$ , or  $CF_3$ ;

 $R^4$ 

is straight chain  $C_1$ - $C_8$  alkyl optionally substituted with F;  $C_3$ - $C_8$  branched alkyl,  $C_3$ - $C_7$  cycloalkyl,  $C_4$ - $C_{10}$  cycloalkylalkyl,  $C_7$ - $C_{14}$  araalkyl where the aryl group is optionally substituted with 1 to 3 groups selected from  $C_1$ - $C_4$  alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN,  $CO_2H$ ,  $CF_3$ ,  $NO_2$ ,  $C_1$ - $C_4$  carboalkoxy,  $NR^7R^8$ , or  $NCOR^7$ ;  $C_3$ - $C_6$  alkenyl or alkynyl,  $C_1$ - $C_3$  perfluoroalkyl, phenyl optionally substituted with 1 to 3 groups selected from  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN,  $CO_2H$ ,  $CF_3$ ,  $NO_2$ ,  $C_1$ - $C_4$  carboalkoxy,  $NR^7R^8$  or  $NCOR^7$ ; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from  $C_1$ - $C_4$  alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN,  $CO_2H$ ,  $CF_3$ ,  $NO_2$ ,  $C_1$ - $C_4$  carboalkoxy,  $NR^7R^8$ , or  $NCOR^7$ ; 2-, 3- or 4-pyridinyl, pyrimidinyl, or biphenyl;

30

35

40

45

55

25

R<sup>5</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, or benzyl;

 $R^6$ 

is H,  $C_1$ - $C_8$  alkyl,  $C_3$ - $C_8$  branched alkyl,  $C_3$ - $C_7$  cycloalkyl,  $C_3$ - $C_8$  alkenyl or alkynyl, phenyl optionally substituted with 1 to 3 groups selected from  $C_1$ - $C_4$  alkyl or alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> carboalkoxy, NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from  $C_1$ - $C_4$  alkyl or alkoxy; F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>- $C_4$  carboalkoxy, NR<sup>7</sup>R<sup>8</sup> at NOOR<sup>7</sup>.

NR<sup>7</sup>R<sup>8</sup>, or NCOR<sup>7</sup>;

 $R^7$  and  $R^8$  are selected independently from H or  $C_1$ - $C_4$  alkyl;

X is  $S(O)_r$ , O,  $NR^5$ ,  $CH_2$ ;

A is  $C_2$ - $C_{10}$  alkyl,  $C_3$ - $C_{10}$  branched alkyl,  $C_3$ - $C_{10}$  alkenyl, or  $C_3$ - $C_{10}$  alkynyl;

Y is 0, S, H<sub>2</sub>;

Z is  $NHR^4$ ,  $OR^4$ , or  $R^4$ ;

r is 0-2,

and, optionally forming a pharmaceutically acceptable salt thereof.

- 12. A process of Claim 11 further comprising removing any protecting group on R<sup>3</sup>.
- 13. A process of Claim 11 further comprising reacting a compound of Formula (I) where Y is O with Lawesson's reagent or diphosphorous pentasulfide to yield a compound of Formula (I) where Y is S.
  - **14.** A process of Claim 11 further comprising reacting a compound of Formula (I) where Y is O with a reducing agent such as lithium aluminum hydride or sodium borohydride, to yield a compound of Formula (I) where Y is H<sub>2</sub>.
  - **15.** A process of Claim 11 further comprising reacting a compound of Formula (I) where X is S with a suitable oxidizing agent to yield either the sulfoxide, SO, where r is 1, or the sulfone, SO<sub>2</sub>, where r is 2.

- **16.** A process of Claim 11 further comprising reacting a compound of Formula (I) where R<sup>3</sup> is H with a suitable alkylating agent such as an alkyl halide, to yield a compound of Formula (I) where R<sup>3</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl, allyl, or benzyl.
- 17. A process for preparing a pharmaceutical composition comprising mixing a therapeutically effective amount of a compound prepared according to any one of claims 1 to 16 and a pharmaceutically acceptable carrier.

# Patentansprüche

#### 10 Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, FR, GB, GR, IT, LI, LU, NL, SE

### 1. Verbindung der Formel

Formel (I)

in welcher

25

30

35

40

45

R1 und R2

unabhängig ausgewählt sind aus H,  $C_1$ - $C_8$ -Alkyl, vorausgesetzt, daß wenn  $R^1$  H ist,  $R^2$  nicht H sein kann und wenn  $R^1$   $C_1$ - $C_8$ -Alkyl ist,  $R^2$  nicht  $C_1$ - $C_8$ -Alkyl sein kann, verzweigtem  $C_3$ - $C_8$ -Alkyl,  $C_3$ - $C_7$ -Cycloalkyl,  $C_4$ - $C_{10}$ -Cycloalkylalkyl,  $C_7$ - $C_{14}$ -Aralkyl, 2-, 3- oder 4-Pyridinyl, 2-Thienyl, 2-Furanyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus F, Cl, Br, OH,  $C_1$ - $C_4$ -Alkoxy,  $C_1$ - $C_4$ -Alkyl, verzweigtem  $C_3$ - $C_8$ -Alkyl,  $C_1$ - $C_8$ -Olkyl,  $C_1$ - $C_1$ - $C_1$ -Olkyl,  $C_1$ - $C_1$ - $C_1$ -Olkyl,  $C_1$ - $C_1$ - $C_1$ - $C_1$ -Olkyl,  $C_1$ - $C_1$ 

R<sup>1</sup> und R<sup>2</sup> zusammengenommen auch

50

55

sein können, worin L O,  $O(CH_2)_{m+1}O$  oder  $(CH_2)_m$  ist, worin m 0-4 ist,

R<sup>3</sup> H, C<sub>1</sub>-C<sub>6</sub>-Alkyl, Allyl, Benzyl oder gegebenenfalls mit F, Cl, CH<sub>3</sub>, CH<sub>3</sub>O oder CF<sub>3</sub> substituiertes Phenyl ist,

R<sup>4</sup> geradkettiges C<sub>1</sub>-C<sub>8</sub>-Alkyl, das gegebenenfalls mit F substituiert ist, verzweigtes C<sub>3</sub>-

geradkettiges  $C_1$ - $C_8$ -Alkyl, das gegebenenfalls mit F substituiert ist, verzweigtes  $C_3$ - $C_8$ -Alkyl,  $C_3$ - $C_7$ -Cycloalkyl,  $C_4$ - $C_{10}$ -Cycloalkylalkyl,  $C_7$ - $C_{14}$ -Aralkyl, worin die Arylgruppe gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus  $C_1$ - $C_4$ -Alkyl oder -Alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>,  $C_1$ - $C_4$ -Carbalkoxy, NR<sup>7</sup>R<sup>8</sup> oder NCOR<sup>7</sup> ausgewählt sind,  $C_3$ - $C_6$ -Alkenyl oder -Alkinyl,  $C_1$ - $C_3$ -Perfluoralkyl, Phenyl, das

gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C<sub>1</sub>-C<sub>4</sub>-Alkyl, C<sub>1</sub>-C<sub>4</sub>-Alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub>-Carbalkoxy, NR<sup>7</sup>R<sup>8</sup> oder NCOR<sup>7</sup> ausgewählt sind, Pentafluorphenyl, Benzyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C<sub>1</sub>-C<sub>4</sub>-Alkyl oder -Alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub>-Carbalkoxy, NR<sup>7</sup>R<sup>8</sup> oder NCOR<sup>7</sup> ausgewählt sind, 2-, 3- oder 4-Pyridinyl, Pyrimidinyl oder Biphenyl ist,

R<sup>5</sup> H, C<sub>1</sub>-C<sub>6</sub>-Alkyl oder Benzyl ist,

H,  $C_1$ - $C_8$ -Alkyl, verzweigtes  $C_3$ - $C_8$ -Alkyl,  $C_3$ - $C_7$ -Cycloalkyl,  $C_3$ - $C_8$ -Alkenyl oder -Alkinyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus  $C_1$ - $C_4$ -Alkyl oder -Alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>- $C_4$ -Carbalkoxy, NR<sup>7</sup>R<sup>8</sup> oder NCOR<sup>7</sup> ausgewählt sind, Pentafluorphenyl, Benzyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus  $C_1$ - $C_4$ -Alkyl oder -Alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub>-Carbalkoxy, NR<sup>7</sup>R<sup>8</sup> oder NCOR<sup>7</sup> ausgewählt sind

R<sup>7</sup> und R<sup>8</sup> unabhängig aus H oder C<sub>1</sub>-C<sub>4</sub>-Alkyl ausgewählt sind,

X  $S(O)_r$ , O,  $NR^5$ ,  $CH_2$  ist,

A C<sub>2</sub>-C<sub>10</sub>-Alkyl, verzweigtes C<sub>3</sub>-C<sub>10</sub>-Alkyl, C<sub>3</sub>-C<sub>10</sub>-Alkenyl oder C<sub>3</sub>-C<sub>10</sub>-Alkinyl ist,

Y O, S,  $H_2$  ist,

Z NHR⁴, OR⁴ oder R⁴ ist,

r 0-2 ist,

5

10

15

20

25

35

40

45

50

55

 $R^6$ 


oder ein pharmazeutisch annehmbares Salz derselben.

ausgewählt sind, oder

# 2. Verbindung des Anspruchs 1, in welcher

R¹ und R² unabhängig ausgewählt sind aus C¹-Cଃ-Alkyl, vorausgesetzt, daß wenn R¹ C¹-Cଃ-Alkyl ist, R² nicht C¹-Cଃ-Alkyl sein kann, verzweigtem C³-Cଃ-Alkyl, C³-C७-Cycloalkyl, C⁴-C¹₀-Cycloalkylalkyl, C७-C¹₄-Aralkyl, 2-, 3- oder 4-Pyridinyl, 2-Thienyl, 2-Furanyl, Phenyl, das gegebenenfalls mit 1 bis 2 Gruppen substituiert ist, die aus F, Cl, Br, OH, C¹-C₄-Alkoxy, C¹-C₄-Alkyl, verzweigtem C³-Cଃ-Alkyl, CH₃S(O)r, NO², CF³ oder NR⁵R³

30 R1 und R2 auch als



zusammengenommen werden können, worin L O, O(CH<sub>2</sub>)<sub>m+1</sub>O oder (CH<sub>2</sub>)<sub>m</sub> ist, worin m 0-4 ist.

# 3. Verbindung des Anspruchs 2, in welcher

R<sup>3</sup> H, CH<sub>3</sub>, Phenyl ist,

R<sup>6</sup> H, C<sub>1</sub>-C<sub>8</sub>-Alkyl, verzweigtes C<sub>3</sub>-C<sub>8</sub>-Alkyl, C<sub>3</sub>-C<sub>7</sub>-Cycloalkyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus CH<sub>3</sub>, CH<sub>3</sub>O, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub> oder Di(C<sub>1</sub>-C<sub>4</sub>)alkylamino ausgewählt sind, oder Benzyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus CH<sub>3</sub>, CH<sub>3</sub>O, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub> oder Di(C<sub>1</sub>-C<sub>4</sub>)alkylamino ausgewählt sind,

 $X = S(O)_r$ ,  $CH_2$  ist,

A C<sub>2</sub>-C<sub>10</sub>-Alkyl, verzweigtes C<sub>4</sub>-C<sub>9</sub>-Alkyl ist.

#### Verbindung des Anspruchs 3, in welcher

unabhängig ausgewählt sind aus C<sub>1</sub>-C<sub>8</sub>-Alkyl, verzweigtem C<sub>3</sub>-C<sub>8</sub>-Alkyl, C<sub>3</sub>-C<sub>7</sub>-Cycloalkyl, C<sub>4</sub>-C<sub>10</sub>-Cycloalkylalkyl, C<sub>7</sub>-C<sub>14</sub>-Aralkyl, 2-, 3- oder 4-Pyridinyl, 2-Thienyl oder Phenyl, das gegebenenfalls mit 1 bis 2 Gruppen substituiert ist, die aus F, Br, Cl, C<sub>1</sub>-C<sub>4</sub>-Alkyl, verzweigtem C<sub>3</sub>-C<sub>8</sub>-Alkyl, CH<sub>3</sub>O, CH<sub>3</sub>S(O)<sub>r</sub>, NO<sub>2</sub>, CF<sub>3</sub> oder Di(C<sub>1</sub>-C<sub>4</sub>)-

alkylamino ausgewählt sind, oder

R<sup>1</sup> und R<sup>2</sup> auch als

10

5

15

20

25

30

zusammengenommen werden können, worin L O oder OCH<sub>2</sub>O ist,

R<sup>3</sup> H ist,

R<sup>4</sup> C<sub>1</sub>-C<sub>8</sub>-Alkyl, verzweigtes C<sub>3</sub>-C<sub>8</sub>-Alkyl, C<sub>3</sub>-C<sub>7</sub>-Cycloalkyl, C<sub>4</sub>-C<sub>10</sub>-Cycloalkylalkyl, C<sub>7</sub>-C<sub>14</sub>-Aralkyl, Phenyl, das mit 1 bis 3 Gruppen substituiert ist, die aus CH<sub>3</sub>, F, Cl, CH<sub>3</sub>O, CN ausgewählt sind, oder Benzyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus CH<sub>3</sub>, CH<sub>3</sub>O, F, Cl oder CN ausgewählt sind,

 $R^6$   $C_1$ - $C_8$ -Alkyl oder Phenyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus  $CH_3$ ,  $CH_3O$ , F, Cl oder CN ausgewählt sind,

A  $C_4-C_9$ -Alkyl ist,

 $X = S(O)_r$  ist,

Y  $O, H_2$  ist.

35

55

### 5. Verbindungen der Ansprüche 1 bis 4, die aus

N'-(2,4-Difluorphenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylharnstoff,

N'-(2,4-Difluorphenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]-N-heptylharnstoff,

N-Butyl-N'-(2,4-difluorphenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]harnstoff,

40 N'-(2,4-Dimethoxyphenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-yl-thio)pentyl]-N-heptylharnstoff,

N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-methylharnstoff,

N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-propylharnstoff,

N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-(3-fluorphenyl)-N-heptylharnstoff,

N'-(2,4-Difluorphenyl)-N-[5-[(4,5-Diphenyl-1H-imidazol-2-yl)sulfonyl])pentyl]-N-heptylharnstoff,

N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-(1-methylethyl)harnstoff,

N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio) pentyl]-2, 4-difluor-N-heptylbenzolacetamid,

N'-Cyclohexyl-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl)-N-heptylharnstoff,

N'-(2,4-Difluorphenyl)-N-[5-[(4,5-Diphenyl-1H-imidazol-2-yl)sulfinyl]pentyl]-N-heptylharnstoff,

N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylbutanamid,

N-[5-[4,5-Bis(1-methylethyl)-1H-imidazol-2-ylthio] pentyl]-N'-(2,4-difluorphenyl)-N-heptylharnstoff,

N-[5-[4,5-Bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylcyclohexanacetamid,

N-[5-[4,5-Bis(2-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorphenyl)-N-heptylharnstoff,

[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbaminsäure-phenylester,

N-[5-[4,5-Bis[4-(dimethylamino)phenyl]-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorphenyl)-N-heptylharnstoff,

N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-octyl-N-phenylharnstoff,

N-[5-[4,5-Bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-2,4-difluor-N-heptylbenzolacetamid,

[5-[4,5-Bis(4-(dimethylamino)phenyl)-1H-imidazol-2-ylthio]pentyl]heptylcarbaminsäure-phenylester und

N-[5-(4,5-Dicyclohexyl-1H-imidazol-2-ylthio)pentyl]-N'-(2,4-difluorphenyl)-N-heptylharnstoff ausgewählt sind.

- **6.** Pharmazeutische Zusammensetzung umfassend eine therapeutisch wirksame Menge einer Verbindung der Ansprüche 1 bis 5 und einen pharmazeutisch annehmbaren Träger.
- 7. Verfahren zum Herstellen einer Verbindung der Formel (I)

in welcher

5

10

15

20

25

30

35

40

45

50

55

 $R^4$ 

R¹ und R² unabhängig ausgewählt sind aus H, C₁-Cଃ-Alkyl, vorausgesetzt, daß wenn R¹ H ist, R²

nicht H sein kann und wenn R¹  $C_1-C_8$ -Alkyl ist, R² nicht  $C_1-C_8$ -Alkyl sein kann, verzweigtem  $C_3-C_8$ -Alkyl,  $C_3-C_7$ -Cycloalkyl,  $C_4-C_{10}$ -Cycloalkylalkyl,  $C_7-C_{14}$ -Aralkyl, 2-, 3- oder 4-Pyridinyl, 2-Thienyl, 2-Furanyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus F, Cl, Br, OH,  $C_1-C_4$ -Alkoxy,  $C_1-C_4$ -Alkyl, verzweig-

tem C<sub>3</sub>-C<sub>8</sub>-Alkyl, CH<sub>3</sub>S(O)<sub>r</sub>, NO<sub>2</sub>, CF<sub>3</sub> oder NR<sup>7</sup>R<sup>8</sup> ausgewählt sind, oder

R<sup>1</sup> und R<sup>2</sup> zusammengenommen auch

sein können, worin L O,  $O(CH_2)_{m+1}O$  oder  $(CH_2)_m$  ist, worin m 0-4 ist,

88

R<sup>3</sup> H, C<sub>1</sub>-C<sub>6</sub>-Alkyl, Allyl, Benzyl oder gegebenenfalls mit F, Cl, CH<sub>3</sub>, CH<sub>3</sub>O oder CF<sub>3</sub> substituiertes Phenyl ist,

substituteries Frienyrist,

geradkettiges  $C_1$ - $C_8$ -Alkyl, das gegebenenfalls mit F substituiert ist, verzweigtes  $C_3$ - $C_8$ -Alkyl,  $C_3$ - $C_7$ -Cycloalkyl,  $C_4$ - $C_{10}$ -Cycloalkylalkyl,  $C_7$ - $C_{14}$ -Aralkyl, worin die Arylgruppe gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus  $C_1$ - $C_4$ -Alkyl oder -Alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>,  $C_1$ - $C_4$ -Carbalkoxy, NR<sup>7</sup>R<sup>8</sup> oder NCOR<sup>7</sup> ausgewählt sind,  $C_3$ - $C_6$ -Alkenyl oder -Alkinyl,  $C_1$ - $C_3$ -Perfluoralkyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus  $C_1$ - $C_4$ -Alkyl,  $C_1$ - $C_4$ -Alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>,  $C_1$ - $C_4$ -Carbalkoxy, NR<sup>7</sup>R<sup>8</sup> oder NCOR<sup>7</sup> ausgewählt sind, Pentafluorphenyl, Benzyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus  $C_1$ - $C_4$ -Alkyl oder -Alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>,  $C_1$ - $C_4$ -Carbalkoxy, NR<sup>7</sup>R<sup>8</sup> oder NCOR<sup>7</sup> ausgewählt sind, 2-, 3- oder 4-Pyridinyl, Pyrimidinyl oder Biphenyl ist,

R<sup>5</sup> H, C<sub>1</sub>-C<sub>6</sub>-Alkyl oder Benzyl ist,

H, C<sub>1</sub>-C<sub>8</sub>-Alkyl, verzweigtes C<sub>3</sub>-C<sub>8</sub>-Alkyl, C<sub>3</sub>-C<sub>7</sub>-Cycloalkyl, C<sub>3</sub>-C<sub>8</sub>-Alkenyl oder -Alkinyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C<sub>1</sub>-C<sub>4</sub>-Alkyl oder -Alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub>-Carbalkoxy, NR<sup>7</sup>R<sup>8</sup> oder NCOR<sup>7</sup> ausgewählt sind, Pentafluorphenyl, Benzyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C<sub>1</sub>-C<sub>4</sub>-Alkyl oder -Alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub>-Carbalkoxy, NR<sup>7</sup>R<sup>8</sup> oder NCOR<sup>7</sup> ausgewählt sind,

R<sup>7</sup> und R<sup>8</sup> unabhängig aus H oder C<sub>1</sub>-C<sub>4</sub>-Alkyl ausgewählt sind,

X S(O)<sub>r</sub>, O, NR<sup>5</sup>, CH<sub>2</sub> ist,

C<sub>2</sub>-C<sub>10</sub>-Alkyl, verzweigtes C<sub>3</sub>-C<sub>10</sub>-Alkyl, C<sub>3</sub>-C<sub>10</sub>-Alkenyl oder C<sub>3</sub>-C<sub>10</sub>-Alkinyl ist,

Y O, S, H<sub>2</sub> ist,

Z NHR<sup>4</sup>, OR<sup>4</sup> oder R<sup>4</sup> ist,

r 0-2 ist,

15

20

25

30

35

40

45

50

55

oder eines pharmazeutisch annehmbaren Salzes derselben, umfas send die Schritte des Umsetzens einer Verbindung der Formel

$$\begin{array}{c|c}
R^1 & N \\
N & X-A-NH -R^6
\end{array}$$

$$\begin{array}{c|c}
R^2 & 6$$

worin R<sup>1</sup>, R<sup>2</sup>, X, A und R<sup>6</sup> wie vorstehend definiert sind, und R<sup>3</sup> wie vorstehend definiert oder eine geeignete Schutzgruppe ist, wie etwa eine Silyl- oder Tritylgruppe, mit

- i) einem Isocyanat der Formel  $R^4$ -N = C = O, worin  $R^4$  wie vorstehend definiert ist, unter Liefern einer Verbindung der vorstehenden Formel (I), worin Y O ist und Z NHR<sup>4</sup> ist, oder
- ii) einem Isothiocyanat der Formel  $R^4$ -N=C=S, worin  $R^4$  wie vorstehend definiert ist, unter Liefern einer Verbindung der vorstehenden Formel (I), worin Y S ist und Z NH $R^4$  ist, oder
- iii) einem Chlorameisensäureester der Formel

worin R<sup>4</sup> wie vorstehend definiert ist, unter Ergeben einer Verbindung der vorstehenden Formel (I), worin Y O ist und Z OR<sup>4</sup> ist, oder

iv) einem Säurechlorid der Formel

oder einer anderen aktivierten Carbonsäure, worin R<sup>4</sup> wie vorstehend definiert ist, unter Liefern einer Verbindung der vorstehenden Formel (I), worin Y O ist und Z R<sup>4</sup> ist.

- 8. Verfahren des Anspruchs 7, das weiter das Entfernen einer etwaigen Schutzgruppe an R³ unter Liefern einer Verbindung der Formel (I), worin R³ H ist, umfaßt.
- Verfahren des Anspruchs 7, das weiter das Umsetzen einer Verbindung der Formel (I), worin Y O ist, mit Lawessons Reagenz oder Diphosphorpentasulfid unter Liefern einer Verbindung der Formel (I),

worin Y S ist, umfaßt.

- 10. Verfahren des Anspruchs 7, das weiter das Umsetzen einer Verbindung der Formel (I), worin Y O ist, mit einem Reduktionsmittel, wie etwa Lithiumaluminiumhydrid oder Natriumborhydrid, unter Liefern einer Verbindung der Formel (I), worin Y H<sub>2</sub> ist, umfaßt.
- 11. Verfahren des Anspruchs 7, das weiter das Umsetzen einer Verbindung der Formel (I), worin X S ist, mit einem geeigneten Oxidationsmittel unter Liefern entweder des Sulfoxids SO, wobei r 1 ist, oder des Sulfons SO<sub>2</sub>, wobei r 2 ist, umfaßt.
- 12. Verfahren des Anspruchs 7, das weiter das Umsetzen einer Verbindung der Formel (I), worin R³ H ist, mit einem geeigneten Alkylierungsmittel wie etwa einem Alkylhalogenid unter Liefern einer Verbindung der Formel (I), worin R³ C<sub>1</sub>-C<sub>6</sub>-Alkyl, Allyl oder Benzyl ist, umfaßt.
- 13. Verfahren, umfassend die Schritte des Alkylierens einer Verbindung der Formel

in welcher

5

10

20

25

30

35

40

45

55

R¹ und R² unabhängig ausgewählt sind aus H, C₁-C₃-Alkyl, vorausgesetzt, daß wenn R¹ H ist, R²

nicht H sein kann und wenn  $R^1$   $C_1$ - $C_8$ -Alkyl ist,  $R^2$  nicht  $C_1$ - $C_8$ -Alkyl sein kann, verzweigtem  $C_3$ - $C_8$ -Alkyl,  $C_3$ - $C_7$ -Cycloalkyl,  $C_4$ - $C_{10}$ -Cycloalkylalkyl,  $C_7$ - $C_{14}$ -Aralkyl, 2-, 3- oder 4-Pyridinyl, 2-Thienyl, 2-Furanyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus F, Cl, Br, OH,  $C_1$ - $C_4$ -Alkoxy,  $C_1$ - $C_4$ -Alkyl, verzweig-

tem C<sub>3</sub>-C<sub>8</sub>-Alkyl, CH<sub>3</sub>S(O)<sub>r</sub>, NO<sub>2</sub>, CF<sub>3</sub> oder NR<sup>7</sup>R<sup>8</sup> ausgewählt sind, oder

R<sup>1</sup> und R<sup>2</sup> zusammengenommen auch

sein können, worin L O,  $O(CH_2)_{m+1}O$  oder  $(CH_2)_m$  ist, worin m 0-4 ist,

 $R^3$  H,  $C_1$ - $C_6$ -Alkyl, Allyl, Benzyl oder gegebenenfalls mit F, Cl,  $CH_3$ ,  $CH_3O$  oder  $CF_3$  substituiertes Phenyl, oder eine geeignete Schutzgruppe ist, wie etwa eine Silyl- oder

Tritylgruppe, und

X O oder S ist, mit einer Verbindung der Formel

90

worin

5

10

15

20

25

M ein Halogenid oder Tosylat ist,

A  $C_2$ - $C_{10}$ -Alkyl, verzweigtes  $C_3$ - $C_{10}$ -Alkyl,  $C_3$ - $C_{10}$ -Alkenyl oder  $C_3$ - $C_{10}$ -Alkinyl ist,

H, C<sub>1</sub>-C<sub>8</sub>-Alkyl, verzweigtes C<sub>3</sub>-C<sub>8</sub>-Alkyl, C<sub>3</sub>-C<sub>7</sub>-Cycloalkyl, C<sub>3</sub>-C<sub>8</sub>-Alkenyl oder -Alkinyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C<sub>1</sub>-C<sub>4</sub>-Alkyl oder -Alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub>-Carbalkoxy, NR<sup>7</sup>R<sup>8</sup> oder NCOR<sup>7</sup> ausgewählt sind, Pentafluorphenyl, Benzyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C<sub>1</sub>-C<sub>4</sub>-Alkyl oder -Alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub>-Carbalkoxy, NR<sup>7</sup>R<sup>8</sup> oder NCOR<sup>7</sup> ausgewählt sind,

Y O, S oder H<sub>2</sub> ist und

Z NHR<sup>4</sup>, OR<sup>4</sup> oder R<sup>4</sup> ist,

unter Liefern einer Verbindung der Formel (I)

R 2 N X-A-N-R 6

30

35

in welcher

R¹ und R² unabhängig ausgewählt sind aus H, C1-C8-Alkyl, verzweigtem C3-C8-Alkyl, C3-C7-

Cycloalkyl,  $C_4$ - $C_{10}$ -Cycloalkylalkyl,  $C_7$ - $C_{14}$ -Aralkyl, 2-, 3- oder 4-Pyridinyl, 2-Thienyl, 2-Furanyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus F, Cl, Br, OH,  $C_1$ - $C_4$ -Alkoxy,  $C_1$ - $C_4$ -Alkyl, verzweigtem  $C_3$ - $C_8$ -Alkyl,  $C_1$ - $C_4$ - $C_4$ -Alkyl,  $C_1$ - $C_4$ -Alkyl, verzweigtem  $C_3$ - $C_8$ -Alkyl,  $C_1$ - $C_4$ - $C_8$ 

oder NR7R8 ausgewählt sind, oder

R<sup>1</sup> und R<sup>2</sup> zusammengenommen auch

40

50

55

45

sein können, worin L O,  $O(CH_2)_{m+1}O$  oder  $(CH_2)_m$  ist, worin m 0-4 ist,

R<sup>3</sup> H, C<sub>1</sub>-C<sub>6</sub>-Alkyl, Allyl, Benzyl oder gegebenenfalls mit F, Cl, CH<sub>3</sub>, CH<sub>3</sub>O oder CF<sub>3</sub>

substituiertes Phenyl ist,

R<sup>4</sup> geradkettiges C<sub>1</sub>-C<sub>8</sub>-Alkyl, das gegebenenfalls mit F substituiert ist, verzweigtes C<sub>3</sub>-

 $C_8\text{-Alkyl},\ C_3\text{-}C_7\text{-Cycloalkyl},\ C_4\text{-}C_{10}\text{-Cycloalkylalkyl},\ C_7\text{-}C_{14}\text{-Aralkyl},\ worin\ die\ Arylgruppe\ gegebenenfalls\ mit\ 1\ bis\ 3\ Gruppen\ substituiert\ ist,\ die\ aus\ C_1\text{-}C_4\text{-Alkyl}\ oder\ -Alkoxy,\ F,\ Br,\ Cl,\ NH_2,\ OH,\ CN,\ CO_2H,\ CF_3,\ NO_2,\ C_1\text{-}C_4\text{-Carbalkoxy},\ NR^7R^8\ oder\ NCOR^7\ ausgewählt\ sind,\ C_3\text{-}C_6\text{-Alkenyl}\ oder\ -Alkinyl,\ C_1\text{-}C_3\text{-Perfluoralkyl},\ Phenyl,\ das\ gegebenenfalls\ mit\ 1\ bis\ 3\ Gruppen\ substituiert\ ist,\ die\ aus\ C_1\text{-}C_4\text{-Alkyl},\ C_1\text{-}C_4\text{-Alkyl},\ C_1\text{-}C_4\text{-Alkyl},\ R^7R^8\ oder\ NCOR^7\ ausgewählt\ sind,\ Pentafluorphenyl,\ Benzyl,\ das\ gegebenenfalls\ mit\ 1\ bis\ 3\ Gruppen\ substituiert\ ist,\ die\ aus\ C_1\text{-}C_4\text{-Alkyl}\ oder\ -Alkoxy,\ F,\ Br,\ Cl,\ NH_2,\ OH,\ CN,\ CO_2H,\ CF_3,\ NO_2,\ C_1\text{-}C_4\text{-Carbalkoxy},\ NR^7R^8\ oder\ NCOR^7\ ausgewählt\ sind,\ 2\text{-},\ 3\text{-}\ oder\ 4\text{-Pyridinyl},\ Pyrimidinyl\ oder\ Biphenyl\ ist,}$ 

R<sup>5</sup> H, C<sub>1</sub>-C<sub>6</sub>-Alkyl oder Benzyl ist,

H, C<sub>1</sub>-C<sub>8</sub>-Alkyl, verzweigtes C<sub>3</sub>-C<sub>8</sub>-Alkyl, C<sub>3</sub>-C<sub>7</sub>-Cycloalkyl, C<sub>3</sub>-C<sub>8</sub>-Alkenyl oder -Alkinyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C<sub>1</sub>-C<sub>4</sub>-Alkyl oder -Alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub>-Carbalkoxy, NR<sup>7</sup>R<sup>8</sup> oder NCOR<sup>7</sup> ausgewählt sind, Pentafluorphenyl, Benzyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C<sub>1</sub>-C<sub>4</sub>-Alkyl oder -Alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub>-Carbalkoxy, NR<sup>7</sup>R<sup>8</sup> oder NCOR<sup>7</sup> ausgewählt sind.

R<sup>7</sup> und R<sup>8</sup> unabhängig aus H oder C<sub>1</sub>-C<sub>4</sub>-Alkyl ausgewählt sind,

20 X  $S(O)_r$ , O,  $NR^5$ ,  $CH_2$  ist,

A C<sub>2</sub>-C<sub>10</sub>-Alkyl, verzweigtes C<sub>3</sub>-C<sub>10</sub>-Alkyl, C<sub>3</sub>-C<sub>10</sub>-Alkenyl oder C<sub>3</sub>-C<sub>10</sub>-Alkinyl ist,

Y 0, S, H<sub>2</sub> ist,

Z NHR<sup>4</sup>, OR<sup>4</sup> oder R<sup>4</sup> ist,

r 0-2 ist,

5

10

15

25

35

40

und gegebenenfalls das Bilden eines pharmazeutisch annehmbaren Salzes derselben.

- 14. Verfahren des Anspruchs 13, das weiter das Entfernen einer etwaigen Schutzgruppe an R<sup>3</sup> umfaßt.
- 15. Verfahren des Anspruchs 13, das weiter das Umsetzen einer Verbindung der Formel (I), worin Y O ist, mit Lawessons Reagenz oder Diphosphorpentasulfid unter Liefern einer Verbindung der Formel (I), worin Y S ist, umfaßt.
  - **16.** Verfahren des Anspruchs 13, das weiter das Umsetzen einer Verbindung der Formel (I), worin Y O ist, mit einem Reduktionsmittel, wie etwa Lithiumaluminiumhydrid oder Natriumborhydrid, unter Liefern einer Verbindung der Formel (I), worin Y H<sub>2</sub> ist, umfaßt.
  - 17. Verfahren des Anspruchs 13, das weiter das Umsetzen einer Verbindung der Formel (I), worin X S ist, mit einem geeigneten Oxidationsmittel unter Liefern entweder des Sulfoxids SO, wobei r 1 ist, oder des Sulfons SO<sub>2</sub>, wobei r 2 ist, umfaßt.
  - 18. Verfahren des Anspruchs 13, das weiter das Umsetzen einer Verbindung der Formel (I), worin R³ H ist, mit einem geeigneten Alkylierungsmittel wie etwa einem Alkylhalogenid unter Liefern einer Verbindung der Formel (I), worin R³ C<sub>1</sub>-C<sub>6</sub>-Alkyl, Allyl oder Benzyl ist, umfaßt.

# 45 Patentansprüche für den Vertragsstaat : ES

1. Verfahren zur Herstellung einer Verbindung der Formel (I)

5	in welcher R¹ und R² R¹ und R²	unabhängig ausgewählt sind aus H, $C_1$ - $C_8$ -Alkyl, vorausgesetzt, daß wenn $R^1$ H ist, $R^2$ nicht H sein kann und wenn $R^1$ $C_1$ - $C_8$ -Alkyl ist, $R^2$ nicht $C_1$ - $C_8$ -Alkyl sein kann, verzweigtem $C_3$ - $C_8$ -Alkyl, $C_3$ - $C_7$ -Cycloalkyl, $C_4$ - $C_{10}$ -Cycloalkylalkyl, $C_7$ - $C_{14}$ -Aralkyl, $C_7$ - $C_7$ - $C_7$ -Aralkyl, $C_7$ - $C_7$ -Alkyl,
10		
15		
20		
25	R <sup>3</sup>	sein können, worin L O, $O(CH_2)_{m+1}O$ oder $(CH_2)_m$ ist, worin m 0-4 ist, H, $C_1$ - $C_6$ -Alkyl, Allyl, Benzyl oder gegebenenfalls mit F, Cl, $CH_3$ , $CH_3O$ oder $CF_3$
	R <sup>4</sup>	substituiertes Phenyl ist, geradkettiges C <sub>1</sub> -C <sub>8</sub> -Alkyl, das gegebenenfalls mit F substituiert ist, verzweigtes C <sub>3</sub> - C <sub>8</sub> -Alkyl, C <sub>3</sub> -C <sub>7</sub> -Cycloalkyl, C <sub>4</sub> -C <sub>10</sub> -Cycloalkylalkyl, C <sub>7</sub> -C <sub>14</sub> -Aralkyl, worin die Aryl- gruppe gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C <sub>1</sub> -C <sub>4</sub> -Alkyl oder
30		-Alkoxy, F, Br, Cl, NH <sub>2</sub> , OH, CN, CO <sub>2</sub> H, CF <sub>3</sub> , NO <sub>2</sub> , C <sub>1</sub> -C <sub>4</sub> -Carbalkoxy, NR <sup>7</sup> R <sup>8</sup> oder NCOR <sup>7</sup> ausgewählt sind, C <sub>3</sub> -C <sub>6</sub> -Alkenyl oder -Alkinyl, C <sub>1</sub> -C <sub>3</sub> -Perfluoralkyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C <sub>1</sub> -C <sub>4</sub> -Alkyl, C <sub>1</sub> -C <sub>4</sub> -Alkoxy, F, Br, Cl, NH <sub>2</sub> , OH, CN, CO <sub>2</sub> H, CF <sub>3</sub> , NO <sub>2</sub> , C <sub>1</sub> -C <sub>4</sub> -Carbalkoxy, NR <sup>7</sup> R <sup>8</sup> oder NCOR <sup>7</sup> ausgewählt sind, Pentafluorphenyl, Benzyl, das gegebenenfalls mit 1 bis 3
35	<b>R</b> ⁵	Gruppen substituiert ist, die aus C <sub>1</sub> -C <sub>4</sub> -Alkyl oder -Alkoxy, F, Br, Cl, NH <sub>2</sub> , OH, CN, CO <sub>2</sub> H, CF <sub>3</sub> , NO <sub>2</sub> , C <sub>1</sub> -C <sub>4</sub> -Carbalkoxy, NR <sup>7</sup> R <sup>8</sup> oder NCOR <sup>7</sup> ausgewählt sind, 2-, 3- oder 4-Pyridinyl, Pyrimidinyl oder Biphenyl ist, H, C <sub>1</sub> -C <sub>6</sub> -Alkyl oder Benzyl ist,
40	R <sup>6</sup>	H, C <sub>1</sub> -C <sub>8</sub> -Alkyl, verzweigtes C <sub>3</sub> -C <sub>8</sub> -Alkyl, C <sub>3</sub> -C <sub>7</sub> -Cycloalkyl, C <sub>3</sub> -C <sub>8</sub> -Alkenyl oder -Alkinyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C <sub>1</sub> -C <sub>4</sub> -Alkyl oder -Alkoxy, F, Br, Cl, NH <sub>2</sub> , OH, CN, CO <sub>2</sub> H, CF <sub>3</sub> , NO <sub>2</sub> , C <sub>1</sub> -C <sub>4</sub> -Carbalkoxy, NR <sup>7</sup> R <sup>8</sup> oder NCOR <sup>7</sup> ausgewählt sind, Pentafluorphenyl, Benzyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C <sub>1</sub> -C <sub>4</sub> -Alkyl oder -Alkoxy, F, Br, Cl, NH <sub>2</sub> , OH, CN, CO <sub>2</sub> H, CF <sub>3</sub> , NO <sub>2</sub> , C <sub>1</sub> -C <sub>4</sub> -Carbalkoxy, NR <sup>7</sup> R <sup>8</sup> oder NCOR <sup>7</sup> ausgewählt
<i>4</i> 5	D7d D8	sind,
	R <sup>7</sup> und R <sup>8</sup> X	unabhängig aus H oder C <sub>1</sub> -C <sub>4</sub> -Alkyl ausgewählt sind,
	A	S(O) <sub>r</sub> , O, NR <sup>5</sup> , CH <sub>2</sub> ist, $C_2$ - $C_{10}$ -Alkyl, verzweigtes $C_3$ - $C_{10}$ -Alkyl, $C_3$ - $C_{10}$ -Alkenyl oder $C_3$ - $C_{10}$ -Alkinyl ist,
	Ϋ́	O, S, H <sub>2</sub> ist,
50	Z	NHR <sup>4</sup> , OR <sup>4</sup> oder R <sup>4</sup> ist,
	r	0-2 ist,
	oder eines pha	armazeutisch annehmbaren Salzes derselben, umfassend die Schritte des Umsetzens

55

einer Verbindung der Formel

$$\begin{array}{c|c}
R^1 & N \\
N & X-A-NH-R \\
\downarrow N & 6
\end{array}$$

worin R¹, R², X, A und R⁵ wie vorstehend definiert sind, und R³ wie vorstehend definiert oder eine geeignete Schutzgruppe ist, wie etwa eine Silyl- oder Tritylgruppe, mit

- i) einem Isocyanat der Formel  $R^4$ -N=C=O, worin  $R^4$  wie vorstehend definiert ist, unter Liefern einer Verbindung der vorstehenden Formel (I), worin Y O ist und Z NHR<sup>4</sup> ist, oder
- ii) einem Isothiocyanat der Formel  $R^4$ -N = C = S, worin  $R^4$  wie vorstehend definiert ist, unter Liefern einer Verbindung der vorstehenden Formel (I), worin Y S ist und Z NHR<sup>4</sup> ist, oder
- iii) einem Chlorameisensäureester der Formel

worin  $R^4$  wie vorstehend definiert ist, unter Ergeben einer Verbindung der vorstehenden Formel (I), worin Y O ist und Z  $OR^4$  ist, oder

iv) einem Säurechlorid der Formel

oder einer anderen aktivierten Carbonsäure, worin R⁴ wie vorstehend definiert ist, unter Liefern einer Verbindung der vorstehenden Formel (I), worin Y O ist und Z R⁴ ist.

2. Verfahren des Anspruchs 1, bei welchem

R¹ und R² unabhängig ausgewählt sind aus C₁-Cଃ-Alkyl, vorausgesetzt, daß wenn R¹ C₁-Cଃ-Alkyl ist, R² nicht C₁-Cଃ-Alkyl sein kann, verzweigtem C₃-Cଃ-Alkyl, C₃-Cȝ-Cycloalkyl, C₄-C¹₀-Cycloalkylalkyl, Cȝ-C¹₄-Aralkyl, 2-, 3- oder 4-Pyridinyl, 2-Thienyl, 2-Furanyl, Phenyl, das gegebenenfalls mit 1 bis 2 Gruppen substituiert ist, die aus F, Cl, Br, OH, C¹-C₄-Alkoxy, C¹-C₄-Alkyl, verzweigtem C₃-Cଃ-Alkyl, CH₃S(O), NO₂, CF₃ oder NR³R8

ausgewählt sind, oder

45 R<sup>1</sup> und R<sup>2</sup> auch als

55

50

5

10

15

20

25

30

35

40

20

25

30

5

10

zusammengenommen werden können, worin L O, O(CH<sub>2</sub>)<sub>m+1</sub>O oder (CH<sub>2</sub>)<sub>m</sub> ist, worin m 0-4 ist.

3. Verfahren des Anspruchs 2, bei welchem

R<sup>3</sup> H, CH<sub>3</sub>, Phenyl ist,

H, C<sub>1</sub>-C<sub>8</sub>-Alkyl, verzweigtes C<sub>3</sub>-C<sub>8</sub>-Alkyl, C<sub>3</sub>-C<sub>7</sub>-Cycloalkyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus CH<sub>3</sub>, CH<sub>3</sub>O, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub> oder Di(C<sub>1</sub>-C<sub>4</sub>)alkylamino ausgewählt sind, oder Benzyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus CH<sub>3</sub>, CH<sub>3</sub>O, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub> oder Di(C<sub>1</sub>-C<sub>4</sub>)alkylamino ausgewählt sind,

 $X = S(O)_r$ ,  $CH_2$  ist,

A C<sub>2</sub>-C<sub>10</sub>-Alkyl, verzweigtes C<sub>4</sub>-C<sub>9</sub>-Alkyl ist.

4. Verfahren des Anspruchs 3, bei welchem

R¹ und R² unabhängig ausgewählt sind aus C<sub>1</sub>-C<sub>8</sub>-Alkyl, verzweigtem C<sub>3</sub>-C<sub>8</sub>-Alkyl, C<sub>3</sub>-C<sub>7</sub>-Cycloalkyl, C<sub>4</sub>-C<sub>10</sub>-Cycloalkylalkyl, C<sub>7</sub>-C<sub>14</sub>-Aralkyl, 2-, 3- oder 4-Pyridinyl, 2-Thienyl oder Phenyl, das gegebenenfalls mit 1 bis 2 Gruppen substituiert ist, die aus F, Br, Cl, C<sub>1</sub>-C<sub>4</sub>-Alkyl, verzweigtem C<sub>3</sub>-C<sub>8</sub>-Alkyl, CH<sub>3</sub>O, CH<sub>3</sub>S(O)<sub>r</sub>, NO<sub>2</sub>, CF<sub>3</sub> oder Di(C<sub>1</sub>-C<sub>4</sub>)-

of of Aikyi, voizwoigtoin og og Aikyi, ongo, ongo(o), noz, or

alkylamino ausgewählt sind, oder

R<sup>1</sup> und R<sup>2</sup> auch als

35

40

45

55

zusammengenommen werden können, worin L O oder OCH<sub>2</sub>O ist,

R<sup>3</sup> H ist,

R<sup>4</sup> C<sub>1</sub>-C<sub>8</sub>-Alkyl, verzweigtes C<sub>3</sub>-C<sub>8</sub>-Alkyl, C<sub>3</sub>-C<sub>7</sub>-Cycloalkyl, C<sub>4</sub>-C<sub>10</sub>-Cycloalkylalkyl, C<sub>7</sub>-C<sub>14</sub>-Aralkyl, Phenyl, das mit 1 bis 3 Gruppen substituiert ist, die aus CH<sub>3</sub>, F, Cl, CH<sub>3</sub>O, CN ausgewählt sind, oder Benzyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus CH<sub>3</sub>, CH<sub>3</sub>O, F, Cl oder CN ausgewählt sind,

R<sup>6</sup> C<sub>1</sub>-C<sub>8</sub>-Alkyl oder Phenyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus CH<sub>3</sub>, CH<sub>3</sub>O, F, Cl oder CN ausgewählt sind,

A C<sub>4</sub>-C<sub>9</sub>-Alkyl ist,

X  $S(O)_r$  ist, Y O,  $H_2$  ist.

5

15

- Verfahren der Ansprüche 1 bis 4, wobei die hergestellten Verbindungen aus N'-(2,4-Difluorphenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylharnstoff,
  - N'-(2,4-Difluorphenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]-N-heptylharnstoff,
  - N-Butyl-N'-(2,4-difluorphenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]harnstoff,
  - N'-(2,4-Dimethoxyphenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-yl-thio)pentyl]-N-heptylharnstoff,
  - N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-methylharnstoff,
- N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-propylharnstoff,
  - N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-(3-fluorphenyl)-N-heptylharnstoff,
  - N'-(2,4-Difluorphenyl)-N-[5-[(4,5-Diphenyl-1H-imidazol-2-yl)sulfonyl])pentyl]-N-heptylharnstoff,
  - N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-(1-methylethyl)harnstoff,
  - N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-2,4-difluor-N-heptylbenzolacetamid,
  - N'-Cyclohexyl-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylharnstoff,
    - N'-(2,4-Difluorphenyl)-N-[5-[(4,5-Diphenyl-1H-imidazol-2-yl)sulfinyl]pentyl]-N-heptylharnstoff,
    - N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylbutanamid,
    - N-[5-[4,5-Bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorphenyl)-N-heptylharnstoff,
    - N-[5-[4,5-Bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylcyclohexanacetamid,
- N-[5-[4,5-Bis(2-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorphenyl)-N-heptylharnstoff, [5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbaminsäure-phenylester, N-[5-[4,5-Bis[4-(dimethylamino)phenyl]-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorphenyl)-N-
  - N-[5-[4,5-Bis[4-(dimethylamino)phenyl]-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorphenyl)-N-heptylharnstoff,
  - N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-octyl-N-phenylharnstoff,
- N-[5-[4,5-Bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-2,4-difluor-N-heptylbenzolacetamid, [5-[4,5-Bis(4-(dimethylamino)phenyl)-1H-imidazol-2-ylthio]pentyl]heptylcarbaminsäure-phenylester und N-[5-(4,5-Dicyclohexyl-1H-imidazol-2-ylthio)pentyl]-N'-(2,4-difluorphenyl)-N-heptylharnstoff ausgewählt sind.
- 30 **6.** Verfahren des Anspruchs 1, das weiter das Entfernen einer etwaigen Schutzgruppe an R<sup>3</sup> unter Liefern einer Verbindung der Formel (I), worin R<sup>3</sup> H ist, umfaßt.
  - 7. Verfahren des Anspruchs 1, das weiter das Umsetzen einer Verbindung der Formel (I), worin Y O ist, mit Lawessons Reagenz oder Diphosphorpentasulfid unter Liefern einer Verbindung der Formel (I), worin Y S ist, umfaßt.
  - 8. Verfahren des Anspruchs 1, das weiter das Umsetzen einer Verbindung der Formel (I), worin Y O ist, mit einem Reduktionsmittel, wie etwa Lithiumaluminiumhydrid oder Natriumborhydrid, unter Liefern einer Verbindung der Formel (I), worin Y H<sub>2</sub> ist, umfaßt.
  - 9. Verfahren des Anspruchs 1, das weiter das Umsetzen einer Verbindung der Formel (I), worin X S ist mit einem geeigneten Oxidationsmittel unter Liefern entweder des Sulfoxids SO, wobei r 1 ist, oder des Sulfons SO<sub>2</sub>, wobei r 2 ist, umfaßt.
- **10.** Verfahren des Anspruchs 1, das weiter das Umsetzen einer Verbindung der Formel (I), worin R<sup>3</sup> H ist, mit einem geeigneten Alkylierungsmittel wie etwa einem Alkylhalogenid unter Liefern einer Verbindung der Formel (I), worin R<sup>3</sup> C<sub>1</sub>-C<sub>6</sub>-Alkyl, Allyl oder Benzyl ist, umfaßt.

50

35

40

55

### 11. Verfahren, umfassend die Schritte des Alkylierens einer Verbindung der Formel

 $\mathbb{R}^{1} \xrightarrow{\stackrel{\mathsf{H}}{\underset{\mathsf{H}^{3}}{\bigvee}}} \mathbb{R}^{3}$ 

in welcher

5

10

15

20

25

30

40

R¹ und R² unabhängig ausgewählt sind aus H, C1-C8-Alkyl, vorausgesetzt, daß wenn R¹ H ist, R²

nicht H sein kann und wenn  $R^1$   $C_1$ - $C_8$ -Alkyl ist,  $R^2$  nicht  $C_1$ - $C_8$ -Alkyl sein kann, verzweigtem  $C_3$ - $C_8$ -Alkyl,  $C_3$ - $C_7$ -Cycloalkyl,  $C_4$ - $C_{10}$ -Cycloalkylalkyl,  $C_7$ - $C_{14}$ -Aralkyl, 2-, 3- oder 4-Pyridinyl, 2-Thienyl, 2-Furanyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus F, Cl, Br, OH,  $C_1$ - $C_4$ -Alkoxy,  $C_1$ - $C_4$ -Alkyl, verzweig-

tem C<sub>3</sub>-C<sub>8</sub>-Alkyl, CH<sub>3</sub>S(O)<sub>r</sub>, NO<sub>2</sub>, CF<sub>3</sub> oder NR<sup>7</sup>R<sup>8</sup> ausgewählt sind, oder

R<sup>1</sup> und R<sup>2</sup> zusammengenommen auch

sein können, worin L O,  $O(CH_2)_{m+1}O$  oder  $(CH_2)_m$  ist, worin m 0-4 ist,

 $R^3$  H,  $C_1$ - $C_6$ -Alkyl, Allyl, Benzyl oder gegebenenfalls mit F, Cl,  $CH_3$ ,  $CH_3O$  oder  $CF_3$  substituiertes Phenyl, oder eine geeignete Schutzgruppe ist, wie etwa eine Silyl- oder

Tritylgruppe, und

X O oder S ist, mit einer Verbindung der Formel

M(A)—N—F

50 worin

M ein Halogenid oder Tosylat ist,

A C<sub>2</sub>-C<sub>10</sub>-Alkyl, verzweigtes C<sub>3</sub>-C<sub>10</sub>-Alkyl, C<sub>3</sub>-C<sub>10</sub>-Alkenyl oder C<sub>3</sub>-C<sub>10</sub>-Alkinyl ist,

H, C<sub>1</sub>-C<sub>8</sub>-Alkyl, verzweigtes C<sub>3</sub>-C<sub>8</sub>-Alkyl, C<sub>3</sub>-C<sub>7</sub>-Cycloalkyl, C<sub>3</sub>-C<sub>8</sub>-Alkenyl oder -Alkinyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C<sub>1</sub>-C<sub>4</sub>-Alkyl oder -Alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub>-Carbalkoxy, NR<sup>7</sup>R<sup>8</sup> oder NCOR<sup>7</sup> ausgewählt sind, Pentafluorphenyl, Benzyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C<sub>1</sub>-C<sub>4</sub>-Alkyl oder -Alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub>-Carbalkoxy, NR<sup>7</sup>R<sup>8</sup> oder NCOR<sup>7</sup> ausgewählt sind,

Y O, S oder H<sub>2</sub> ist und Z NHR<sup>4</sup>, OR<sup>4</sup> oder R<sup>4</sup> ist, unter Liefern einer Verbindung der Formel (I)

5

10

15

20

in welcher

R1 und R2

unabhängig ausgewählt sind aus H,  $C_1$ - $C_8$ -Alkyl, verzweigtem  $C_3$ - $C_8$ -Alkyl,  $C_3$ - $C_7$ -Cycloalkyl,  $C_4$ - $C_{10}$ -Cycloalkylalkyl,  $C_7$ - $C_{14}$ -Aralkyl, 2-, 3- oder 4-Pyridinyl, 2-Thienyl, 2-Furanyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus F, Cl, Br, OH,  $C_1$ - $C_4$ -Alkoxy,  $C_1$ - $C_4$ -Alkyl, verzweigtem  $C_3$ - $C_8$ -Alkyl,  $C_8$ -Oly,  $C_9$ 0 oder  $C_8$ -Alkyl,  $C_9$ - $C_9$ 0 ausgewählt sind, oder

R<sup>1</sup> und R<sup>2</sup>

zusammengenommen auch

25

30

35

40

45

sein können, worin L O, O(CH2)m+1O oder (CH2)m ist, worin m 0-4 ist,

 $R^3$ 

H,  $C_1$ - $C_6$ -Alkyl, Allyl, Benzyl oder gegebenenfalls mit F, Cl,  $CH_3$ ,  $CH_3O$  oder  $CF_3$  substituiertes Phenyl ist,

R⁴

geradkettiges  $C_1$ - $C_8$ -Alkyl, das gegebenenfalls mit F substituiert ist, verzweigtes  $C_3$ - $C_8$ -Alkyl,  $C_3$ - $C_7$ -Cycloalkyl,  $C_4$ - $C_{10}$ -Cycloalkylalkyl,  $C_7$ - $C_{14}$ -Aralkyl, worin die Arylgruppe gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus  $C_1$ - $C_4$ -Alkyl oder -Alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>,  $C_1$ - $C_4$ -Carbalkoxy, NR<sup>7</sup>R<sup>8</sup> oder NCOR<sup>7</sup> ausgewählt sind,  $C_3$ - $C_6$ -Alkenyl oder -Alkinyl,  $C_1$ - $C_3$ -Perfluoralkyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus  $C_1$ - $C_4$ -Alkyl,  $C_1$ - $C_4$ -Alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>,  $C_1$ - $C_4$ -Carbalkoxy, NR<sup>7</sup>R<sup>8</sup> oder NCOR<sup>7</sup> ausgewählt sind, Pentafluorphenyl, Benzyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus  $C_1$ - $C_4$ -Alkyl oder -Alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>,  $C_1$ - $C_4$ -Carbalkoxy, NR<sup>7</sup>R<sup>8</sup> oder NCOR<sup>7</sup> ausgewählt sind, 2-, 3- oder 4-Pyridinyl, Pyrimidinyl oder Biphenyl ist,

50

H, C<sub>1</sub>-C<sub>6</sub>-Alkyl oder Benzyl ist,

R⁵ R<sup>6</sup>

H,  $C_1$ - $C_8$ -Alkyl, verzweigtes  $C_3$ - $C_8$ -Alkyl,  $C_3$ - $C_7$ -Cycloalkyl,  $C_3$ - $C_8$ -Alkenyl oder -Alkinyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus  $C_1$ - $C_4$ -Alkyl oder -Alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, C<sub>1</sub>- $C_4$ -Carbalkoxy, NR<sup>7</sup>R<sup>8</sup> oder NCOR<sup>7</sup> ausgewählt sind, Pentafluorphenyl, Benzyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus  $C_1$ - $C_4$ -Alkyl oder -Alkoxy, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>,  $C_1$ - $C_4$ -Carbalkoxy, NR<sup>7</sup>R<sup>8</sup> oder NCOR<sup>7</sup> ausgewählt

sind,

R<sup>7</sup> und R<sup>8</sup> unabhängig aus H oder C<sub>1</sub>-C<sub>4</sub>-Alkyl ausgewählt sind,

 $X = S(O)_r$ , O, NR<sup>5</sup>, CH<sub>2</sub> ist,

A C<sub>2</sub>-C<sub>10</sub>-Alkyl, verzweigtes C<sub>3</sub>-C<sub>10</sub>-Alkyl, C<sub>3</sub>-C<sub>10</sub>-Alkenyl oder C<sub>3</sub>-C<sub>10</sub>-Alkinyl ist,

Y  $O, S, H_2 \text{ ist,}$ 

Z NHR<sup>4</sup>, OR<sup>4</sup> oder R<sup>4</sup> ist,

r 0-2 ist,

5

15

30

40

45

50

55

und gegebenenfalls das Bilden eines pharmazeutisch annehmbaren Salzes derselben.

- 10 12. Verfahren des Anspruchs 11, das weiter das Entfernen einer etwaigen Schutzgruppe an R<sup>3</sup> umfaßt.
  - 13. Verfahren des Anspruchs 11, das weiter das Umsetzen einer Verbindung der Formel (I), worin Y O ist, mit Lawessons Reagenz oder Diphosphorpentasulfid unter Liefern einer Verbindung der Formel (I), worin Y S ist, umfaßt.
  - 14. Verfahren des Anspruchs 11, das weiter das Umsetzen einer Verbindung der Formel (I), worin Y O ist, mit einem Reduktionsmittel, wie etwa Lithiumaluminiumhydrid oder Natriumborhydrid, unter Liefern einer Verbindung der Formel (I), worin Y H<sub>2</sub> ist, umfaßt.
- 15. Verfahren des Anspruchs 11, das weiter das Umsetzen einer Verbindung der Formel (I), worin X S ist, mit einem geeigneten Oxidationsmittel unter Liefern entweder des Sulfoxids SO, wobei r 1 ist, oder des Sulfons SO<sub>2</sub>, wobei r 2 ist, umfaßt.
- 16. Verfahren des Anspruchs 11, das weiter das Umsetzen einer Verbindung der Formel (I), worin R³ H ist, mit einem geeigneten Alkylierungsmittel wie etwa einem Alkylhalogenid unter Liefern einer Verbindung der Formel (I), worin R³ C₁-C₆-Alkyl, Allyl oder Benzyl ist, umfaßt.
  - 17. Verfahren zum Herstellen einer pharmazeutischen Zusammensetzung umfassend das Mischen einer therapeutisch wirksamen Menge einer gemäß einem der Ansprüche 1 bis 16 hergestellten Verbindung und eines pharmazeutisch annehmbaren Trägers.

#### Revendications

Revendications pour les Etats contractants suivants : AT, BE, CH, DE, FR, GB, GR, IT, LI, LU, NL, SE

35 **1.** Un composé de formule:

Formule (I)

dans laquelle: R1 et R2

sont choisis, indépendamment l'un de l'autre, dans le groupe comprenant un atome d'hydrogène, un radical alkyle en  $C_1$  à  $C_8$ , à condition que lorsque  $R^1$  est un atome d'hydrogène, alors  $R^2$  ne peut être un atome d'hydrogène et que lorsque  $R^1$  est un radical alkyle en  $C_1$  à  $C_8$ , alors  $R^2$  ne peut pas être un radical alkyle en  $C_1$  à  $C_8$ , un radical alkyle ramifié en  $C_3$  à  $C_8$ , cycloalkyle en  $C_3$  à  $C_7$ , cycloalkylalkyle en  $C_4$  à  $C_{10}$ , aralkyle en  $C_7$  à  $C_{14}$ ,  $C_{14}$ ,  $C_{15}$ , ou 4-pyridinyle, 2-thiényle, 2-furanyle, phényle éventuelle-

ment substitué par 1 à 3 groupes sélectionnés parmi: atomes de fluor, chlore, brome, un groupe OH, un radical alcoxy en  $C_1$  à  $C_4$ , alkyle en  $C_1$  à  $C_4$ , alkyle ramifié en  $C_3$  à  $C_8$ ,  $CH_3S(O)_r$ ,  $NO_2$ ,  $CF_3$  ou  $NR^7R^8$ ; ou

R<sup>1</sup> et R<sup>2</sup> peuvent former ensemble un groupe:

5

10

15

25

30

35

40

45

50

20 dans lequel:

 $R^4$ 

L est O,  $O(CH_2)_{m+1}O$ , ou  $(CH_2)_m$ , m étant un nombre de 0 à 4;

R<sup>3</sup> est un atome d'hydrogène, un radical alkyle en  $C_1$  à  $C_6$ , allyle, benzyle ou phényle éventuellement substitué par un atome de fluor, de chlore, un groupe  $CH_3$ ,  $CH_3O$  ou  $CF_3$ ;

est un radical alkyle linéaire en C<sub>1</sub> à C<sub>8</sub> éventuellement substitué par un atome de fluor; un radical alkyle ramifié en C<sub>3</sub> à C<sub>8</sub>, cycloalkyle en C<sub>3</sub> à C<sub>7</sub>, cycloalkylalkyle en C<sub>4</sub> à C<sub>10</sub>, aralkyle en C<sub>7</sub> à C<sub>14</sub>, dans lequel le radical aryle est éventuellement substitué par un à trois groupes choisis parmi les radicaux alcoxy ou alkyle en C<sub>1</sub> à C<sub>4</sub>, les atomes de fluor, brome, chlore, les groupes NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, carboalcoxy en C<sub>1</sub> à C<sub>4</sub>, NR<sup>7</sup>R<sup>8</sup> ou NCOR<sup>7</sup>; les radicaux alkynyle ou alkényle en C<sub>3</sub> à C<sub>6</sub>, perfluoroalkyle en C<sub>1</sub> à C<sub>3</sub>, phényle éventuellement substitué par un groupe choisi parmi les radicaux alcoxy ou alkyle en C<sub>1</sub> à C<sub>4</sub>, les atomes de fluor, brome, chlore, les groupes NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, les radicaux carboalcoxy en C<sub>1</sub> à C<sub>4</sub>, NR<sup>7</sup>R<sup>8</sup> ou NCOR<sup>7</sup>; les radicaux pentafluorophényle, benzyle éventuellement substitué par 1 à 3 groupes choisis parmi les radicaux alcoxy ou alkyle en C<sub>1</sub> à C<sub>4</sub>, les atomes de fluor, brome, chlore, les groupes NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, carboalcoxy en C<sub>1</sub> à C<sub>4</sub>, NR<sup>7</sup>R<sup>8</sup> ou NCOR<sup>7</sup>; les radicaux 2-, 3- ou 4- pyridinyle, pyrimidinyle ou biphényle;

 $R^5$  est un atome d'hydrogène ou un radical alkyle en  $C_1$  à  $C_6$  ou benzyle; est un atome d'hydrogène, un radical alkyle en  $C_1$  à  $C_8$ , alkyle ram

est un atome d'hydrogène, un radical alkyle en  $C_1$  à  $C_8$ , alkyle ramifié en  $C_3$  à  $C_8$ , cycloalkyle en  $C_3$  à  $C_7$ , alkynyle ou alkényle en  $C_3$  à  $C_8$ , phényle éventuellement substitué par 1 à 3 groupes choisis parmi les radicaux alcoxy ou alkyle en  $C_1$  à  $C_4$ , les atomes de fluor, brome, chlore, les groupes  $NH_2$ , OH, CN,  $CO_2H$ ,  $CF_3$ ,  $NO_2$ , carboalcoxy en  $C_1$  à  $C_4$ ,  $NR^7R^8$  ou  $NCOR^7$ ; les radicaux pentafluorophényle, benzyle éventuellement substitué par 1 à 3 groupes choisi parmi les radicaux alcoxy ou alkyle en  $C_1$  à  $C_4$ , les atomes de fluor, brome, chlore, les groupes  $NH_2$ , OH, CN,  $CO_2H$ ,  $CF_3$ ,  $NO_2$ , carboalcoxy en  $C_1$  à  $C_4$ ,  $NR^7R^8$  ou  $NCOR^7$ ;

 $R^7$  et  $R^8$  sont choisis, indépendamment l'un de l'autre, parmi l'atome d'hydrogène ou les radicaux alkyles en  $C_1$  à  $C_4$ ;

X est  $S(O)_r$ , O,  $NR^5$ ,  $CH_2$ ;

A est un radical alkyle en C<sub>2</sub> à C<sub>10</sub>, alkyle ramifié en C<sub>3</sub> à C<sub>10</sub>, alkényle en C<sub>3</sub> à C<sub>10</sub>, ou alkynyle en C<sub>3</sub> à C<sub>10</sub>;

Y est O, S ou  $H_2$ ;

Z est NHR<sup>4</sup>, OR<sup>4</sup> ou R<sup>4</sup>;

r est un nombre de 0 à 2,

ou un sel pharmaceutiquement acceptable en dérivant.

2. Un composé selon la revendication 1, dans lequel:

R¹ et R² sont choisis, indépendamment l'un de l'autre, parmi les radicaux alkyles en C₁ à C₃, à

condition que lorsque  $R^1$  est un radical alkyle en  $C_1$  à  $C_8$ ,  $R^2$  ne puisse pas être un radical alkyle en  $C_1$  à  $C_8$ , un radical alkyle ramifié en  $C_3$  à  $C_8$ , cycloalkyle en  $C_3$  à  $C_7$ , cycloalkylalkyle en  $C_4$  à  $C_{10}$ , aralkyle en  $C_7$  à  $C_{14}$ , 2-, 3- ou 4-pyridinyle, 2-thiényle, 2-furanyle, phényle éventuellement substitué par 1 ou 2 groupes choisis parmi F, Cl, Br, OH, alcoxy en  $C_1$  à  $C_4$ , alkyle en  $C_1$  à  $C_4$ , alkyle ramifié en  $C_3$  à  $C_8$ ,  $CH_3S(O)_r$ ,  $NO_2$ ,  $CF_3$  ou  $NR^7R^8$ ; ou encore

R<sup>1</sup> et R<sup>2</sup> peuvent former ensemble un groupe:

5

25

30

35

40

15 20

dans lequel:

L est O,  $O(CH_2)_{m+1}O$ , ou  $(CH_2)_m$ , m étant un nombre de 0 à 4.

3. Un composé selon la revendication 2, dans lequel:

R³ est un atome d'hydrogène, un groupe CH₃, ou un groupe phényle;

R<sup>6</sup> est un atome d'hydrogène, un radical alkyle en C<sub>1</sub> à C<sub>8</sub>, alkyle ramifié en C<sub>3</sub> à C<sub>8</sub>, cycloalkyle en C<sub>3</sub> à C<sub>7</sub>, phényle éventuellement substitué par 1 à 3 groupes choisis parmi CH<sub>3</sub>, CH<sub>3</sub>O, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub> ou dialkyl-(C<sub>1</sub> à C<sub>4</sub>)-amino; ou benzyle éventuellement substitué par 1 à 3 groupes choisis parmi CH<sub>3</sub>, CH<sub>3</sub>O, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub> ou dialkyl-(C<sub>1</sub> à C<sub>4</sub>)-amino;

X est  $S(O)_r$ ,  $CH_2$ ;

A est un radical alkyle en C<sub>2</sub>-C<sub>10</sub>, ou alkyle ramifié en C<sub>4</sub>- C<sub>9</sub>.

4. Un composé selon la revendication 3, dans lequel:

R¹ et R² sont choisis, indépendamment l'un de l'autre, parmi les radicaux alkyle en C₁ à C8, alkyle ramifié en C3 à C8, cycloalkyle en C3 à C7, cycloalkylalkyle en C4 à C10, aralkyle en C7 à C14, 2-, 3- ou 4-pyridinyle, 2-thiényle ou phényle éventuellement substitué par 1 ou 2 groupes choisis parmi F, Br, Cl, alkyle en C1 à C4, alkyle ramifié en C3 à C8, CH3O, CH3S(O)r, NO2, CF3 ou dialkyl-(C1 à C4)-amino; ou

R<sup>1</sup> et R<sup>2</sup> peuvent former ensemble un groupe:

50 L

dans lequel:

L est 0 ou OCH<sub>2</sub>O;

R<sup>3</sup> est un atome d'hydrogène;

est un radical alkyle en C<sub>1</sub> à C<sub>8</sub>, alkyle ramifié en C<sub>3</sub> à C<sub>8</sub>, cycloalkyle en C<sub>3</sub> à C<sub>7</sub>, cycloalkylalkyle en C<sub>4</sub> à C<sub>10</sub>, aralkyle en C<sub>7</sub> à C<sub>14</sub>, phényle substitué par 1 à 3 groupes choisis parmi CH<sub>3</sub>, F, Cl, CH<sub>3</sub>O, CN, ou benzyle éventuellement substitué par

1 à 3 groupes choisis parmi CH<sub>3</sub>, CH<sub>3</sub>O, F, Cl ou CN;

R<sup>6</sup> est un radical alkyle en C<sub>1</sub> à C<sub>8</sub> ou phényle éventuellement substitué par 1 à 3 groupes

choisis parmi CH3, CH3O, F, Cl ou CN;

A est un radical alkyle en C<sub>4</sub> à C<sub>9</sub>;

 $X = est S(O)_r$ ;

5

10

15

20

25

30

35

45

50

55

Y est O, H<sub>2</sub>.

5. Composé selon les revendications 1 à 4, choisi parmi ceux appartenant à la liste comprenant:

. N'-(2,4-difluorophényl)-N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptylurée;

. N'-(2,4-difluorophényl)-N-[8-(4,5-diphényl-1H-imidazol-2-ylthio)octyl]-N-heptylurée;

. N-butyl-N'-(2,4-difluorophényl)-N-[8-(4,5-diphényl-1H-imidazol-2-ylthio)octyl]urée;

. N'-(2,4-diméthoxyphényl)-N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptylurée;

. N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-méthylurée;

. N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-propylurée;

. N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N'-(3-fluorophényl)-N-heptylurée;

. N'-(2,4-difluorophényl)-N-[5-[(4,5-diphényl-1H-imidazol-2-yl)sulfonyl]pentyl]-N-heptylurée;

. N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-(1-méthyléthyl)urée;

. N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-2,4-difluoro-N-heptylbenzèneacétamide;

. N'-cyclohexyl-N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptylurée;

. N'-(2,4-difluorophényl)-N-[5-([4,5-diphényl-1H-imidazol-2-yl)sulfinyl]pentyl]-N-heptylurée;

. N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptylbutanamide;

. N-[5-[4,5-bis(1-méthyléthyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophényl)-N-heptylurée;

. N-[5-[4,5-bis(1-méthyléthyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylcyclohexaneacétamide;

. N-[5-[4,5-bis(2-méthoxyphényl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophényl)-N-heptylurée;

. Phényl-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate;

. N-[5-[4,5-bis[4-(diméthylamino)phényl]-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophényl)-N-heptylurée:

. N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N'-octyl-N-phénylurée;

. N-[5-[4,5-bis(4-méthoxyphényl)-1H-imidazol-2-ylthio]pentyl]-2,4-difluoro-N-heptylbenzèneacétamide;

. Phényl-[5-[(4,5-bis-(4-diméthylamino)phényl)-1H-imidazol-2-ylthio]pentyl]-heptylcarbamate; et

. N-[5-(4,5-dicyclohexyl-1H-imidazol-2-ylthio)pentyl]-N'-(2,4-difluorophényl)-N-heptylurée.

**6.** Une composition pharmaceutique comprenant une quantité efficace du point de vue thérapeutique d'un composé selon une des revendications 1 à 5 ainsi qu'un support pharmaceutiquement acceptable.

7. Un procédé de préparation d'un composé de formule (I):

 $\begin{array}{c|c}
R & 1 \\
R & 2 & N \\
R & 3 & X - A - N - R & 6
\end{array}$ 

dans laquelle:

R¹ et R² sont choisis, indépendamment l'un de l'autre, dans le groupe comprenant un atome d'hydrogène, un radical alkyle en C¹ à C₃, à condition que lorsque R¹ est un atome

d'hydrogène, alors  $R^2$  ne peut être un atome d'hydrogène et que lorsque  $R^1$  est un radical alkyle en  $C_1$  à  $C_8$ , alors  $R^2$  ne peut pas être un radical alkyle en  $C_1$  à  $C_8$ , un radical alkyle ramifié en  $C_3$  à  $C_8$ , cycloalkyle en  $C_3$  à  $C_7$ , cycloalkylalkyle en  $C_4$  à  $C_{10}$ , aralkyle en  $C_7$  à  $C_{14}$ , 2-, 3- ou 4-pyridinyle, 2-thiényle, 2-furanyle, phényle éventuellement substitué par 1 à 3 groupes sélectionnés parmi: atomes de fluor, chlore, brome, un groupe OH, un radical alcoxy en  $C_1$  à  $C_4$ , alkyle en  $C_1$  à  $C_4$ , alkyle ramifié en  $C_3$  à  $C_8$ ,  $C_$ 

R<sup>1</sup> et R<sup>2</sup> peuvent former ensemble un groupe:

dans lequel:

est O, O(CH<sub>2</sub>)<sub>m+1</sub>O, ou (CH<sub>2</sub>)<sub>m</sub>, m étant un nombre de 0 à 4;

R<sup>3</sup> est un atome d'hydrogène, un radical alkyle en C<sub>1</sub> à C<sub>6</sub>, allyle, benzyle ou phényle éventuellement substitué par un atome de fluor, de chlore, un groupe CH<sub>3</sub>, CH<sub>3</sub>O ou CF<sub>3</sub>;

R⁴ est

L

 $R^6$ 

5

10

15

20

25

30

35

40

45

50

55

est un radical alkyle linéaire en  $C_1$  à  $C_8$  éventuellement substitué par un atome de fluor; un radical alkyle ramifié en  $C_3$  à  $C_8$ , cycloalkyle en  $C_4$  à  $C_7$ , cycloalkyle en  $C_8$  à  $C_7$ , cycloalkyle en  $C_8$  à  $C_8$ , aralkyle en  $C_8$  à  $C_8$ ,  $C_8$ , aralkyle en  $C_8$  à  $C_8$ , perfluoroalkyle en  $C_8$  à  $C_8$ , perfluoroalkyle en  $C_8$  à  $C_8$ , phényle éventuellement substitué par un groupe choisi parmi les radicaux alcoxy ou alkyle en  $C_8$  à  $C_8$ , les atomes de fluor, brome, chlore, les groupes  $C_8$ ,  $C_8$ ,

R<sup>5</sup> est un atome d'hydrogène ou un radical alkyle en C<sub>1</sub> à C<sub>6</sub> ou benzyle;

est un atome d'hydrogène, un radical alkyle en C<sub>1</sub> à C<sub>8</sub>, alkyle ramifié en C<sub>3</sub> à C<sub>8</sub>, cycloalkyle en C<sub>3</sub> à C<sub>7</sub>, alkynyle ou alkényle en C<sub>3</sub> à C<sub>8</sub>, phényle éventuellement substitué par 1 à 3 groupes choisis parmi les radicaux alcoxy ou alkyle en C<sub>1</sub> à C<sub>4</sub>, les atomes de fluor, brome, chlore, les groupes NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, carboalcoxy en C<sub>1</sub> à C<sub>4</sub>, NR<sup>7</sup>R<sup>8</sup> ou NCOR<sup>7</sup>; les radicaux pentafluorophényle, benzyle éventuellement substitué par 1 à 3 groupes choisi parmi les radicaux alcoxy ou alkyle en C<sub>1</sub> à C<sub>4</sub>, les atomes de fluor, brome, chlore, les groupes NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>,

carboalcoxy en C<sub>1</sub> à C<sub>4</sub>, NR<sup>7</sup>R<sup>8</sup> ou NCOR<sup>7</sup>;

R<sup>7</sup> et R<sup>8</sup> sont choisis, indépendamment l'un de l'autre, parmi l'atome d'hydrogène ou les radicaux alkyles en C<sub>1</sub> à C<sub>4</sub>;

X est  $S(O)_r$ , O,  $NR^5$ ,  $CH_2$ ;

A est un radical alkyle en C<sub>2</sub> à C<sub>10</sub>, alkyle ramifié en C<sub>3</sub> à C<sub>10</sub>, alkényle en C<sub>3</sub> à C<sub>10</sub>, ou alkynyle en C<sub>3</sub> à C<sub>10</sub>;

Y est O, S ou  $H_2$ ;

Z est NHR<sup>4</sup>, OR<sup>4</sup> ou R<sup>4</sup>;

r est un nombre de 0 à 2,

ou un sel pharmaceutiquement acceptable en dérivant; comprenant les étapes de:

- réaction d'un composé de formule:

5

10

15

dans laquelle:

R<sup>1</sup>, R<sup>2</sup>, X, A et R<sup>6</sup>

sont tels que définis ci-dessus; et

 $R^3$ 

est également tel que défini ci-dessus, ou est un groupe protecteur convenable tel qu'un groupe silyle ou trilyle,

avec:

i) un isocyanate de formule:

$$R^4-N=C=O$$

20

dans laquelle R<sup>4</sup> est tel que défini ci-dessus, pour conduire à un composé représenté par la formule (I) décrite ci-dessus, dans laquelle Y représente O et Z est NHR<sup>4</sup>; ou

ii) un isothiocyanate de formule:

25 
$$R^4 - N = C = S$$

dans laquelle R4 est tel que défini ci-dessus, pour conduire à un composé représenté par la formule

- (I) décrite ci-dessus, dans laquelle Y est S et Z est NHR4; ou
- iii) un chloroformiate de formule:

30


$$R^4$$
-O-C  $C1$ 

35

dans laquelle R<sup>4</sup> est tel que défini ci-dessus, pour conduire à un composé représenté par la formule (I) décrite ci-dessus, dans laquelle Y représente O et Z est OR<sup>4</sup>; ou

iv) un chlorure d'acide de formule:

40



45

ou un autre acide carboxylique activé, dans laquelle  $R^4$  est tel que défini ci-dessus, pour conduire à un composé représenté par la formule (I) décrite ci-dessus, dans laquelle Y représente O et Z est  $R^4$ .

50

- 8. Un procédé selon la revendication 7, comprenant en outre l'élimination de tout groupe protecteur sur R³ pour conduire à un composé de formule (I) dans laquelle R³ est H.
- 9. Un procédé selon la revendication 7, comprenant en outre la réaction d'un composé de formule (I) dans laquelle Y est O, avec un réactif de Lawesson ou un pentasulfure diphosphoreux, pour conduire à un composé de formule (I) dans laquelle Y est S.

- 10. Un procédé selon la revendication 7, comprenant en outre la réaction d'un composé de formule (I) dans laquelle Y est O, avec un agent réducteur tel que l'hydrure d'aluminium lithium ou du borohydrure de sodium, pour conduire à un composé de formule (I) dans laquelle Y est H<sub>2</sub>.
- 11. Un procédé selon la revendication 7, comprenant en outre la réaction d'un composé de formule (I) dans laquelle X est S, avec un agent d'oxydation convenable pour obtenir soit le sulfoxyde SO, dans lequel r est égal à 1, soit la sulfone SO<sub>2</sub>, dans lequel r est égal à 2.
  - 12. Un procédé selon la revendication 7, comprenant en outre la réaction d'un composé de formule (I) dans laquelle R³ est un atome d'hydrogène, avec un agent d'alkylation convenable tel qu'un halogénure d'alkyle, pour conduire à l'obtention d'un composé de formule (I) dans laquelle R³ est un radical alkyle en C₁ à C₆, allyle ou benzyle.
  - 13. Un procédé comprenant les étapes d'alkylation d'un composé de formule:

dans laquelle:

10

15

20

25

30

35

40

45

50

55

R¹ et R² sont choisis, indépendamment l'un de l'autre, le groupe comprenant un atome d'hydrogène, un radical alkyle en C₁ à C₃, à condition que lorsque R¹ est un atome d'hydrogène, alors R² ne peut être un atome d'hydrogène et que lorsque R¹ est un radical alkyle en C₁ à C₃, alors R² ne peut pas être un radical alkyle en C₁ à C₃, un radical alkyle ramifié en C₃ à C₃, cycloalkyle en C₃ à C₁, cycloalkylalkyle en C₄ à C₁₀, aralkyle en C₂ à C₁₄, 2-, 3- ou 4-pyridinyle, 2-thiényle, 2-furanyle, phényle éventuellement substitué par 1 à 3 groupes sélectionnés parmi: atomes de fluor, chlore, brome, un groupe OH, un radical alcoxy en C₁ à C₄, alkyle en C₁ à C₄, alkyle ramifié en C₃ à C₃, CH₃S(O)r, NO₂, CF₃ ou NR<sup>7</sup>R³; ou

R<sup>1</sup> et R<sup>2</sup> peuvent former ensemble un groupe:

dans lequel:

L est O,  $O(CH_2)_{m+1}O$ , ou  $(CH_2)_m$ , m étant un nombre de 0 à 4;

R<sup>3</sup> est un atome d'hydrogène, un radical alkyle en C<sub>1</sub> à C<sub>6</sub>, allyle, benzyle ou phényle éventuellement substitué par un atome de fluor, de chlore, un groupe CH<sub>3</sub>, CH<sub>3</sub>O ou CF<sub>3</sub>; ou un groupe protecteur convenable tel qu'un groupe silyle ou trilyle; et

X est O ou S, avec un composé de formule:

$$M(A) \longrightarrow N \longrightarrow R^{6}$$

dans laquelle:

5

10

15

20

35

40

M est un halogénure ou un tosylate;

A est un radical alkyle en  $C_2$  à  $C_{10}$ , alkyle ramifié en  $C_3$  à  $C_{10}$ , alkényle en  $C_3$  à  $C_{10}$ , ou alkynyle en  $C_3$  à  $C_{10}$ ;

R<sup>6</sup> est un atome d'hydrogène, un radical alkyle en C<sub>1</sub> à C<sub>8</sub>, alkyle ramifié en C<sub>3</sub> à C<sub>8</sub>, cycloalkyle en C<sub>3</sub> à C<sub>7</sub>, alkynyle ou alkényle en C<sub>3</sub> à C<sub>8</sub>, phényle éventuellement substitué par 1 à 3 groupes choisis parmi alcoxy ou alkyle en C<sub>1</sub> à C<sub>4</sub>, les atomes de fluor, brome, chlore, les groupes NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, carboalcoxy en C<sub>1</sub> à C<sub>4</sub>, NR<sup>7</sup>R<sup>8</sup> ou NCOR<sup>7</sup>; pentafluorophényle, benzyle éventuellement substitué par 1 à 3 groupes choisi parmi alcoxy ou alkyle en C<sub>1</sub> à C<sub>4</sub>, les atomes de fluor, brome, chlore, les groupes NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, carboalcoxy en C<sub>1</sub> à C<sub>4</sub>, NR<sup>7</sup>R<sup>8</sup> ou NCOR<sup>7</sup>;

Y est O, S ou H<sub>2</sub>; et

Z est NHR<sup>4</sup>, OR<sup>4</sup> ou R<sup>4</sup>,

pour conduire à un composé de formule (I):

dans laquelle:

R¹ et R² sont choisis, indépendamment l'un de l'autre, dans le groupe comprenant un atome d'hydrogène, un radical alkyle en C¹ à C³, alkyle ramifié en C³ à C³, cycloalkyle en C³ à C¹, aralkyle en C³ à C³, aralkyle en C³ à C³, alkyle en C³ à C³, alkyle en C³ à C³, alkyle ramifié en C³ à C³, CH³S(O), NO², CF³ ou NR²R³; ou

R<sup>1</sup> et R<sup>2</sup> peuvent former ensemble un groupe:

dans lequel:

	L R³	est O, $O(CH_2)_{m+1}O$ , ou $(CH_2)_m$ , m étant un nombre de 0 à 4; est un atome d'hydrogène, un radical alkyle en $C_1$ à $C_6$ , allyle, benzyle ou phényle
		éventuellement substitué par un atome de fluor, de chlore, un groupe CH <sub>3</sub> , CH <sub>3</sub> O ou
5	R⁴	CF <sub>3</sub> ; est un radical alkyle linéaire en C <sub>1</sub> à C <sub>8</sub> éventuellement substitué par un atome de fluor; un radical alkyle ramifié en C <sub>3</sub> à C <sub>8</sub> , cycloalkyle en C <sub>3</sub> à C <sub>7</sub> , cycloalkylalkyle en C <sub>4</sub> à C <sub>10</sub> , aralkyle en C <sub>7</sub> à C <sub>14</sub> , dans lequel le radical aryle est éventuellement substitué par un à trois groupes choisis parmi les radicaux alcoxy ou alkyle en C <sub>1</sub> à C <sub>4</sub> ,
10		les atomes de fluor, brome, chlore, les groupes $NH_2$ , $OH$ , $CN$ , $CO_2H$ , $CF_3$ , $NO_2$ , carboalcoxy en $C_1$ à $C_4$ , $NR^7R^8$ ou $NCOR^7$ ; les radicaux alkynyle ou alkényle en $C_3$ à $C_6$ , perfluoroalkyle en $C_1$ à $C_3$ , phényle éventuellement substitué par un groupe choisi parmi les radicaux alcoxy ou alkyle en $C_1$ à $C_4$ , les atomes de fluor, brome, chlore, les groupes $NH_2$ , $OH$ , $CN$ , $CO_2H$ , $CF_3$ , $NO_2$ , les radicaux carboalcoxy en $C_1$ à $C_4$ , $NR^7R^8$
15		ou NCOR <sup>7</sup> ; les radicaux pentafluorophényle, benzyle éventuellement substitué par 1 à 3 groupes choisis parmi les radicaux alcoxy ou alkyle en C <sub>1</sub> à C <sub>4</sub> , les atomes de fluor, brome, chlore, les groupes NH <sub>2</sub> , OH, CN, CO <sub>2</sub> H, CF <sub>3</sub> , NO <sub>2</sub> , carboalcoxy en C <sub>1</sub> à C <sub>4</sub> , NR <sup>7</sup> R <sup>8</sup> ou NCOR <sup>7</sup> ; les radicaux 2-, 3- ou 4-pyridinyle, pyrimidinyle ou biphényle;
	R <sup>5</sup>	est un atome d'hydrogène ou un radical alkyle en C <sub>1</sub> à C <sub>6</sub> ou benzyle;
	$R^{\scriptscriptstyle{6}}$	est un atome d'hydrogène, un radical alkyle en C <sub>1</sub> à C <sub>8</sub> , alkyle ramifié en C <sub>3</sub> à C <sub>8</sub> ,
20		cycloalkyle en C <sub>3</sub> à C <sub>7</sub> , alkynyle ou alkényle en C <sub>3</sub> à C <sub>8</sub> , phényle éventuellement substitué par 1 à 3 groupes choisis parmi les radicaux alcoxy ou alkyle en C <sub>1</sub> à C <sub>4</sub> , les atomes de fluor, brome, chlore, les groupes NH <sub>2</sub> , OH, CN, CO <sub>2</sub> H, CF <sub>3</sub> , NO <sub>2</sub> , carboalcoxy en C <sub>1</sub> à C <sub>4</sub> , NR <sup>7</sup> R <sup>8</sup> ou NCOR <sup>7</sup> ; les radicaux pentafluorophényle, benzyle éventuellement substitué par 1 à 3 groupes choisi parmi les radicaux alcoxy ou alkyle en C <sub>1</sub>
25		à C <sub>4</sub> , les atomes de fluor, brome, chlore, les groupes NH <sub>2</sub> , OH, CN, CO <sub>2</sub> H, CF <sub>3</sub> , NO <sub>2</sub> ,
	R <sup>7</sup> et R <sup>8</sup>	carboalcoxy en C <sub>1</sub> à C <sub>4</sub> , NR <sup>7</sup> R <sup>8</sup> ou NCOR <sup>7</sup> ; sont, indépendamment l'un de l'autre, choisis parmi l'atome d'hydrogène ou les radicaux alkyles en C <sub>1</sub> à C <sub>4</sub> ;
	X	est S(O) <sub>r</sub> , O, NR <sup>5</sup> , CH <sub>2</sub> ;
30	A	est un radical alkyle en $C_2$ à $C_{10}$ , alkyle ramifié en $C_3$ à $C_{10}$ , alkényle en $C_3$ à $C_{10}$ , ou alkynyle en $C_3$ à $C_{10}$ ;
	Υ	est O, S ou H <sub>2</sub> ;
	Z	est NHR <sup>4</sup> , OR <sup>4</sup> ou R <sup>4</sup> ;
	r	est un nombre de 0 à 2,
35	et formant éventuellement un sel pharmaceutiquement acceptable en dérivant.	

- 14. Un procédé selon la revendication 13, comprenant en outre l'élimination de tout groupe protecteur sur
- 40 **15.** Un procédé selon la revendication 13, comprenant en outre la réaction d'un composé de formule (I) dans laquelle Y est O, avec un réactif de Lawesson ou un pentasulfure diphosphoreux, pour conduire à un composé de formule (I) dans laquelle Y est S.

 $\mathbb{R}^3$ .

50

55

- 16. Un procédé selon la revendication 13, comprenant en outre la réaction d'un composé de formule (I) dans laquelle Y est O, avec un agent réducteur tel que l'hydrure d'aluminium lithium ou du borohydrure de sodium, pour conduire à un composé de formule (I) dans laquelle Y est H<sub>2</sub>.
  - 17. Un procédé selon la revendication 13, comprenant en outre la réaction d'un composé de formule (I) dans laquelle X est S, avec un agent d'oxydation convenable pour obtenir soit le sulfoxyde SO, dans lequel r est égal à 1, soit la sulfone SO<sub>2</sub>, dans laquelle r est égal à 2.
  - 18. Un procédé selon la revendication 13, comprenant en outre la réaction d'un composé de formule (I) dans laquelle R³ est un atome d'hydrogène, avec un agent d'alkylation convenable tel qu'un halogénure d'alkyle, pour conduire à l'obtention d'un composé de formule (I) dans laquelle R³ est un radical alkyle en C₁ à C₅, allyle ou benzyle.

#### Revendications pour l'Etat contractant suivant : ES

1. Un procédé de préparation d'un composé de formule (I):

R 2 N X -A -N -R

dans laquelle:

R1 et R2

sont choisis, indépendamment l'un de l'autre, dans le groupe comprenant un atome d'hydrogène, un radical alkyle en  $C_1$  à  $C_8$ , à condition que lorsque  $R^1$  est un atome d'hydrogène, alors  $R^2$  ne peut être un atome d'hydrogène et que lorsque  $R^1$  est un radical alkyle en  $C_1$  à  $C_8$ , alors  $R^2$  ne peut pas être un radical alkyle en  $C_1$  à  $C_8$ , un radical alkyle ramifié en  $C_3$  à  $C_8$ , cycloalkyle en  $C_3$  à  $C_7$ , cycloalkylalkyle en  $C_4$  à  $C_{10}$ , aralkyle en  $C_7$  à  $C_{14}$ , 2-, 3- ou 4-pyridinyle, 2-furanyle, phényle éventuellement substitué par 1 à 3 groupes sélectionnés parmi: atomes de fluor, chlore, brome, un groupe OH, un radical alcoxy en  $C_1$  à  $C_4$ , alkyle en  $C_1$  à  $C_4$ , alkyle ramifié en  $C_3$  à  $C_8$ ,  $C_{13}$ S(O)<sub>17</sub>,NO<sub>2</sub>,  $C_{13}$ S ou NR<sup>7</sup> R<sup>8</sup>; ou

R<sup>1</sup> et R<sup>2</sup> peuvent former ensemble un groupe:

30

5

10

15

20

25

40

45

50

35

dans lequel:

L est O, O(CH<sub>2</sub>)<sub>m+1</sub>O, ou (CH<sub>2</sub>)<sub>m</sub>, m étant un nombre de 0 à 4;

 $R^3$ 

est un atome d'hydrogène, un radical alkyle en  $C_1$  à  $C_6$ , allyle, benzyle ou phényle éventuellement substitué par un atome de fluor, de chlore, un groupe  $CH_3$ ,  $CH_3O$  ou  $CF_3$ ;

R<sup>4</sup>

est un radical alkyle linéaire en  $C_1$  à  $C_8$  éventuellement substitué par un atome de fluor; un radical alkyle ramifié en  $C_3$  à  $C_8$ , cycloalkyle en  $C_3$  à  $C_7$ , cycloalkylalkyle en  $C_4$  à  $C_{10}$ , aralkyle en  $C_7$  à  $C_{14}$ , dans lequel le radical aryle est éventuellement substitué par un à trois groupes choisis parmi les radicaux alcoxy ou alkyle en  $C_1$  à  $C_4$ , les atomes de fluor, brome, chlore, les groupes  $NH_2$ , OH, CN,  $CO_2H$ ,  $CF_3$ ,  $NO_2$ , carboalcoxy en  $C_1$  à  $C_4$   $NR^7R^8$  ou  $NCOR^7$ ; les radicaux alkynyle ou alkényle en  $C_3$  à  $C_5$ , perfluoroalkyle en  $C_1$  à  $C_3$ , phényle éventuellement substitué par un groupe choisi parmi les radicaux alcoxy ou alkyle en  $C_1$  à  $C_4$ , les atomes de fluor, brome, chlore, les groupes  $NH_2$ , OH, CN,  $CO_3H$ ,  $CF_3$ ,  $NO_2$ , les radicaux carboalcoxy en  $C_1$  à  $C_4$ ,  $NR^7R^8$  ou  $NCOR^7$ ; les radicaux pentafluorophényle, benzyle éventuellement substitué par 1 à 3 groupes choisis parmi les radicaux alcoxy ou alkyle en  $C_1$  à  $C_4$ , les atomes de fluor,

brome, chlore, les groupes NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, carboalcoxy en C<sub>1</sub> à C<sub>4</sub>, NR<sup>7</sup>R<sup>8</sup> ou NCOR<sup>7</sup>; les radicaux 2-, 3- ou 4-pyridinyle, pyrimidinyle ou biphényle;

R<sup>5</sup> est un atome d'hydrogène ou un radical alkyle en C<sub>1</sub> à C<sub>6</sub> ou benzyle;

est un atome d'hydrogène, un radical alkyle en C<sub>1</sub> à C<sub>8</sub>, alkyle ramifié en C<sub>3</sub> à C<sub>8</sub>, cycloalkyle en C<sub>3</sub> à C<sub>7</sub>, alkynyle ou alkényle en C<sub>3</sub> à C<sub>8</sub>, phényle éventuellement substitué par 1 à 3 groupes choisis parmi les radicaux alcoxy ou alkyle en C<sub>1</sub> à C<sub>4</sub>, les atomes de fluor, brome, chlore, les groupes NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, carboalcoxy en C<sub>1</sub> à C<sub>4</sub>, NR<sup>7</sup>R<sup>8</sup> ou NCOR<sup>7</sup>; les radicaux pentafluorophényle, benzyle éventuellement substitué par 1 à 3 groupes choisi parmi les radicaux alcoxy ou alkyle en C<sub>1</sub> à C<sub>4</sub>, les atomes de fluor, brome, chlore, les groupes NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>,

NO<sub>2</sub>, carboalcoxy en C<sub>1</sub> à C<sub>4</sub>, NR<sup>7</sup>R<sup>8</sup> ou NCOR<sup>7</sup>;

 $R^7$  et  $R^8$  sont choisis, indépendamment l'un de l'autre, parmi l'atome d'hydrogène ou les radicaux alkyles en  $C_1$  à  $C_4$ ;

X est  $S(O)_r$ , O,  $NR^5$ ,  $CH_2$ ;

A est un radical alkyle en C<sub>2</sub> à C<sub>10</sub>, alkyle ramifié en C<sub>3</sub> à C<sub>10</sub>, alkényle en C<sub>3</sub> à C<sub>10</sub>, ou

alkynyle en C<sub>3</sub> à C<sub>10</sub>;

Y est O, S ou  $H_2$ ; Z est NHR<sup>4</sup>, OR<sup>4</sup> ou R<sup>4</sup>;

r est NHR<sup>+</sup>, OR<sup>+</sup> ou R<sup>+</sup>; r est un nombre de 0 à 2,

ou un sel pharmaceutiquement acceptable en dérivant; comprenant les étapes de:

- réaction d'un composé de formule:

$$\begin{array}{c|c}
R^1 & N \\
 & N \\
R^2 & N \\
R^3 & 6
\end{array}$$

30 dans laquelle:

 $R^6$ 

5

10

15

20

25

35

40

45

50

55

R<sup>1</sup>, R<sup>2</sup>, X, A et R<sup>6</sup> sont tels que définis ci-dessus; et

R<sup>3</sup> est également tel que défini ci-dessus, ou est un groupe protecteur convenable tel qu'un groupe silyle ou trilyle,

avec:

i) un isocyanate de formule:

 $R^4-N=C=O$ 

dans laquelle R<sup>4</sup> est tel que défini ci-dessus, pour conduire à un composé représenté par la formule (I) décrite ci-dessus, dans laquelle Y représente O et Z est NHR<sup>4</sup>; ou

ii) un isothiocyanate de formule:

 $R^4-N=C=S$ 

dans laquelle R<sup>4</sup> est tel que défini ci-dessus, pour conduire à un composé représenté par la formule (I) décrite ci-dessus, dans laquelle Y est S et Z est NHR<sup>4</sup>; ou

iii) un chloroformiate de formule:

$$R^4$$
-0-C  $C1$ 

dans laquelle R<sup>4</sup> est tel que défini ci-dessus, pour conduire à un composé représenté par la formule (I) décrite ci-dessus, dans laquelle Y représente O et Z est OR<sup>4</sup>; ou

iv) un chlorure d'acide de formule:

5

10

15

20


25

30

35

45

55




ou un autre acide carboxylique activé, dans laquelle  $R^4$  est tel que défini ci-dessus, pour conduire à un composé représenté par la formule (I) décrite ci-dessus, dans laquelle Y représente O et Z est  $R^4$ .

2. Un procédé selon la revendication 1, dans lequel:

R1 et R2

sont choisis, indépendamment l'un de l'autre, parmi les radicaux alkyles en  $C_1$  à  $C_8$ , à condition que lorsque  $R^1$  est un radical alkyle en  $C_1$  à  $C_8$ ,  $R^2$  ne puisse pas être un radical alkyle en  $C_1$  à  $C_8$ , un radical alkyle ramifié en  $C_3$  à  $C_8$ , cycloalkyle en  $C_3$  à  $C_7$ , cycloalkylalkyle en  $C_4$  à  $C_{10}$ , aralkyle en  $C_7$  à  $C_{14}$ , 2-, 3- ou 4-pyridinyle, 2-furanyle, phényle éventuellement substitué par 1 ou 2 groupes choisis parmi F, Cl, Br, OH, alcoxy en  $C_1$  à  $C_4$ , alkyle en  $C_1$  à  $C_4$ , alkyle ramifié en  $C_3$  à  $C_8$ ,  $CH_3S(O)_r$ ,  $NO_2$ ,  $CF_3$  ou  $NR^7R^8$ ; ou encore

R<sup>1</sup> et R<sup>2</sup> peuvent former ensemble un groupe:



dans lequel:

L est O,  $O(CH_2)_{m+1}O$ , ou  $(CH_2)_m$ , m étant un nombre de 0 à 4.

- 40 3. Un procédé selon la revendication 2, dans lequel:
  - R<sup>3</sup> est un atome d'hydrogène, un groupe CH<sub>3</sub>, ou un groupe phényle;

R<sup>6</sup> est un atome d'hydrogène, un radical alkyle en C<sub>1</sub> à C<sub>8</sub>, alkyle ramifié en C<sub>3</sub> à C<sub>8</sub>, cycloalkyle en C<sub>3</sub> à C<sub>7</sub>, phényle éventuellement substitué par 1 à 3 groupes choisis parmi CH<sub>3</sub>, CH<sub>3</sub>O, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub> ou dialkyl-(C<sub>1</sub> à C<sub>4</sub>)-amino; ou benzyle éventuellement substitué par 1 à 3 groupes choisis parmi CH<sub>3</sub>, CH<sub>3</sub>O, F, Br, Cl, NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub> ou dialkyl-(C<sub>1</sub> à C<sub>4</sub>)-amino;

X est  $S(O)_r$ ,  $CH_2$ ;

A est un radical alkyle en C<sub>2</sub>-C<sub>10</sub>, ou alkyle ramifié en C<sub>4</sub>- C<sub>9</sub>.

50 4. Un procédé selon la revendication 3, dans lequel:

R¹ et R² sont choisis, indépendamment l'un de l'autre, parmi les radicaux alkyle en C₁ à C8, alkyle ramifié en C3 à C8, cycloalkyle en C3 à C7, cycloalkylalkyle en C4 à C10, aralkyle en C7 à C14, 2-, 3- ou 4-pyridinyle, 2-thiényle ou phényle éventuellement substitué par 1 ou 2 groupes choisis parmi F, Br, Cl, alkyle en C1 à C4, alkyle ramifié en C3 à C8, CH3O, CH3S(O)r, NO2, CF3 ou dialkyl-(C1 à C4)-amino; ou

R<sup>1</sup> et R<sup>2</sup> peuvent former ensemble un groupe:

20

25

30

35

40

45

50

5

dans lequel:

L est 0 ou OCH<sub>2</sub>O;

R<sup>3</sup> est un atome d'hydrogène;

R<sup>4</sup> est un radical alkyle en C<sub>1</sub> à C<sub>8</sub>, alkyle ramifié en C<sub>3</sub> à C<sub>8</sub>, cycloalkyle en C<sub>3</sub> à C<sub>7</sub>, cycloalkylalkyle en C<sub>4</sub> à C<sub>10</sub>, aralkyle en C<sub>7</sub> à C<sub>14</sub>, phényle substitué par 1 à 3 groupes choisis parmi CH<sub>3</sub>, F, Cl, CH<sub>3</sub>O, CN, ou benzyle éventuellement substitué par 1 à 3 groupes choisis parmi CH<sub>3</sub>, CH<sub>3</sub>O, F, Cl ou CN;

R<sup>6</sup> est un radical alkyle en C<sub>1</sub> à C<sub>8</sub> ou phényle éventuellement substitué par 1 à 3 groupes choisis parmi CH<sub>3</sub>, CH<sub>3</sub>O, F, CI ou CN;

A est un radical alkyle en C<sub>4</sub> à C<sub>9</sub>;

X est  $S(O)_r$ ;

Y est O. H₂.

- 5. Un procédé selon les revendications 1 à 4, dans lequel les composés sont choisis parmi ceux appartenant à la liste comprenant:
  - . N'-(2,4-difluorophényl)-N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptylurée;
  - . N'-(2,4-difluorophényl)-N-[8-(4,5-diphényl-1H-imidazol-2-ylthio)octyl]-N-heptylurée;
  - . N-butyl-N'-(2,4-difluorophényl)-N-[8-(4,5-diphényl-1H-imidazol-2-ylthio)octyl]urée;
  - N'-(2,4-diméthoxyphényl)-N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptylurée;
  - . N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-méthylurée;
  - . N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-propylurée;
  - . N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N'-(3-fluorophényl)-N-heptylurée;
  - . N'-(2,4-difluorophényl)-N-[5-[(4,5-diphényl-1H-imidazol-2-yl)sulfonyl)pentyl]-N-heptylurée;
  - . N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-(1-méthyléthyl)urée;
  - . N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-2,4-difluoro-N-heptylbenzèneacétamide;
  - . N'-cyclohexyl-N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptylurée;
  - . N'-(2,4-difluorophényl)-N-[5-([4,5-diphényl-1H-imidazol-2-yl)sulfinyl]pentyl]-N-heptylurée;
  - . N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptylbutanamide;
  - N-[5-[4,5-bis(1-méthyléthyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophényl)-N-heptylurée;
  - N-[5-[4,5-bis(1-méthyléthyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylcyclohexaneacétamide;
  - . N-[5-[4,5-bis(2-méthoxyphényl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophényl)-N-heptylurée;
  - . Phényl-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate;
  - . N-[5-[4,5-bis[4-(diméthylamino)phényl]-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophényl)-N-heptylurée;
  - N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N'-octyl-N-phénylurée;
  - . N-[5-[4,5-bis(4-méthoxyphényl)-1H-imidazol-2-ylthio]pentyl]-2,4-difluoro-N-heptylbenzèneacétamide;
  - . Phényl-[5-[(4,5-bis-(4-diméthylamino)phényl)-1H-imidazol-2-ylthio]pentyl]-heptylcarbamate; et
  - N-[5-(4,5-dicyclohexyl-1H-imidazol-2-ylthio)pentyl]-N'-(2,4-difluorophényl)-N-heptylurée.

55

6. Un procédé selon la revendication 1, comprenant en outre l'élimination de tout groupe protecteur sur R³ pour conduire à un composé de formule (I) dans laquelle R³ est H.

- 7. Un procédé selon la revendication 1, comprenant en outre la réaction d'un composé de formule (I) dans laquelle Y est O, avec un réactif de Lawesson ou un pentasulfure diphosphoreux, pour conduire à un composé de formule (I) dans laquelle Y est S.
- 8. Un procédé selon la revendication 1, comprenant en outre la réaction d'un composé de formule (I) dans laquelle Y est O, avec un agent réducteur tel que l'hydrure d'aluminium lithium ou du borohydrure de sodium, pour conduire à un composé de formule (I) dans laquelle Y est H<sub>2</sub>.
- 9. Un procédé selon la revendication 1, comprenant en outre la réaction d'un composé de formule (I) dans laquelle X est S, avec un agent d'oxydation convenable pour obtenir soit le sulfoxyde SO, dans lequel r est égal à 1, soit la sulfone SO<sub>2</sub>, dans laquelle r est égal à 2.
  - 10. Un procédé selon la revendication 1, comprenant en outre la réaction d'un composé de formule (I) dans laquelle R³ est un atome d'hydrogène, avec un agent d'alkylation convenable tel qu'un halogénure d'alkyle, pour conduire à l'obtention d'un composé de formule (I) dans laquelle R³ est un radical alkyle en C₁ à C₅, allyle ou benzyle.
  - 11. Un procédé comprenant les étapes d'alkylation d'un composé de formule:

25

35

40

15

$$\begin{array}{c}
 & H \\
 & N \\$$

30 dans laquelle:


R1 et R2

sont choisis, indépendamment l'un de l'autre, le groupe comprenant un atome d'hydrogène, un radical alkyle en  $C_1$  à  $C_8$ , à condition que lorsque  $R^1$  est un atome d'hydrogène, alors  $R^2$  ne peut être un atome d'hydrogène et que lorsque  $R^1$  est un radical alkyle en  $C_1$  à  $C_8$ , alors  $R^2$  ne peut pas être un radical alkyle en  $C_1$  à  $C_8$ , un radical alkyle ramifié en  $C_3$  à  $C_8$ , cycloalkyle en  $C_3$  à  $C_7$ , cycloalkylalkyle en  $C_4$  à  $C_{10}$ , aralkyle en  $C_7$  à  $C_{14}$ ,  $C_8$ , ou 4-pyridinyle, 2-thiényle, 2-furanyle, phényle éventuellement substitué par 1 à 3 groupes sélectionnés parmi: atomes de fluor, chlore, brome, un groupe OH, un radical alcoxy en  $C_1$  à  $C_4$ , alkyle en  $C_1$  à  $C_4$ , alkyle ramifié en  $C_3$  à  $C_8$ ,  $C_8$ ,  $C_8$ ,  $C_8$ ,  $C_8$ ,  $C_8$ ,  $C_8$ , ou  $C_8$ ,  $C_8$ , ou  $C_8$ , ou  $C_8$ , ou

R1 et R2

peuvent former ensemble un groupe:

45



55

50

dans lequel:

L est O,  $O(CH_2)_{m+1}O$ , ou  $(CH_2)_m$ , m étant un nombre de 0 à 4;

R³ est un atome d'hydrogène, un radical alkyle en C₁ à C₆, allyle, benzyle ou phényle éventuellement substitué par un atome de fluor, de chlore, un groupe CH₃, CH₃O ou CF₃; ou un groupe protecteur convenable tel qu'un groupe silyle ou trilyle; et

X est O ou S,

avec un composé de formule:

5

10

15


20

25

40

45

50



dans laquelle:

M est un halogénure ou un tosylate;

A est un radical alkyle en  $C_2$  à  $C_{10}$ , alkyle ramifié en  $C_3$  à  $C_{10}$ , alkényle en  $C_3$  à  $C_{10}$ , ou alkynyle en  $C_3$  à  $C_{10}$ ;

R<sup>6</sup> est un atome d'hydrogène, un radical alkyle en C<sub>1</sub> à C<sub>8</sub>, alkyle ramifié en C<sub>3</sub> à C<sub>8</sub>, cycloalkyle en C<sub>3</sub> à C<sub>7</sub>, alkynyle ou alkényle en C<sub>3</sub> à C<sub>8</sub>, phényle éventuellement substitué par 1 à 3 groupes choisis parmi alcoxy ou alkyle en C<sub>1</sub> à C<sub>4</sub>, les atomes de fluor, brome, chlore, les groupes NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, carboalcoxy en C<sub>1</sub> à C<sub>4</sub>, NR<sup>7</sup>R<sup>8</sup> ou NCOR<sup>7</sup>; pentafluorophényle, benzyle éventuellement substitué par 1 à 3 groupes choisi parmi alcoxy ou alkyle en C<sub>1</sub> à C<sub>4</sub>, les atomes de fluor, brome, chlore, les groupes NH<sub>2</sub>, OH, CN, CO<sub>2</sub>H, CF<sub>3</sub>, NO<sub>2</sub>, carboalcoxy en C<sub>1</sub> à C<sub>4</sub>, NR<sup>7</sup>R<sup>8</sup> ou NCOR<sup>7</sup>;

Y est O, S ou H<sub>2</sub>; et

Z est NHR<sup>4</sup>, OR<sup>4</sup> ou R<sup>4</sup>,

pour conduire à un composé de formule (I):

dans laquelle:

R¹ et R² sont choisis, indépendamment l'un de l'autre, dans le groupe comprenant un atome d'hydrogène, un radical alkyle en C₁ à C₂, alkyle ramifié en C₃ à C₃, cycloalkyle en C₃ à C₁, cycloalkylalkyle en C₄ à C₁₀, aralkyle en C₂ à C₁₄, 2-, 3- ou 4-pyridinyle, 2-thiényle, 2-furanyle, phényle éventuellement substitué par 1 à 3 groupes sélectionnés parmi: atomes de fluor, chlore, brome, groupe OH, radical alcoxy en C₁ à C₄, alkyle en C₁ à C₄, alkyle ramifié en C₃ à C₃, CH₃S(O), NO₂, CF₃ ou NR<sup>7</sup>R<sup>8</sup>; ou

R<sup>1</sup> et R<sup>2</sup> peuvent former ensemble un groupe:

55

L	
	$\bigvee$
	_"

 $R^4$ 

 $R^6$ 

5

10

15

20

25

30

35

40

45

50

dans lequel:

L est O,  $O(CH_2)_{m+1}O$ , ou  $(CH_2)_m$ , m étant un nombre de 0 à 4;

R³ est un atome d'hydrogène, un radical alkyle en  $C_1$  à  $C_6$ , allyle, benzyle ou phényle éventuellement substitué par un atome de fluor, de chlore, un groupe  $CH_3$ ,  $CH_3O$  ou

CF<sub>3</sub>;

est un radical alkyle linéaire en  $C_1$  à  $C_8$  éventuellement substitué par un atome de fluor; un radical alkyle ramifié en  $C_3$  à  $C_8$ , cycloalkyle en  $C_3$  à  $C_7$ , cycloalkylalkyle en  $C_4$  à  $C_{10}$ , aralkyle en  $C_7$  à  $C_{14}$ , dans lequel le radical aryle est éventuellement substitué par un à trois groupes choisis parmi les radicaux alcoxy ou alkyle en  $C_1$  à  $C_4$ , les atomes de fluor, brome, chlore, les groupes  $NH_2$ , OH, CN,  $CO_2H$ ,  $CF_3$ ,  $NO_2$ , carboalcoxy en  $C_1$  à  $C_4$ ,  $NR^7R^8$  ou  $NCOR^7$ ; les radicaux alkynyle ou alkényle en  $C_3$  à  $C_5$ , perfluoroalkyle en  $C_1$  à  $C_3$ , phényle éventuellement substitué par un groupe choisi parmi les radicaux alcoxy ou alkyle en  $C_1$  à  $C_4$ , les atomes de fluor, brome, chlore, les groupes  $NH_2$ , OH, CN,  $CO_2H$ ,  $CF_3$ ,  $NO_2$ , les radicaux carboalcoxy en  $C_1$  à  $C_4$ ,  $NR^7R^8$  ou  $NCOR^7$ ; les radicaux pentafluorophényle, benzyle éventuellement substitué par 1 à 3 groupes choisis parmi les radicaux alcoxy ou alkyle en  $C_1$  à  $C_4$ , les atomes de fluor, brome, chlore, les groupes  $NH_2$ , OH, CN,  $CO_2H$ ,  $CF_3$ ,  $NO_2$ , carboalcoxy en  $C_1$  à  $C_4$ ,  $NR^7R^8$  ou  $NCOR^7$ ; les radicaux 2-, 2-, ou 2-pyridinyle, pyrimidinyle ou biphényle;

R<sup>5</sup> est un atome d'hydrogène ou un radical alkyle en C<sub>1</sub> à C<sub>6</sub> ou benzyle;

est un atome d'hydrogène, un radical alkyle en  $C_1$  à  $C_8$ , alkyle ramifié en  $C_3$  à  $C_8$ , cycloalkyle en  $C_3$  à  $C_7$ , alkynyle ou alkényle en  $C_3$  à  $C_8$ , phényle éventuellement substitué par 1 à 3 groupes choisis parmi les radicaux alcoxy ou alkyle en  $C_1$  à  $C_4$ , les atomes de fluor, brome, chlore, les groupes  $NH_2$ , OH, CN,  $CO_2H$ ,  $CF_3$ ,  $NO_2$ , carboalcoxy en  $C_1$  à  $C_4$ ,  $NR^7R^8$  ou  $NCOR^7$ ; les radicaux pentafluorophényle, benzyle éventuellement substitué par 1 à 3 groupes choisi parmi les radicaux alcoxy ou alkyle en  $C_1$  à  $C_4$ , les atomes de fluor, brome, chlore, les groupes  $NH_2$ , OH, CN,  $CO_2H$ ,  $CF_3$ ,  $C_1$ 0 a  $C_1$ 1 a  $C_2$ 2 a  $C_3$ 3 c  $C_4$ 3 a  $C_4$ 4 a les atomes de fluor, brome, chlore, les groupes  $C_1$ 3 a  $C_2$ 4 a  $C_3$ 5 c  $C_4$ 6 a  $C_4$ 7 a  $C_4$ 8 a  $C_4$ 9 a  $C_5$ 9 a  $C_7$ 9 a  $C_$ 

NO<sub>2</sub>, carboalcoxy en C<sub>1</sub> à C<sub>4</sub>, NR<sup>7</sup>R<sup>8</sup> ou NCOR<sup>7</sup>;

 $R^7$  et  $R^8$  sont, indépendamment l'un de l'autre, choisis parmi l'atome d'hydrogène ou les radicaux alkyles en  $C_1$  à  $C_4$ ;

X est  $S(O)_r$ , O,  $NR^5$ ,  $CH_2$ ;

A est un radical alkyle en C<sub>2</sub> à C<sub>10</sub>, alkyle ramifié en C<sub>3</sub> à C<sub>10</sub>, alkényle en C<sub>3</sub> à C<sub>10</sub>, ou alkynyle en C<sub>3</sub> à C<sub>10</sub>;

Y est O, S ou  $H_2$ ;

Z est NHR<sup>4</sup>, OR<sup>4</sup> ou R<sup>4</sup>;

r est un nombre de 0 à 2,

et formant éventuellement un sel pharmaceutiquement acceptable en dérivant.

- 12. procédé selon la revendication 11, comprenant en outre l'élimination de tout groupe protecteur sur R3.
- 13. Un procédé selon la revendication 11, comprenant en outre la réaction d'un composé de formule (I) dans laquelle Y est O, avec un réactif de Lawesson ou un pentasulfure diphosphoreux, pour conduire à un composé de formule (I) dans laquelle Y est S.

- 14. Un procédé selon la revendication 11, comprenant en outre la réaction d'un composé de formule (I) dans laquelle Y est O, avec un agent réducteur tel que l'hydrure d'aluminium lithium ou du borohydrure de sodium, pour conduire à un composé de formule (I) dans laquelle Y est H<sub>2</sub>.
- 15. Un procédé selon la revendication 11, comprenant en outre la réaction d'un composé de formule (I) dans laquelle X est S, avec un agent d'oxydation convenable pour obtenir soit le sulfoxyde SO, dans lequel r est égal à 1, soit la sulfone SO<sub>2</sub>, dans laquelle r est égal à 2.
- 16. Un procédé selon la revendication 11, comprenant en outre la réaction d'un composé de formule (I) dans laquelle R³ est un atome d'hydrogène, avec un agent d'alkylation convenable tel qu'un halogénure d'alkyle, pour conduire à l'obtention d'un composé de formule (I) dans laquelle R³ est un radical alkyle en C₁ à C₆, allyle ou benzyle.
  - 17. Un procédé de préparation d'une composition pharmaceutique consistant à mélanger une quantité efficace du point de vue thérapeutique d'un composé préparé selon l'une quelconque des revendications 1 à 16, et un support pharmaceutiquement acceptable.